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1 – Abstract 
Lipids are amphiphilic molecules which function not only as sources of energy and structural 
components of cells, but are involved in signal transduction. Fatty acids (FAs) are the simplest 
lipid building block, and contain an unbranched carbon chain that can be decorated with cis 
double bonds. They serve as modular components of more complex lipids through further 
functionalization of the polar headgroup, affording an expansive collection of molecules whose 
structures are as diverse as their functions. Although lipids are vital to most, if not all, cellular 
processes, few tools exist which allow researchers to perturb lipid-dependent processes with 
a high degree of spatiotemporal precision. To achieve greater control over the function of 
small molecules, our lab designs photoswitchable ligands that interact with their target under 
the control of light, a field we call photopharmacology. This technique has enabled optical 
control of a variety of transmembrane and intracellular proteins, but has been mostly focused 
on soluble small-molecule ligands that interact directly with their target. 
Here, we aim to place lipid signaling under photopharmacological control using 
photoswitchable lipids, or photolipids. We prepared a series of photoswitchable FAs, the 
FAAzos, which contain an azobenzene photoswitch replacing the double bonds in the FA 
aliphatic chain. This allows the researcher to fine-tune the pharmacological and biophysical 
properties of each molecule in a reversible manner on illumination. Given the ubiquity of 
protein-lipid interactions in cell physiology, the photolipids are broadly applicable tools for 
controlling signal transduction. The FAAzos themselves can be used to control FA-signaling 
through interactions with voltage-activated K+ channels and G protein-coupled receptors 
(GPCRs) such as GPR40. They can also be further derivatized to create more sophisticated 
photolipids; including vanilloids, glycerolipids, phosphoinositides, and sphingolipids. These 
photolipids enable optical control of ion channels such as TRPV1 or enzymes like protein 
kinase C (PKC), providing researchers with tools to manipulate nociception, synaptic 
transmission, and excretion. In contrast to optogenetic approaches, these tools do not require 
genetic encoding. As such, they are applicable to a variety of different cell types, and can 
even be used in vivo. The photolipids can also be incorporated into synthetic membranes, 
where they affect membrane properties such as permeability, fluidity, and curvature. Taken 
together, we demonstrate how discrete alterations in lipid properties are crucial towards their 
effects within the cell. More generally, this work directs photopharmacology towards the 
plasma membrane, and provides researchers with tools to manipulate lipid signaling with the 
high spatiotemporal precision of light.   
  
2 − Introduction 
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2 – Introduction to photolipids 
Lipids are fundamental to compartmentalized organic life, as they define the permeability 
barriers between cells and organelles1–3. They serve as stores of energy, and are also 
essential signaling molecules which act as first and second-messengers, ligands or allosteric 
modulators in most, if not all, signaling events4. Lipids can be generically defined as 
hydrophobic or amphiphilic molecules that are soluble in nonpolar organic solvents, however 
their chemical structures are as diverse as their functions5. The characterization of a cellular 
lipid content, alongside the individual functions of each molecule, has been coined lipidomics6. 
In contrast to genomics, which developed rapidly alongside technology enabling the efficient 
analysis and manipulation of genetic information and proteins4, lipidomics was late to gain 
momentum as technology for precise and quantitative lipid detection was limited. However, 
recent advances in mass spectrometry and computational methods for storing and processing 
data have triggered an explosion in lipidomics7. We now know that the lipidome of an average 
cell contains over 1000 unique molecules8,9, and a significant portion of the proteome is 
dedicated to controlling the amount and location of specific lipids10. Lipids are the solvent in 
which transmembrane proteins function, and the clustering of lipids into distinct microdomains 
is thought to organize signaling events within the plane of the membrane11,12. As our ability to 
observe and manipulate lipids grows, we are only now beginning to grasp the complex roles 
of lipids in cell physiology. 
 FAs are aliphatic carboxylic acids that represent the simplest lipid unit. They most 
often contain a unbranched chain of 4 to 28 carbon atoms, and can possess one or more 
degrees of unsaturation in the form of cis double bonds13 (Fig. 2.1a). The chain length and 
degree of unsaturation determines the biophysical and pharmacological properties of each 
FA, and this has a significant effect on the fluidity and curvature of the membrane in which 
they are embedded. As a particularly noteworthy example, arachidonic acid (AA) possesses 
a linear 20 carbon chain with four skipped cis double bonds that are vital for its effects in the 
cell (Fig. 2.1b). AA acts as a second messenger, and is a ligand for several ion channels and 
GPCRs14,15. It also and serves as a precursor to highly potent signaling hormones such as 
leukotrienes and eicosanoids16. More generally, FAs serve as the hydrophobic components 
of more elaborate lipids through conjugation to polar headgroups of varying complexity. These 
range from simple net-neutral units such as phosphocholine, to the chiral charged headgroups 
of phosphoinositides or glycolipids (Fig. 2.1c). The different headgroups and acyl chains are 




distinct role within the membrane. As our understanding of these molecules becomes more 
sophisticated, novel chemical and genetic tools must be developed to manipulate individual 
lipid species with greater precision. These tools may be useful for understanding lipid function, 
both in normal cell physiology and disease states. 
To enable greater control over signal transduction, researchers often endow proteins 
or small molecules with light sensitivity17. Light can be applied with an unmatched degree of 
spatial and temporal precision, and a light-responsive effector can translate the applied 
stimulus towards a target protein, initiating a cellular response. Optogenetics, for example, 
utilizes light-responsive proteins with naturally occurring chromophores18 to enable optical 
control of specific cells or signaling pathways19–21. This approach allows researchers to control 
complex tissues and organisms with light using relatively well-established genetic methods22. 
Alternatively, synthetic small molecules can be rendered light-responsive and used to target 
proteins that are not normally associated with a natural chromophore. Caged ligands23, 
including caged lipids24, have already been developed and used extensively in a variety of 
applications25–31. In this case, the active pharmacophore is masked with a light-labile 
protecting group32, allowing the free ligand to be released almost instantaneously upon a flash 
of light. This approach dramatically increases the precision at which a ligand can be applied, 
however uncaging is an irreversible process, and once switched ON the activity relies on 
metabolism or active transport to be turned OFF. 




Figure 2.1 | Fatty acids are modular components of more complex lipids. (a) Chemical 
structures of various FAs of different lengths and degrees of unsaturation. (b) The chemical 
structure of AA, a second messenger lipid with unique biophysical properties. (c) The 






Complementary to this technique, photoswitchable small molecules can be used to 
enable reversible optical control of cellular function33. This approach has been coined 
photopharmacology34. A synthetic photoswitch can be incorporated into the target molecule, 
and permits cycling between distinct conformations with light in a reversible manner. Research 
in our lab has focused primarily on the azobenzene photoswitch, which can be rapidly 
isomerized from the thermally more stable trans-configuration to the higher-energy cis-form 
with UV-A light (Fig. 2.2a). This process can be reversed by irradiation with blue light, and 
photoswitching can be performed over hundreds of cycles without photobleaching or the 
generation of harmful singlet oxygen species35 (Fig. 2.2b). The azobenzene is a relatively 
small photoswitch (about 9 Å long in the trans-form) and exhibits a large conformational 
change (about 3 Å shortening between the para-positions) alongside a significant increase in 
polarity on isomerization to cis. Azobenzenes can be readily synthesized using a variety of 
methods, and can be spectrally tuned to respond to longer irradiation wavelengths36,37 
(Fig. 2.2c,d). This lower energy and deeper-penetrating light facilitates application to more 
complex tissues38,39. Photopharmacology was first successfully applied to ion channels40, 
where a photoswitchable pharmacophore was covalently tethered to an engineered cysteine 
on the protein of interest via maleimide chemistry41 (Fig. 2.3a). More recently, this approach 
has been extended to utilize new bioconjugation techniques such as self-labeling protein 
tags42, and enables optical control of a target protein with a high degree of specificity driven 
by the protein-ligand conjugation. Alternatively, freely diffusible photoswitchable small 
molecules, the so-called photochromic ligands (PCLs), can place endogenous protein function 
under optical control without the need for genetic manipulation (Fig. 2.3b)43. In both cases, 
the ligand has been rendered photoswitchable through synthetic modifications, and exhibits a 
change in efficacy towards its target on isomerization between the two distinct conformational 
states (Fig. 2.3c). Photopharmacology has now been expanded to GPCRs, enzymes, and 
transcription factors, enabling reversible control of a number of proteins with the 
spatiotemporal precision of light35,44.  
  




Figure 2.2 | The azobenzene as a photoswitch. (a) Chemical structure of the azobenzene 
in its trans and cis states. (b) UV-Vis spectra demonstrate that the a standard azobenzene 
can be isomerized between its cis and trans states over many cycles with UV-A and blue light, 
respectively. (c) Chemical structure of the tetra-ortho-chloro azobenzene in its trans and cis 
states. The cis-form can be generated by green (λ = 560 nm) irradiation. (d) The chemical 
structures of various functionalized azobenzene derivatives, which can be isomerized to the 







Figure 2.3 | Photopharmacology enables optical control of cell signaling. 
(a) Photoswitched tethered ligands (PTLs) can be tethered to an engineered cysteine on a 
target protein, enabling optical control with high specificity. (b) Photochromic ligands (PCLs) 
are freely diffusing photoswitchable ligands which change in efficacy on isomerization 
between two distinct states. (c) PCLs or PTLs can enable optical control of cellular signaling. 
For example, action potential (AP) firing in neurons can be triggered by a flash of light. 
 
 
In this thesis, I describe our efforts in extending the reach of photopharmacology to 
control lipid signaling. Although photoswitchable lipids, also called photolipids, have been 
investigated before, this work was limited and mostly restricted to biophysical studies in 
artificial membranes45–48. In some cases, the photoswitch was incorporated into the polar 
headgroup of the molecule, which often defines the identity and function of a given lipid for its 
effector proteins49,50. Given the modularity of FAs across almost all lipid classes, we 
recognized that incorporating a photoswitch into the fatty acyl chain would allow us to 
construct a wide range of photolipids from only a few synthetic building blocks. This approach 
would also retain the identity of the headgroup, preserving the lipids identity and native activity 
within the cell. Photoisomerization within the acyl chain(s) would allow us to fine-tune the 
molecule’s efficacy towards its target effectors, either through direct interaction with the target 
protein, or with the surrounding membranes. To this end, we designed and synthesized a set 
of photoswitchable FAs, the FAAzos, which consist of an aliphatic carboxylic acid and an 
azobenzene photoswitch to mimic the double bonds. We discovered that the azobenzene can 
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be easily incorporated into the fatty acyl chain without disrupting the compounds biological 
activities. In some cases, the FAAzos behave as an AA that can be turned ON and OFF with 
light. By attaching the FAAzos to different polar headgroups, we created a library of photolipids 
which enable optical control of lipid-mediated signaling events37,51,52, and can also be applied 
to model membrane systems53. By harnessing the spatiotemporal precision of light, the 
photolipids are broadly applicable tools to study the roles of lipids in cell signaling and 
membrane structure.  
 
  
3 − Project affiliations 
9 
 
3 – Project affiliation disclosure 
In this statement, I proclaim that the findings in the following dissertation are the result of a 
team-driven effort involving many individuals.  I will discuss the findings of our group and our 
collaborators, compiling the work of many into a description of our findings. Alongside the 
supervision of Prof. Dr. Dirk Trauner, the following individuals added significantly to this work 
through conceptual and/or experimental contributions: 
 
Chapter 4 – Photoswitchable fatty acids enable optical control of TRPV1 
Dr. Mirko Moroni1 (electrophysiology), Dr. Med. Rabih Moshourab1,2 (C-fiber experiments), 
David Konrad3 (synthesis of red-AzCA-4), Dr. Martin Sumser3 (supervision and 
electrophysiology), Prof. Dr. Gary R. Lewin1 (supervision).  
1Molecular Physiology of Somatic Sensation, Max Delbrück Center for Molecular 
Medicine, 13125 Berlin, Germany. 2Department of Anesthesiology, Campus Charité 
Mitte und Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Augustburgerplatz 
1, 13353 Berlin, Germany. 3Department of Chemistry and Center for Integrated Protein 
Science, Ludwig Maximilians University Munich, Butenandtstraße 5–13, 81377 
Munich, Germany. 
 
Chapter 5 – Photoswitchable diacylglycerols enable optical control of protein 
kinase C 
Prof. Dr. Carsten Schultz1 (supervision), Dr. Dmytro A. Yushchenko1,2 (imaging), Dr. David J. 
Hodson3,4,5 (imaging and secretion experiments), Dr. Noa Lipstein6 (electrophysiology), Dr. 
Jatin Nagpal7,8 (C. elegans experiments), Prof. Dr. Guy A. Rutter3 (supervision), Dr. Jeong-
Seop Rhee6 (supervision), Prof. Dr. Alexander Gottschalk7,8 (supervision), Prof. Dr. Nils 
Brose6 (supervision). 
1European Molecular Biology Laboratory (EMBL), Cell Biology & Biophysics Unit, 
Meyerhofstraße 1, 69117 Heidelberg, Germany. 2Institute of Organic Chemistry and 
Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo namesti 2, 
16610 Prague 6, Czech Republic. 3Section of Cell Biology and Functional Genomics, 
Department of Medicine, Imperial College London, ICTEM, Hammersmith Hospital, Du 
Cane Road, London W12 0NN, UK. 4Institute of Metabolism and Systems Research 
(IMSR), University of Birmingham, Birmingham B15 2TT, UK. 5Centre for 
Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, 
3 − Project affiliations 
10 
 
B15 2TH, UK. 6Department of Molecular Neurobiology, Max Planck Institute of 
Experimental Medicine, Hermann-Rein Straße 3, 37075 Göttingen, Germany. 
7Buchmann Institute for Molecular Life Sciences, Goethe University, Max von Laue 
Strasse 15, D-60438 Frankfurt, Germany. 8Institute of Biochemistry, Department for 
Biochemistry, Chemistry and Pharmacy, Goethe University, Max von Laue Strasse 9, 
D-60438 Frankfurt, Germany. 
Chapter 6 – Synthesis of photoswitchable glycerophospholipids  
Prof. Dr. Carsten Schultz1 (supervision), Dr. Rainer Müller1 (synthesis). 
1European Molecular Biology Laboratory (EMBL), Cell Biology & Biophysics Unit, 
Meyerhofstraße 1, 69117 Heidelberg, Germany. 
 
Chapter 7 – Optical control of arachidonate signalling in pancreatic β-cells 
 
Prof. Dr. Carsten Schultz1 (supervision), Dr. Dmytro A. Yushchenko1,2 (imaging), Dr. David J. 
Hodson3,4,5 (β-cell imaging and secretion experiments), Nick Fine3,4,5 (β-cell imaging and 
secretion experiments), Margherita Duca6 (synthesis). 
 
1European Molecular Biology Laboratory (EMBL), Cell Biology & Biophysics Unit, 
Meyerhofstraße 1, 69117 Heidelberg, Germany. 2Institute of Organic Chemistry and 
Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo namesti 2, 
16610 Prague 6, Czech Republic. 3Section of Cell Biology and Functional Genomics, 
Department of Medicine, Imperial College London, ICTEM, Hammersmith Hospital, Du 
Cane Road, London W12 0NN, UK. 4Institute of Metabolism and Systems Research 
(IMSR), University of Birmingham, Birmingham B15 2TT, UK. 5Centre for 
Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, 
B15 2TH, UK. 6Department of Chemistry and Center for Integrated Protein Science, 




3 − Project affiliations 
11 
 
Chapter 8 – Optical control of lipid rafts with photoswitchable ceramides 
Dr. Henri G. Franquelim1 (atomic force microscopy), Prof. Dr. Petra Schwille1 (supervision), 
Margherita Duca2 (synthesis). 
1Department of Cellular and Molecular Biophysics, Max Planck Institute of 
Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany. 2Department of 
Chemistry and Center for Integrated Protein Science, Ludwig Maximilians University 




The minds and wills of many individuals have come together and our combined efforts have 
enabled me to write this dissertation. However, this thesis has been compiled under my own 
initiative, and I am solely responsible for any errors contained within the following text.
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4 – Photoswitchable fatty acids enable optical control of TRPV1 
This work has been published in Nature Communications (2015)51 and Chemistry - a 
European Journal (2016)37. 
 
4.1 – Introduction 
Lipids serve not only as sources of energy and integral components of membranes, but are 
also involved in cellular communication through participation in a variety of signaling cascades 
and the modulation of transmembrane proteins54. Over the past several decades, interest in 
lipid chemistry has been overshadowed by advancements in proteomic and genomic 
technologies. However, recent developments in lipid research, including analysis of the 
lipidome4, have shed new light on the roles of these molecules at all levels of biology. Many 
lipid are comprised of FAs. These ancient molecular building blocks typically feature a long 
linear carbon chain (up to 28 carbons)13 that often contains one or several cis- double bonds. 
 The Vanilloid Receptor 1 (TRPV1), is the most studied of the transient receptor 
potential (TRP) ion channels55,56. This family of non-selective cation channels is renowned for 
its ability to respond to a wide variety of chemical and physical inputs57,58. TRPV1 is involved 
in the regulation of body temperature59 and the transduction of painful stimuli from the 
periphery towards the central nervous system60. It is expressed in sub-populations of sensory 
nerve fibers within the dorsal root and trigeminal ganglia61 where it responds to temperatures 
greater than 43 °C62, protons63, as well as environmental toxins and poisons64,65. Importantly, 
TRPV1 is modulated by a plethora of FA amides, including the endogenous AA derivatives 
anandamide66 and N-arachidonoyl dopamine67. Its most famous exogenous agonist is the 
vanilloid capsaicin (CAP), the pungent component of chili peppers62. Synthetic TRPV1 
agonists include olvanil68 and arvanil69, which are FA-derived vanilloids developed as non-
pungent CAP analogs. 
 TRPV1 is not only involved in responses to noxious stimuli, but is also believed to 
initiate the neurogenic inflammatory response70 which has made it an attractive target for 
novel analgesics62. However, these attempts have proven more challenging than anticipated 
as TRPV1 is involved in a variety of other biological pathways that can lead to unwanted side 
effects. An agonist or antagonist that could be applied globally but activated only locally could 




untangling the complex interactions that TRPV1 has with other proteins, such as the serotonin 
(5-HT), bradykinin (BK), and recently GABAB1 receptors56,71,72. 
 Precision control can be achieved through photoswitchable small molecules that act 
as transducers between a light stimulus and protein function33,34,73. In 2013, our group was 
the first to place TRPV1 under reversible optical control when we developed a series of 
photoswitchable antagonists which could optically control TRPV1 in the presence of CAP to 
activate the channel74. Based on the structure of CAP and other TRPV1 agonists, we saw the 
opportunity to develop a photoswitchable TRPV1 agonist, which would permit optical control 
over the ion channel without the use of a second factor.  
In this study, we present a toolkit of photolipids that allow us to place lipid-modulated 
biological targets, such as TRPV1, under the precise spatial and temporal control of light. We 
show that AzCA-4 permits optical control over TRPV1 in complex neural systems with a higher 
degree of spatiotemporal precision than what is currently possible via other methods. More 
generally, this work represents the first example of the fusion of photopharmacology with lipid 
signaling, and consequently sets the groundwork for future research in this field.
 
 
4.2 – Results 
4.2.1 – Photolipid synthesis 
In an effort to mimic FAs with a chain length of 18 carbons, we prepared a series of eight 
photoswitchable FA-derivatives, FAAzo-1-8. Each of these compounds contained an 
azobenzene photoswitch which allowed for controllable cis/trans-isomerization along the 
length of the chain (Fig. 4.1a). FAAzo-1-8 were prepared in between 2 and 6 steps in 
moderate yield (Fig. 4.2)75. In their dark-adapted state, the FAAzos existed predominantly in 
the trans-configuration. UV-Vis spectroscopy showed that isomerization from trans- to cis- 
could be achieved by irradiation at λ = 365 nm, and this process could be reversed by 
λ = 460 nm light. 




Figure 4.1 | Photolipids for the optical control of TRPV1. (a) Chemical structures of AA 
and FAAzo-1-8. (b) Chemical structures of TRPV1 agonists capsaicin (CAP), arvanil, olvanil, 
N-arachidonoyl dopamine and anandamide alongside photoswitchable vanilloids, AzCA-1-8. 
(c) Chemical synthesis of AzCA-4. Isomerization between cis- and trans-AzCA-4 could be 






Figure 4.2 | The syntheses of photoswitchable fatty acids, FAAzo-1-8. (a) The synthesis 
of FAAzo-1. (b) FAAzo-2-4 were synthesized via the Mills reaction. FAAzo-2: n = 1, 
R = hexyl (27%). FAAzo-3: n = 2, R = pentyl (27%). FAAzo-4:  n = 3, R = butyl (91%). 
(c) FAAzo-8 was synthesized in 6 steps from 7-octyn-1-ol in 10% overall yield. FAAzo-5-7 
were synthesized in an analogous fashion.  
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Supported by structure activity relationships (SAR) and recent structural data76, we 
envisioned a unique opportunity to create a series of photoswitchable vanilloids for the optical 
control of TRPV1. Our approach combined the vanilloid head group of CAP with the FAAzos 
which would act as a photoswitchable tail mimicking that of N-arachidonoyl dopamine, 
anandamide, olvanil or arvanil (Fig. 4.1b). The preparation of these compounds (Fig. 4.1c, 
Fig. 4.3) required only a peptide coupling between vanillylamine and the appropriate FAAzo 
to afford 8 photoswitchable vanilloids, AzCA-1-8, in good yields (Fig. 4.1b). Photoswitching 
of AzCA-1-8 was also achieved using λ = 365/460 nm, and they showed similar 
photoswitching properties when compared to the FAAzos (Fig. 4.4). As such, both FAAzos 
and AzCAs could be classified as “regular” azobenzenes that require UV-A light for 
isomerization to their thermally unstable cis-form.  
 
 
Figure 4.3 | The syntheses of photoswitchable vanilloids, AzCA-1-8. Photoswitchable 
vanilloids, AzCA-1-8, were prepared from the corresponding FAAzo via peptide coupling with 
vanillylamine. AzCA-1: n = 0, R = heptyl (89%). AzCA-2: n = 1, R = hexyl (48%). 
AzCA-3: n = 2, R = pentyl (89%). AzCA-4: n = 3, R = butyl (87%). AzCA-5: n = 4, 
R = propyl (90%). AzCA-6: n = 5, R = ethyl (86%). AzCA-7: n = 6, R = methyl (81%). 






Figure 4.4 | UV-Vis spectra of FAAzo- and AzCA-derivatives. Photoswitching of 
(a) FAAzo-4 and (b) AzCA-4 could be visualized with UV-Vis spectroscopy. The spectra for 
all FAAzo- and AzCA-derivatives showed nearly identical profiles among the group. An initial 
spectrum was recorded (dark adapted state, black) and then again following illumination at 
the λmax for the π-π* transition (λ = 350 nm) for 3 min (cis-adapted state, grey). A third spectrum 
was recorded after irradiation at the λmax for the n-π* transition (λ = 450 nm) for 3 min (trans-
adapted state, blue). 
 
4.2.2 – Optical control over TRPV1 in HEK293T cells 
We evaluated the photopharmacology of AzCA-1-8 using whole-cell electrophysiology in 
human embryonic kidney (HEK) 293T cells transiently expressing the YFP-tagged ion channel 
(TRPV1-YFP)77. Each compound (1 µM) was continuously applied while alternating between 
irradiation at λ = 350 nm and λ = 450 nm until a steady state of activity/desensitization was 
achieved upon photoswitching. Their relative light-dependent activities were then assessed 
by performing voltage ramps (–100 to +100 mV over 5 s) under irradiation at both wavelengths 
(Fig. 4.5a, Fig. 4.6a). Among the 8 derivatives tested, three compounds: AzCA-2, AzCA-3, 
and AzCA-4 (at 1 µM), showed the most profound TRPV1 photoswitching effect (Fig. 4.5b, 
Fig. 4.6b). For all 3 derivatives, larger currents were observed under irradiation at λ = 350 nm, 
indicating that these compounds had higher efficacies towards TRPV1 in their cis-
configuration. At higher concentrations (˃300 nM, bath application), smaller cellular currents 
were observed upon application of the AzCAs in their dark-adapted states. This showed that 
in both configurations, the AzCAs were TRPV1 agonists, however in all cases a larger current 
was observed under λ = 350 nm irradiation. Working at an optimized concentration (1 µM by 
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puff pipette), the AzCAs could be applied to cells in the dark without any observable effect, 
and allowed immediate TRPV1 activation upon irradiation with UV-A light (Fig. 4.7). 
Photoswitching could be repeated over multiple cycles and only minor channel desensitization 
was observed (Fig. 4.5c).  
   
 
Figure 4.5 | AzCAs permit optical control of TRPV1 in HEK293T cells. HEK293T cells 
expressing TRPV1-YFP were observed using whole-cell patch-clamp electrophysiology after 
the application of an AzCA-derivative (1 µM). (a) Voltage ramps were applied under both 
λ = 350 nm and λ = 450 nm irradiation. Larger currents were observed under λ = 350 nm 
irradiation (AzCA-4). (b) AzCA-2, AzCA-3 and AzCA-4 emerged as photoswitchable TRPV1 
agonists. (c) When voltage clamped, photoswitching could be repeated over many cycles 





Figure 4.6 | AzCA photoswitching characterization. A representative electrophysiological 
recording for AzCA-3 (1 µM) is displayed here. (a) The typical procedure which was used to 
apply and assess each AzCA-derivative. (b) ∆I determination by voltage ramp analysis.  
 




Figure 4.7 | AzCA-4 possesses a higher efficacy towards TRPV1 in its cis-configuration. 
AzCA-4 was applied (1 µM) to HEK293T cells transiently expressing TRPV1-YFP under both 
λ = 350 nm (grey) and λ = 450 nm (blue) irradiation. When the membrane potential was 
clamped at −60 mV, an inward current was only observed upon irradiation with λ = 350 nm 
(cis), but not under λ = 450 nm (trans) upon application of AzCA-4. This showed that AzCA-4 
was a more potent TRPV1 agonist in its cis-configuration. Both traces are sequential 








4.2.3 – Capsazepine antagonizes AzCA-4 activity 
The washout of AzCA-4 with buffer was very slow and photoswitching currents 
persisted for minutes under constant perfusion. However, application of capsazepine (CPZ, 
5 µM), a TRPV1 antagonist known to bind competitively against CAP, was capable of 
displacing AzCA-4 and rapidly abolished inward currents upon UV-stimulation (Fig. 4.8)78,79. 
In control experiments, no light-induced activity was observed in cells lacking TRPV1, before 
the application of an AzCA-derivative (Fig. 4.9a) or after the application of CAP (1 µM) 
(Fig. 4.9b). The application of FAAzo-2, FAAzo-3 and FAAzo-4 caused no effect (5 µM, n ≥ 3 
for each) in TRPV1-responding cells. 
 
 
Figure 4.8 | Capsazepine blocked AzCA-4 photoswitching activity. AzCA-4 (1 µM, puff 
application) was continuously applied upon photoswitching between λ = 350 nm and 
λ = 450 nm (10 s alternating pulses). After a steady state of activity/desensitization had been 
reached, the cells were washed with either capsazepine (CPZ, 5 µM in extracellular buffer, n 
= 4, black) or extracellular buffer (control, n = 4, grey). The maximum current amplitude for 
each UV pulse was calculated relative to the steady-state inward current and plotted as a 
function of pulse number after the washing was started. With buffer only, AzCA-4 washout 
was slow and photoswitching persisted for >8 pulses. Addition of CPZ rapidly blocked TRPV1 
currents upon photoswitching. Error bars were calculated as ±s.e.m.   




Figure 4.9 | Capsaicin did not permit the optical control of TRPV1. Control experiments 
using whole-cell voltage clamp electrophysiology showed that capsaicin (CAP) did not endow 
optical control over TRPV1-YFP in HEK293T cells. Voltage ramps (from –100 mV to +100 mV 
over 5 s) were applied (a) before and (b) after the application of CAP (1 µM). The ramp profile 
changed between the two measurements due to residual TRPV1 activation, but no significant 
light-dependent currents were observed. 
 
4.2.4 – AzCA-4 enables precision control of TRPV1 at varied stimulation wavelengths 
In voltage clamp experiments, the magnitude of the cellular currents could be controlled by 
adjusting the ON wavelength between λ = 350-390 nm. As shown by an action spectrum, the 
largest currents were observed under λ = 350 nm and they became smaller towards λ = 390 
nm (Fig. 4.10a, Fig. 4.11). Current clamp experiments revealed that the cellular membrane 
potential could be controlled in a similar fashion, with λ = 360 nm yielding the largest 
depolarization (Fig. 4.10b). Through exponential curve fitting, we evaluated the effects of 
irradiation on the TRPV1 activation kinetics. The fastest ON response was observed at 
λ = 360 nm and all other τon values were normalized to this τ-value for comparison 
(Fig. 4.10c). At longer wavelengths, a slower response was observed. Taken together, these 
results indicate that the AzCAs permit precise, optical control over the activity of TRPV1 that 
cannot be achieved with other lipophilic agonists, such as CAP, alone. Because AzCA-4 could 






Figure 4.10 | TRPV1 activation can be precisely controlled with light. Cellular currents 
were observed using whole-cell patch-clamp electrophysiology in HEK293T cells expressing 
TRPV1-YFP after the application of an AzCA-derivative (1 µM). (a) The current magnitude 
could be controlled by adjusting the ON wavelength between λ = 350-390 nm (AzCA-3). 
(b) When current clamped, the membrane potential could be controlled by adjusting the ON 
wavelength between λ = 350-400 nm (AzCA-4). (c) The activation rate could be controlled by 
adjusting the ON wavelength between λ = 350-390 nm (AzCA-3, n = 3). Error bars were 
calculated as ±s.e.m. 
 
Figure 4.11 | The magnitude of cellular currents was a function of the ON wavelength. 
When voltage clamped at –60 mV, the magnitude of the cellular current could be precisely 
controlled by adjusting the ON wavelength in HEK293T cells expressing TRPV1-YFP after 
the application of AzCA-3 (1 µM). The values were calculated as the current change from the 
baseline while irradiating with λ = 450 nm, and the maximum inward current observed upon 
irradiation at the ON wavelength (λ = 350-390 nm) for 5 s. The resulting currents were 
normalized to the largest current value (with λ = 350 nm) and averaged over multiple cells 
(n = 3) to yield a relative current. Error bars were calculated as ±s.e.m. 
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4.2.5 – AzCA-4 permits optical control over cultured DRG neurons 
Having demonstrated that AzCA-4 acts as a photoswitchable TRPV1 agonist that is relatively 
inactive in the dark, we next evaluated its activity in isolated wild type (wt) mouse DRG 
neurons using both electrophysiology and intracellular Ca2+ imaging. Whole-cell patch-clamp 
electrophysiology showed that AzCA-4 (200 nM) enabled reversible optical control over DRG 
neuronal activity. Switching between λ = 365 nm and λ = 460 nm in the voltage-clamp 
configuration at a holding potential of –60 mV resulted in reversible control over the 
transmembrane currents (Fig. 4.12a). Accordingly, the membrane potential and excitability of 
DRG neurons could be optically controlled as well. Action potential (AP) firing was reversibly 
switched ON and OFF by irradiation with λ = 365 nm and λ = 460 nm, respectively 
(Fig. 4.12b). 
 Bath application of AzCA-4 (100 nM) and irradiation at λ = 365 nm (5 s), caused an 
increase in intracellular Ca2+ concentration ([Ca2+]i) in about 30% of DRG neurons cultured 
from 2-3 week old mice (Fig. 4.12c, Fig. 4.13). The remaining 70% of the DRG neurons did 
not respond to AzCA-4 but still responded to a high potassium (Hi-K+) solution (100 mM) 
(Fig. 4.12d). The percentage of AzCA-4 responding neurons was consistent with the 
percentage of TRPV1 containing DRG neurons at this stage of mouse development 





Figure 4.12 | AzCA-4 enabled optical control over cultured wt DRG neurons. (a) After the 
bath application of AzCA-4 (200 nM), neuronal currents could be modulated by 
monochromatic irradiation. When clamped at a holding potential of –60 mV, an inward current 
was observed upon irradiation with λ = 365 nm and this effect could be reversed with 
irradiation at λ = 460 nm. (b) When clamped at a current of 0 pA and after the application of 
AzCA-4 (200 nM), the neuronal membrane potential could be controlled. AP firing could be 
induced by irradiation at λ = 365 nm, and halted with λ = 460 nm. This process could be 
repeated over many cycles. (c) Intracellular Ca2+ imaging showed that AzCA-4 (100 nM) 
significantly increased the [Ca2+]i in TRPV1-positive neurons only after irradiation at 
λ = 365 nm (5 s). (d) Cells which did not respond to AzCA-4 showed no increase in [Ca2+]i 
after the bath application of AzCA-4 and a UV pulse (6 pulses, 100 nM, 5 s at λ = 365 nm). 
These cells still responded to a Hi-K+ solution (100 mM), suggesting that they did not possess 
TRPV1. Error bars were calculated as ±s.e.m. 




Figure 4.13 | AzCA-4 caused a significant increase in [Ca2+]i after a UV pulse in DRG 
neurons. (a) A baseline fluorescence image was recorded before the application of any 
compound. (b) A fluorescence image was then recorded 45 s after the application of AzCA-4 
(100 nM, bath application) and directly before UV irradiation. (c) A fluorescence image was 
then recorded immediately after a 5 s flash of λ = 365 nm irradiation. A marked increase in 






4.2.6 – AzCA-4 is selective for TRPV1 sensitive neurons in the DRG 
TRPV1 knockout mutant mice (Trpv1-/-) have proven to be an excellent negative control to 
study the functional aspects of TRPV1 and the role of CAP-sensitive afferent neurons in the 
mammalian nervous system81. We utilized this mouse line to assay the selectivity of AzCA-4 
in DRG neurons. As expected, Ca2+ imaging in Trpv1-/- mouse DRG neurons showed no neural 
activity in response to AzCA-4 (300 nM) or CAP (300 nM). Control experiments showed that 
these neurons still responded to menthol (100 µM, data not shown), adenosine 5’-triphosphate 
(ATP, 20 µM) and Hi-K+ (100 mM) solutions (Fig. 4.14). Combined, these results indicate that 
AzCA-4 acted solely on TRPV1-positive neurons in the DRG. 
 
Figure 4.14 | AzCA-4 was selective for TRPV1-positive DRG neurons. Intracellular Ca2+ 
imaging revealed that AzCA-4 had no action in cultured mouse Trpv1 knockout mutant 
(Trpv1-/-) DRG neurons. (a) No fluorescence increase was observed upon application of 
AzCA-4 (300 nM) and a UV pulse (λ = 365 nm, 5 s) or CAP (300 nM). The neurons were still 
responsive to ATP (20 µM) and a Hi-K+ (100 mM) solution (n = 11). (b) A baseline 
fluorescence image was recorded before the application of any compound. (c) Another image 
was then recorded after the application of AzCA-4 (300 nM, bath application) and a UV pulse 
(λ = 365 nm, 5 s). No response was observed in any of the DRG neurons. (d) After application 
of a Hi-K+ solution (100 mM), a large increase in [Ca2+]i was observed. 
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4.2.7 – Optical control of C-fiber nociceptors 
We next evaluated the effects of AzCA-4 on heat sensitive C-fiber nociceptors (C-MH) in the 
ex vivo skin nerve preparation of the saphenous nerve. In wt mice, 19 out of 35 C-MH 
responded to AzCA-4 photoswitching compared to none of the 11 C-MH examined in Trpv1-
/- mice (P < 0.001, χ2 test; Fig. 4.15a). We compared the activation of AzCA-4 to that of CAP 
on C-MH in terms of the latency time to the first AP spike, as well as the AP discharge rates. 
Peak discharge rates during photostimulation with λ = 365 nm surged rapidly to 9.6 spikes/s 
and lasted on average 11.0±6.9 s (Fig. 4.15b). The average peak discharge rates of C-MH 
due to AzCA-4 photoswitching where not significantly different from CAP stimulation 
(Fig. 4.15c). However, the mean latency time to the first AP spike upon irradiation with 
λ = 365 nm in the presence of AzCA-4 was significantly shorter (1.9±0.5 s; mean ± SEM) 
when compared to the latencies to the first spike after CAP application (9.5±3.5 s) (Fig. 4.15d, 
Mann-Whitney Test, P < 0.05). The discharges of C-MH in response to AzCA-4 were usually 
transient and adapted during the 20 s photostimulation period. These responses were 
completely reproducible after a 5 min recovery interval, during which AzCA-4 was kept on the 
receptive field with no signs of desensitization (Fig. 4.15e). Therefore, the photoswitching of 
AzCA-4 could selectively activate TRPV1 receptors on the peripheral terminals of cutaneous 
C-MH to a similar magnitude as CAP. Advantageously, AzCA-4 had the ability to trigger a 






Figure 4.15 | Optical activation of TRPV1 in C-fiber nociceptors.  (a) A typical sample 
trace showing the activation of a heat sensitive C-fiber nociceptor (C-MH) by optical switching 
of AzCA-4 (1 µM) with λ = 365 nm light, and CAP (1 µM) application in wt mice. No 
photostimulation occurred in Trpv1-/- mice. (b,c) The average AP spiking rate (red) and the 
spiking rate for individual C-MHs (grey) in response to photostimulation in the presence of 
AzCA-4 (1 µM, n = 19), and activation by CAP (1 µM, n = 6). (d) The latencies to the 
occurrence of the first AP spikes after photostimulation and after the application of CAP 
(*P < 0.05, Mann-Whitney Test). (e) A second photostimulation in the presence of AzCA-4 by 
λ = 460 nm light can be triggered 5 min after the first photostimulation; the data is represented 
as the mean and SD of the number of spikes per 1 s bins of all activated C-MH.  
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4.2.8 – Serotonin and bradykinin sensitize DRG neurons to AzCA-4 
TRPV1 mediated hyperalgesia is a complex process which underlies inflammatory pain70,82. 
At sites of tissue injury, a number of chemical agents are released which cause an 
inflammatory response resulting in an increased thermal pain sensation in response to 
normally non-painful stimuli. Several GPCRs mediate TRPV1 sensitization82,83. Bradykinin 
(BK)- and serotonin (5-HT)-triggered GPCR cascades are able to decrease the threshold for 
TRPV1 activation and increase the number of receptors at the cell surface56,82,84,85. 
 We utilized intracellular Ca2+ imaging in cultured wt mouse DRG neurons to determine 
whether these endogenous inflammatory agents still sensitized TRPV1 towards AzCA-4. Our 
experiments showed that TRPV1 became sensitized to AzCA-4 (200 nM) after the application 
of both BK (200 nM) and 5-HT (100 µM) (Fig. 4.16a,b). After 5 pulses of AzCA-4 and UV 
irradiation, a steady-state of TRPV1 desensitization was reached and the cells were washed 
with the sensitizing agent for 5 min (Fig. 4.16a). In both cases, a final pulse of AzCA-4 and 
UV irradiation resulted in increased [Ca2+]i when compared to the previous pulse. Experiments 
with both inflammatory agents produced similar results to those achieved when using CAP as 
the channel agonist (Fig. 4.16b, Fig. 4.17). These results suggest that AzCA-4 could be used 






Figure 4.16 | Serotonin and bradykinin sensitized TRPV1 to AzCA-4. Intracellular Ca2+ 
imaging showed that both BK and 5-HT sensitized TRPV1 to CAP (100 nM), and AzCA-4 
(200 nM) with UV irradiation (λ = 365 nm, 5 s) in cultured wt DRG neurons. (a) After the 
application of BK (200 nM), an increased intensity and duration of Ca2+ influx was observed 
upon application of AzCA-4 with UV irradiation when compared to the previous pulse. The 
neurons responded to a Hi-K+ solution (100 mM). Shown here are 5 representative traces 
(grey) and average ∆F/F value (red). (b) TRPV1 sensitization experiments in wt mouse DRG 
neurons (grey) and the Trpv1Cre/GCaMP3 mouse line (orange). The results were plotted as the 
ratio of peak heights for Peak 6/Peak 5 for the wt mouse as: CAP with no sensitization agent 
(n = 520), CAP with BK (n = 210), CAP with 5-HT (n = 175), AzCA-4 with no sensitizing agent 
(n = 36), AzCA-4 with BK (n = 15), and AzCA-4 with 5-HT (n = 12). For the Trpv1Cre/GCaMP3 
mouse line the results are plotted for: AzCA-4 with BK (n = 28) and AzCA-4 with 5-HT (n = 10). 
Error bars were calculated as ±s.e.m. 
 
Figure 4.17 | Bradykinin and serotonin sensitized TRPV1 to capsaicin. Intracellular Ca2+ 
imaging showed that cultured wild type mouse DRG neurons were sensitized towards CAP 
(100 nM) by both (a) serotonin (5-HT, 100 µM, n = 175) and (b) bradykinin (BK, 200 nM, 
n = 210). The cells were pulsed 5 times with CAP, followed by a 5 min wash with the 
sensitizing agent. A final CAP pulse showed a marked increase in both intensity and duration 
of the fluorescence increase in CAP-responding DRG neurons when compared with the 
previous pulse. The neurons still responded to a Hi-K+ solution (100 mM).  
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4.2.9 – AzCA-4 is compatible with genetic tools  
Genetically encoded [Ca2+]i indicators, such as GCaMP386, have proven very useful for the 
study of neuronal activity in vitro and in vivo. We therefore tested the ability of AzCA-4 to work 
in combination with this genetic tool. We crossed a mouse line that expresses the 
Cre-recombinase under the promoter of TRPV187, with a reporter mouse line that expresses 
GCaMP3 in a Cre-dependent manner (Trpv1Cre/GCaMP3). Since the majority of DRG neurons 
express TRPV1 at embryonic stage E14.580, we observed that 90% of the DRG neurons in 
culture showed a faint basal fluorescence, confirming that recombination had occurred in most 
neurons at an earlier developmental stage.  
However, upon application of CAP or AzCA-4 alongside UV irradiation, only 30% of 
the neurons showed a Ca2+ dependent increase in fluorescence. This confirmed not only the 
correct function and localization of GCaMP3 in TRPV1-positive DRG neurons, but also that 
this small molecular photoswitch, AzCA-4, can be used in combination with a genetic tool. 
To further confirm the applicability of AzCA-4 and the use of genetically encoded 
[Ca2+]i indicators to address physiologically relevant issues, we repeated the sensitization 
experiments on the Trpv1Cre/GCaMP3 mouse line (Fig. 4.16b, orange). These results again 
confirmed that TRPV1 could be sensitized to AzCA-4 by BK or 5-HT, even in the 
Trpv1Cre/GCaMP3 mouse line. 
 
4.2.10 – QX-314 can be selectively transported into DRG neurons 
QX-314 is a permanently charged lidocaine derivative that blocks sodium channels from the 
intracellular side but is unable to penetrate the plasma membrane due to its charged nature88. 
It has been shown that QX-314, and its photoswitchable derivative QAQ43, could be shuttled 
into cells via TRPV1 when co-applied with CAP to open the channel89. We hypothesized that 
[Ca2+]i build-up is not only caused by Ca2+-influx through TRPV1, but is a consequence of AP 
firing leading to Ca2+ release from intracellular stores. We showed AzCA-4 (200 nM) in 
combination with λ = 365 nm irradiation, opened TRPV1 and allowed QX-314 to enter TRPV1-
positive neurons in the DRG. The cells were first washed with a Hi-K+ solution (40 mM) 
causing massive electrical activity. After the cells recovered, 4 pulses of AzCA-4 (200 nM, 5 s 
at λ = 365 nm) reached a steady state of TRPV1 desensitization. Next, AzCA-4 was co-




Hi-K+ solution. By comparing the peak heights of the first and final Hi-K+ pulses (HK1 and HK2, 
respectively), we observed that the cells which were responsive to AzCA-4 showed a lower 
HK2/HK1 ratio when compared to cells which did not respond to AzCA-4 (Fig. 4.18). These 
results indicate that in combination with AzCA-4, TRPV1 could be used as an import channel 




Figure 4.18 | QX-314 could be shuttled into TRPV1-positive DRG neurons using AzCA-4. 
After the co-application of AzCA-4 (200 nM) and QX-314 (5 mM), the peak heights of the Ca2+ 
signals of the Hi-K+ (40 mM) pulses before (HK1), and after (HK2) drug application were 
compared. The results were plotted as the peak-height ratio of two pulses, HK2/HK1, 
calculated for both AzCA-4 responding, and AzCA-4 non-responding neurons. Error bars 
were calculated as ±s.e.m. 
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4.2.11 – Synthesis and characterization of a red-shifted AzCA derivative 
Azobenzenes can be synthetically modified to allow isomerization between the trans- and cis-
states with longer-wavelength irradiation90. This lower-energy light is less damaging to cells 
and allows deeper penetration into tissue. Tetra-ortho-chlorination of the azobenzene core 
enables photoswitching between the trans- and cis-states with violet/blue and green light, 
respectively91. This bioisosteric modification eliminates the need for UV light during 
photostimulation, and causes a relatively minimal change to the azobenzene structure. 
Recently, our lab developed a method to synthesize tetra-ortho-chloro azobenzenes via late-
stage functionalization of an already existing azobenzene core37. This method utilizes a Pd-
catalyzed C-H activation in AcOH, with N-chlorosuccinimide as a chlorine source. We applied 
this method to synthesize the first red-shifted fatty acid, red-FAAzo-4 (Fig. 4.19a). Sequential 
attachment of the vanilloid headgroup afforded red-AzCA-4 in high yield. The activation 
wavelength of red-AzCA-4 was significantly shifted by 200 nm towards the visible range, as 
it could be isomerized to its active cis-form with green light. The maximum cis-content was 
achieved on irradiation at λ = 560 nm green light, and maximum trans-content under 
λ = 400 nm violet light (Fig 4.19b). 
 
 
Figure 4.19 | Synthesis and characterization of a red-shifted AzCA. (a) The tetra-ortho 
chlorinated photoswitch red-AzCA-4 was synthesized from the red-shifted FA, red-FAAzo-4. 
(b) The UV-Vis absorption spectra of red-AzCA-4 in its dark-adapted, violet-adapted (λ = 400 
nm) and green-adapted (λ = 560 nm) states. The greatest trans-content was achieved under 







4.2.12 – Red-shifted optical control of TRPV1 with tetra-ortho chlorinated azobenzenes 
We then tested the utility of red-AzCA-4 as a photoswitchable vanilloid in HEK293T cells 
expressing TRPV1-YFP. Like its parent compound, red-AzCA-4 displayed an increased 
efficacy towards the ion channel when isomerized to its cis-configuration on irradiation with 
green light. Whole-cell voltage clamp experiments revealed an increased current in the 
presence of cis-red-AzCA-4 when compared to trans-red-AzCA-4 (Fig. 4.20a). The 
application of red-AzCA-4 (500 nM) under λ = 400 nm irradiation caused only a small inward 
current when the cell was held at −60 mV, which could be greatly potentiated by green light 
(Fig. 4.20b). As previously described for other tetra-ortho-chloro substituted azobenzene 
derivatives91, red-AzCA-4 could be photoactivated with UV-A light as well (Fig. 4.20c,d). 
These results demonstrate that the tetra-ortho-chlorination of AzCA-4 did not hinder its utility 
as a photoswitchable TRPV1-agonist, and will facilitate the compounds use in more complex 
tissues by eliminating the need for high-energy UV-A light for photoactivation. 
  




Figure 4.20 | red-AzCA-4 enables control of TRPV1 with green light. In HEK293T cells 
transiently expressing TRPV1-YFP: (a) the current-voltage plot showed that red-AzCA-4 
(500 nM) was a more potent TRPV1-agonist in its cis-configuration (n = 3), displayed as the 
change in current from the baseline holding potential (−60 mV, pA/pF) as a function of the IV 
holding potential (mV). (b) Application of red-AzCA-4 (500 nM) under violet light produced 
only a small inward current, which was reversibly potentiated with green light. (c) TRPV1 could 
be repeatedly cycled ON and OFF with UV-A (λ = 350 nm)/green (λ = 560 nm) and violet light 
(λ = 400 nm), respectively, as was also shown by (d) an action spectrum. Holding potential 






4.3 – Discussion 
In this study, we present eight photoswitchable FAs, the FAAzos. We expect that these 
lipophilic modules will allow us to place a variety of lipid-modulated biological targets under 
photopharmacological control. The FAAzos are FAs mimetics, resembling in particular highly 
unsaturated FAs like AA. These compounds could be used as molecular building blocks for 
the construction of more complicated photolipids which could facilitate the optical control of a 
wide range of ion channels, GPCRs, and enzymes associated with FA signaling. 
 We hypothesized that an azobenzene photoswitch would be best suited towards 
integration into the FA backbone, as its hydrophobic nature may cause only a minimal 
disruption to the properties of a natural aliphatic chain. The FAAzos allow the position of the 
switch to be fine-tuned in order to complement SARs between the ligand and its target. As a 
first installment illustrating this concept, we showed that the FAAzos could be incorporated 
into other photolipids through a simple amide coupling reaction. In HEK293T cells, three 
AzCAs stood out as the most promising candidates to enable the optical control of TRPV1 
and showed significant, light-dependent efficacy at concentrations as low as 100 nM. All three 
compounds were more potent in their cis-configuration. Due to the structural similarities 
between the AzCAs and other vanilloid TRPV1 agonists, we presume that the AzCAs act on 
the same vanilloid binding site as CAP, olvanil and arvanil. This is further supported by the 
requirement of the vanilloid headgroup, as was shown by the inactivity of FAAzo-2-4. Channel 
activation by AzCA-4 can also be completely blocked by the application of CPZ, a known 
competitive antagonist for CAP, suggesting a common binding site and mode of activation. 
 We then demonstrated that AzCA-4 was a powerful modulator of DRG neurons in wt 
mice and the Trpv1Cre/GCaMP3 mouse line. Control experiments in untransfected HEK293T cells 
and Trpv1-/- mice showed no response to AzCA-4, even upon light stimulation. These results 
rule out the possibility of action through off-target mechanisms. This characteristic is essential 
for the study of signal transduction in the nociceptive neurons involved in inflammatory pain. 
To this end, we envision that AzCA-4 could be used to study TRPV1-mediated hyperalgesia 
and the physiological processes involved with the inflammatory state that occurs at sites of 
tissue injury. We showed that application of components of the so-called “inflammatory soup”, 
such as BK or 5-HT, could sensitize TRPV1 to AzCA-4 in DRG neurons. Furthermore, we 
proved that AzCA-4 could be used in conjunction with genetic tools such as the GCaMP3 
[Ca2+]i indicator selectively expressed in TRPV1-positive mouse neurons.  
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Importantly, AzCA-4 allowed for greater temporal control over TRPV1 than that which 
can be achieved by other small molecule agonists such as CAP, olvanil and arvanil. By 
working at an optimized concentration, AzCA-4 showed no activity towards TRPV1 in its 
trans-configuration, but rapid TRPV1 activation was observed when it was isomerized to its 
cis-configuration. This ON and OFF effect became even more pronounced in neuronal 
systems when the non-linear, “all or nothing,” nature of the AP took effect. Previous studies 
have suggested that the rate of TRPV1 activation determines the balance between agonist 
potency and pungency42-45. Molecular weight and lipophilicity normally define the 
pharmacodynamics of TRPV1 agonists92,93. In the case of AzCAs, light provides another level 
of control. We showed that the magnitude and rate of cellular activation could be precisely 
tuned by adjusting the ON wavelength between λ = 350-390 nm. Therefore, AzCAs could 
provide a platform for the further understanding of hyperalgesia and could lead to the 
development of new anesthetics. 
 When using CAP to stimulate C-fibers in the saphenous nerve, a relatively slow 
increase in AP firing was observed. This effect was likely caused by the time required for CAP 
to diffuse through the skin and plasma membrane to reach the vanilloid binding site96–98. We 
showed that AzCA-4 could be applied to neurons its dark-adapted, relatively inactive 
configuration. Upon isomerization, TRPV1 was activated and AP firing was immediately 
observed. It is this characteristic which makes AzCA-4 a useful tool for the study of 
nociception, a process that relies on the rapid transmission of noxious stimuli from the 
periphery towards the coordinating centers of the central nervous system. AzCA-4 also 
possesses significant advantages when compared to other small molecules that have been 
used to place TRPV1 under the control of light. Caged CAP is a useful tool that has increased 
the level of control with which we are able to activate TRPV199. However, compound uncaging 
and TRPV1 activation is a non-reversible, one-shot process. Repeated activation by uncaging 
relies on fast acting transporters or deactivating enzymes to clear the synapse of the free 
ligand24. The fact that CAP and its analogs exhibit long-lasting effects suggests that they do 
not undergo transporter-mediated reuptake or significant enzymatic hydrolysis. These aspects 
are circumvented by the use of AzCA-4, which allows for successive rounds of 
activation/inactivation without the requirement for washout of the drug. Previously, we showed 
that photoswitchable TRPV1 antagonists can optically control the activity of a constitutively 
active agonist upon photoswitching74. In comparison, AzCA-4 greatly simplifies this system 
and is capable of activating TRPV1 directly. This permits the optical control of neuronal 




in the dark, therefore a more rapid and reproducible initiation of activity can be achieved after 
it has distributed itself uniformly within more complex tissues. 
 We also demonstrated that the tetra-ortho-chlorination of the FAAzos is a useful 
method to red-shift their activation wavelength. In this case, the ortho-hydrogen atoms on the 
azobenzene are substituted with chlorine atoms, enabling isomerization to the cis-state with 
longer-wavelength irradiation. In this case, this bioisosteric modification did not affect the 
activity of the pharmacophore. red-AzCA-4 possessed similar potency to the parent 
compound AzCA-4. This suggests that TRPV1 efficacy is generally quite tolerant of 
modifications in the hydrophobic portion of the molecule. We envision that this new red-shifted 
tool will enable the optical control of TRPV1 in more complex tissues, and facilitate in vivo 
applications. 
 In conclusion, this study provides the first application of photopharmacology to lipid 
signaling. Given the ubiquitous distribution of FA derivatives at all levels of nature, we envision 
that the FAAzos and their conjugates will emerge as broadly applicable tools for the optical 
control of biological functions which rely on protein-lipid interactions. 
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4.4 – Supporting information 
4.4.1 – Whole-cell electrophysiology in HEK293T cells 
HEK293T cells (obtained from the Leibniz-Institute DSMZ: #305) were incubated at 37 °C 
(10% CO2) in Dulbecco´s Modified Eagle Medium (DMEM) + 10% fetal bovine serum (FBS) 
and were split at 80-90% confluency. For cell detachment, the medium was removed and the 
cells were washed with Ca2+-free PBS buffer and treated with trypsin for 2 min at 37 °C. The 
detached cells were diluted in growth medium and plated on acid-etched coverslips coated 
with poly-L-lysine in a 24-well plate. 50,000 cells were added to each well in 500 µL standard 
growth medium along with the DNA (per coverslip: 500 ng TRPV1-YFP77) and JetPRIME® 
transfection reagents according to the manufacturer's instructions (per coverslip: 50 µL 
JetPRIME® buffer, 0.5 µL JetPRIME® transfection reagent). The transfection medium was 
exchanged for normal growth media 4 h after transfection and electrophysiological 
experiments were carried out 20-40 h later. Whole cell patch clamp experiments were 
performed using a standard electrophysiology setup equipped with a HEKA Patch Clamp 
EPC10 USB amplifier and PatchMaster software (HEKA Electronik). Micropipettes were 
generated from “Science Products GB200-F-8P with filament” pipettes using a Narishige 
PC-10 vertical puller. The patch pipette resistance varied between 5-9 MΩ. The bath solution 
contained: Solution A (in mM): 150 NaCl, 6.0 CsCl, 1.0 MgCl2, 1.5 CaCl2, 10 HEPES, 
10 D-glucose (adjusted to pH 7.4 with 3 M NaOH)100 or Solution B (in mM): 140 NaCl, 5 KCl, 
5 HEPES, 1 MgCl, 5 D-glucose (adjusted to pH 7.4 with 3 M NaOH). The pipette solution 
contained: Solution A' (in mM): 150 NaCl, 3 MgCl2, 10 HEPES, 5 EGTA (adjusted to pH 7.2 
with 3M NaOH) or solution B' (in mM): 100 K-gluconate, 40 KCl, 5 HEPES, 5 MgATP, 1 MgCl2 
(adjusted to pH 7.2 with 1M KOH). The cells were first visualized to contain TRPV1-YFP by 
irradiation at λ = 480 nm using a Polychrome V (Till Photonics) monochromator. All cells had 
a leak current between –15 to –300 pA upon break-in at –60 mV. All voltage clamp 
measurements were carried out at a holding potential of –60 mV. The cells were held at 0 pA 
for current clamp measurements. The compounds were applied by puff pipette using a 
“Toohey Spritzer pressure system IIe” at 25 psi. The puff pipette resistance varied between 





4.4.2 – Determination of AzCA photoswitching properties  
The photoswitching properties of the prepared compounds were assessed using whole-cell 
voltage clamp electrophysiology in HEK293T cells transiently expressing TRPV1-YFP77. The 
compounds were dissolved as stock solutions in DMSO (2-6 mM) and then diluted into 
warmed extracellular solution at a concentration of 1 µM. The cell was held at –60 mV and 
voltage ramps (–100 to +100 mV over 5 s) were applied under both λ = 450 nm and 
λ = 350 nm irradiation. The AzCA-derivative (1 µM) was then constantly applied (puff pipette 
application) while switching between the two wavelengths until a steady state of 
activity/desensitization was observed upon photoswitching (Fig. 4.6a). The voltage ramps 
were applied again under each wavelength and the current change (∆I) between the baseline 
(–60 mV) and the ramp maximum (+100 mV) was recorded (Fig. 4.6b). ∆I(350 nm) was 
normalized to ∆I(450 nm) and this potentiation factor was averaged over multiple cells and 
plotted in Fig. 4.5b. TRPV1 activation and inactivation kinetics were determined by 
exponential curve fitting in Igor Pro. 
 
4.4.3 – Dorsal root ganglion neuronal culture 
Dorsal root ganglia (DRG) were quickly dissected, collected in ice-cold DRG medium and 
digested in 1 mg/mL Collagenase IV (Gibco) at 37 °C for 50 min to dissociate the tissue 
followed by incubation in 0.05% trypsin (Gibco) in phosphate-buffered saline (PBS) at 37 °C 
for 15 min. The trypsin was removed and cells were re-suspended in 1 mL of DRG medium. 
After gentle trituration, the DRGs were loaded onto a 2 mL BSA pillow and centrifuged at 
250 g for 10 min to separate the myelin and debris. The resulting cell pellet was suspended 
in 50 µL fresh DRG medium and plated onto poly-D-lysine (100 µg/mL) and laminin (10 µg/mL) 
coated coverslips. The cells were flooded with medium 30 min after plating. 
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4.4.4 – Whole-cell electrophysiology in cultured DRG neurons 
Electrophysiological recordings of DRG neurons from 14-21 days old mice were performed 
using a HEKA 10 amplifier (HEKA instrument) and an ITC Analog Digital Converter (HEKA) 
in whole-cell voltage clamp or current clamp configuration. The currents were filtered with a 
built-in 5 kHz 8-pole Bessel filter and digitized at 50 kHz. The currents were analyzed using 
Clampfit 10.3 (Molecular Devices) and graphs were plotted in Prism 5 (Graphpad). 
Experiments were performed 1-3 days after plating. The Trpv1Cre and the GCaMP3 reporter 
mice were acquired from Jackson laboratory. DRG neurons were prepared for imaging from 
25 wk old Trpv1Cre/GCaMP3 mice. The extracellular solution contained in mM: 150 NaCl, 5 KCl, 
10 HEPES, 10 D-glucose, 2 CaCl2, 1 MgCl2. The intracellular solution contained (values in 
mM): 130 KCl, 10 HEPES, 10 EGTA, 1 CaCl2, 1 MgCl2, 2 MgATP, 1 NaGTP, 4 NaCl, 
4 PhosphoCreatine.   
Thick walled electrodes (Harvard apparatus, 1.17x0.87 mm, external and internal 
diameter respectively) were pulled with a Sutter P-197 puller to a final resistance of 3-5 MΩ. 
After the break-through, the intracellular solution was dialyzed with the intracellular medium 
for at least 1 min prior to the beginning of the recordings. Series resistance compensation 
reached values between 70-90%. Neurons were selected to have a leak current less 
than −100 pA upon break-in at –60 mV. All experimental procedures were carried out in 
accordance with the State of Berlin Animal Welfare requirements and were approved by this 
authority. 
 
4.4.5 – Intracellular Ca2+ imaging 
DRG neurons plated on a 5 mm glass coverslip were placed in a recording chamber of 300 
µL volume (Harvard Apparatus) and were continuously perfused with extracellular solution at 
a rate of 2 mL/min. Wild type (wt) neurons cells were loaded with Cal-520 (5 µM, AAT-
Bioquest) Ca2+ dye for 1 h at 37 °C in the presence of pluronic acid 0.02% dissolved in Ringer 
solution (values in mM): 140 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2, 10 HEPES and 10 D-glucose, 
adjusted to pH 7.4. CAP (100 nM, Tocris) was dissolved in extracellular solution from a stock 
concentration of 10 mM in ethanol. Fluorescent images were acquired with Metafluor Software 
(Molecular Devices) and analyzed in Clampfit. All experiments were performed at room 
temperature. The dye excitation was performed at λ = 480 nm. The results were plotted as 




4.4.6 – Ex vivo skin nerve preparation 
*Note: ex vivo skin nerve experiments were performed by Dr. Med. Rabih Moshourab (MDC 
Berlin) and are included here for clarity. 
 
The skin-nerve preparation was used as previously described to record from single primary 
afferents101. Mice were sacrificed with CO2 inhalation for 2-4 min followed by cervical 
dislocation. The saphenous nerve and the shaved skin of the hind limb were dissected free 
and placed in an organ bath at 32 °C. The chamber was perfused with a synthetic interstitial 
fluid (SIF buffer) the composed of (in mM): 123 NaCl; 3.5 KCl; 0.7 MgSO4; 1.7 NaH2PO4; 
2.0 CaCl2; 9.5 Na-gluconate; 5.5 D-glucose; 7.5 sucrose; and 10 HEPES, at a pH of 7.4. The 
skin was placed with the corium side up in the organ bath for pharmacological application to 
the receptive fields of single sensory units. The saphenous nerve was placed in an adjacent 
chamber on a mirror and under microscopy, fine filaments were teased from the nerve and 
placed on the recording electrode. Electrical isolation was achieved with mineral oil. Signals 
from the filaments were amplified (Neurolog System, Digitimer Ltd) and sampled using a data 
acquisition system (PowerLab 4.0, ADInstruments). The receptive fields of individual 
mechanically sensitive C-fiber units were identified by manually probing the skin with the 
blunted tip of a glass probe. Their conduction velocities (calculated by dividing conduction 
distance over electrical latency for the first spike) were determined using an electrical 
stimulator (1 MΩ).  All C-fibers studied were identified by mechanical probing and were heat 
sensitive (C-MH). The conduction velocities were in the C-fiber range (< 1 m/s). The thermal 
sensitivity of identified C-fibers was tested with a computer controlled peltier device (3x5 mm, 
Yale University medical school, Medical Instruments, New Haven, USA). A heat ramp was 
delivered from 32 to 48 °C at a rate of 1 °C/s to the mechanically localized receptive fields of 
single C-fibers. The receptive fields of heat sensitive C-fibers were isolated with a metal 
cylinder ring (5 mm inner diameter, 10 mm in height, and 1.44 g weight) for the administration 
of the drugs (AzCA-4 or CAP). The metal ring was tested for leakage before drug application. 
A stock solution of AzCA-4 was prepared in dimethyl sulfoxide and diluted in SIF buffer. 
100 µL of a 1 µM AzCA-4 solution dissolved in SIF buffer was applied into the ring. The 
pharmacological testing protocol with AzCA-4 had 4 distinct successive phases: 1) 60 s 
recording time prior to the application of AzCA-4; 2) 60 s recording after application of 
AzCA-4; 3) 20 s of recording during photostimulation of AzCA-4 with LED light, λ = 365 nm 
(Mic-LED-365, Prizmatix); 4) 20 s of recording during photoinhibition of AzCA-4 with LED light, 
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λ = 460 nm (UHP-LED-460, Prizmatix). AzCA-4 was kept in the ring for 300 s and a second 
photostimulation with LED light λ = 360 nm for 20 s was applied to test the reproducibility of 
the initial responses. 100 µL of CAP (1 µM, Sigma) were administered onto the receptive field 
of another set of heat sensitive C-fibers for 20 s before wash out. Recordings were obtained 
for 1 min prior-to, and 2 min after CAP administration. Spikes were discriminated off-line with 
the spike histogram extension of the software. Data was obtained from 6 skin-nerve 
preparations (2 Trpv1-/- and 4 wt C57Bl/6N mice).  All experimental procedures were carried 
out in accordance with the State of Berlin Animal Welfare requirements and were approved 
by this authority. 
 
4.4.7 – Compound switching 
Compound switching for electrophysiology in HEK293T cells was achieved using a 
Polychrome V (Till Photonics) monochromator and the light beam was guided via a fiber-optic 
cable through the microscope objective and operated by the amplifier and PatchMaster 
software (HEKA Electronik). 
Compound switching for electrophysiology in DRG neurons was achieved using a 
Prizmatix Mic-LED-365 high power UV LED light source for illumination at λ = 365 nm, and 
the Prizmatix UHP-Mic-LED-460 ultra-high power LED light source for illumination 
at λ = 460 nm. The light beam was guided by a fiber-optic cable and pointed directly towards 
the cells from above at an angle of about 45 ° from the side. The distance between the end of 
the cable and the cells was no greater than 2 cm. UV illumination during intracellular Ca2+ 
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4.4.8 – Compound synthesis and characterization 
 
 
Figure 4.21 | Photolipid numbering system. Numbering of the atoms in the lipid chains was 
set in relation to the carboxylic acid, which was labelled atom #1, and then increasing towards 




Figure 4.22 | Chemical synthesis of AzCA-1. 




Figure 4.23 | Chemical synthesis of AzCA-2. 
 
 
Figure 4.24 | Chemical synthesis of AzCA-3. 
 
 
Figure 4.25 | Chemical synthesis of AzCA-4. 








Figure 4.27 | Chemical synthesis of AzCA-6. 
 




Figure 4.28 | Chemical synthesis of AzCA-7. 
 
 
Figure 4.29 | Chemical synthesis of AzCA-8. 
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4.4.8.1 – 4-((4-Heptylphenyl)diazenyl)benzoic acid (FAAzo-1) 
 
A solution of methyl 4-aminobenzoate (0.30 g, 2.0 mmol, 1.0 equiv.) in CH2Cl2 (20 mL) was 
treated with a solution of Oxone® (1.52 g, 5 mmol, 2.5 equiv.) in H2O (20 mL) at 23 °C. The 
resulting biphasic reaction mixture was stirred vigorously at room temperature overnight or 
until all the aniline was consumed, as observed by TLC analysis. Subsequently, the phases 
were separated and the aqueous phase was extracted with CH2Cl2 (2x20 mL). The combined 
organic extracts were washed with H2O (2x30 mL) and to the washed organic solution was 
then added 4-heptylaniline (0.38 g, 2.0 mmol, 1.0 equiv.) followed by AcOH (20 mL). The 
CH2Cl2 was removed under reduced pressure and the solution was left to stir overnight. The 
reaction mixture was then concentrated under reduced pressure and the residue was 
dissolved in CH2Cl2 (200 mL). The organic phase was washed with a saturated aqueous 
NaHCO3 solution (2x50 mL), followed by H2O (3x75 mL). The washed organic phase was 
dried over anhydrous Na2SO4 and then filtered. The filtrate was then concentrated under 
reduced pressure. The residue was dissolved in THF (18 mL) and MeOH (18 mL). This 
solution was treated with a 1 M aqueous lithium hydroxide solution (9 mL), and this solution 
was stirred for 2 h. The organic solvent was then removed under reduced pressure. The 
mixture was then acidified with a 2 M aqueous hydrochloric acid solution, and extracted with 
EtOAc (2x30 mL). The combined organic phases were washed with H2O (2x40 mL), the 
washed solution was dried over anhydrous Na2SO4 and the dried solution was filtered. The 
filtrate was then concentrated under reduced pressure, and after being pre-absorbed onto 
SiO2 (5 g, loaded from THF), the residue was purified by flash silica gel chromatography (50 g 
SiO2, 99:1 CH2Cl2:H2O) to yield 4-((4-heptylphenyl)diazenyl)benzoic acid (FAAzo-1, 
450 mg, 67%) as a red solid. 
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TLC (CH2Cl2): Rf = 0.35 (cis), 0.52 (trans).  
1H NMR (D6-DMSO, 400 MHz, 25 °C): δ 8.13 (d, 2H, H3a,b, J3,4 = 8.6 Hz), 7.94 (d, 2H, H4a,b, 
J4,3 = 8.6 Hz), 7.86 (d, 2H, H9a,b, J9,10 = 8.4 Hz), 7.43 (d, 2H, H10a,b, J10,9 = 8.4 Hz), 2.66 (m, 
2H, H12a,b), 1.64-1.54 (m, 2H, H13a,b), 1.31-1.19 (m, 8H, H14a,b, H15a,b, H16a,b, H17a,b), 0.84 (t, 
3H, H18a,b,c, J18,17 = 6.9 Hz).  
13C NMR (D6-DMSO, 101 MHz, 25 °C): δ 166.8 (C1), 154.4 (C5), 150.2 (C8), 147.4 (C11), 
132.6 (C2), 130.6 (C3a,b), 129.5 (C10a,b), 123.0 (C9a,b), 122.5 (C4a,b), 35.1 (C12), 31.3 (Calk), 
30.8 (C13), 28.7 (Calk), 28.6 (Calk), 22.1 (Calk), 14.0 (C18).  
IR (neat, ATR): ṽ = 2952, 2920, 2850, 2662, 2543, 1678, 1601, 1582, 1501, 1424, 1289, 
1221, 1143, 1125, 1111, 1098, 1011, 944, 868, 840, 805, 755, 722, 690, 672.  
HRMS (EI+): m/z calcd. for [C20H24N2O2]+: 324.1838, found: 324.1834 ([M-e-]+). 
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A solution of 4-((4-heptylphenyl)diazenyl)benzoic acid (FAAzo-1, 25 mg, 77 µmol, 
1.0 equiv.)  and TBTU (25 mg, 77 µmol, 1.0 equiv.) in EtOAc (3.0 mL) was treated with NEt3 
(24 mg, 3.0 equiv.) under an argon atmosphere at room temperature. After 1 h, vanillylamine 
hydrochloride (29 mg, 0.15 mmol, 2.0 equiv.) was added and stirring was continued at room 
temperature for 2 h. The solution was then diluted with EtOAc (15 mL) and washed with H2O 
(2x20 mL). The phases were separated and the organic layer was dried over anhydrous 
Na2SO4. The solvent was removed under reduced pressure and the residue was purified by 
flash silica gel chromatography (9.0 g SiO2, 40:1 CH2Cl2:MeOH) to yield N-(4-hydroxy-3-
methoxybenzyl)-4-((4-heptylphenyl)diazenyl)benzamide (AzCA-1, 31 mg, 89%) as a red 
solid. 
 
TLC (hexane/EtOAc, 1:1): Rf = 0.48.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.95-7.90 (m, 4H, H3a,b, H4a,b), 7.88-7.84 (m, 2H, H9a,b, 
J9,10 = 8.4 Hz), 7.35-7.31 (m, 2H, H10a,b, J10,9 = 8.4 Hz), 6.92-6.86 (m, 3H, H21, H24, H25), 
6.40 (t, 1H, NH, JNH,19 = 6.5 Hz), 5.63 (s, 1H, OH), 4.59 (d, 2H, H19a,b, J19,NH = 6.5 Hz), 3.90 (s, 
3H, H26a,b,c), 2.69 (t, 2H, H12a,b, J12,13 = 7.6 Hz), 1.70-1.61 (m, 2H, H13a,b), 1.37-1.23 (m, 8H, 
H14a,b, H15a,b, H16a,b, H17a,b), 0.88 (t, 3H, H18a,b,c, J18,17 = 6.5 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 166.7 (C1), 154.5 (Cazo), 150.9 (Cazo), 147.5 (C2), 
146.9 (C22), 145.4 (C23), 135.9 (C11), 130.0 (C20), 129.3 (2C, Cazo), 128.1 (2C, Cazo), 
123.3 (2C, Cazo), 122.9 (2C, Cazo), 121.2 (C21), 114.6 (C24), 111.0 (C25), 56.1 (C26), 
44.4 (C19), 36.1 (C12), 31.9 (Calk), 31.4 (C13), 29.4 (Calk), 29.3 (Calk), 22.8 (C17), 14.2 (C18).  
IR (neat, ATR): ṽ = 3350, 3199, 2922, 2851, 1627, 1605, 1572, 1547, 1523, 1491, 1452, 
1360, 1287, 1214, 1159, 1127, 1040, 868, 809, 773.  
HRMS (ESI+): m/z calcd. for [C28H34N3O3]+: 460.2600, found: 460.2592 ([M+H+]+). 
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4.4.8.3 – 2-(4-((4-Hexylphenyl)diazenyl)phenyl)acetic acid (FAAzo-2) 
 
 
A solution of 4-hexylaniline (3.0 g, 17 mmol, 1.5 equiv.) in CH2Cl2 (200 mL), was treated with 
a solution of Oxone® (30.4 g, 99 mmol, 9.0 equiv.) in H2O (200 mL) at 23 °C. The resulting 
biphasic reaction mixture was stirred vigorously at room temperature overnight or until all the 
aniline was consumed, as observed by TLC analysis. Subsequently, the phases were 
separated and the aqueous phase was extracted with CH2Cl2 (2x140 mL). The combined 
organic extracts were washed sequentially with a 1 M aqueous hydrochloric acid solution 
(240 mL), saturated aqueous NaHCO3 (240 mL), and H2O (3x240 mL). The washed organic 
layer was treated with 4-aminophenylacetic acid (1.7 g, 11 mmol, 1.0 equiv.) and AcOH 
(150 mL). The CH2Cl2 was then removed under reduced pressure at 35 °C and the solution 
was stirred overnight. The AcOH was then removed under reduced pressure and the red oil 
was azeotroped from toluene (PhMe, 100 mL). The residue was then purified by flash silica 
gel chromatography (0.30 kg SiO2, 99:1 CH2Cl2:AcOH) to yield 2-(4-((4-
hexylphenyl)diazenyl)phenyl)acetic acid (FAAzo-2, 1.00 g, 27%) as a red solid. 
 
TLC (hexane/EtOAc, 1:1): Rf = 0.79.  
1H NMR (D6-DMSO, 400 MHz, 25 °C): δ 12.45 (s, 1H, HCOOH), 7.84-7.79 (m, 4H, H5a,b, H10a,b, 
J5,4 ≈ J10,11 ≈ 8.3 Hz), 7.49-7.46 (m, 2H, H11a,b, J11,10 ≈ 8.4 Hz), 7.42-7.38 (m, 2H, H4a,b, 
J4,5 ≈ 8.4 Hz), 3.69 (s, 2H, H2a,b), 2.66 (t, 2H, H13a,b, J13,14 = 7.4 Hz), 1.65-1.56 (m, 2H, H14a,b), 
1.35-1.22 (m, 6H, H15a,b, H16a,b, H17a,b), 0.85 (t, 3H, H18a,b,c, J18,17 = 7.0 Hz).  
13C NMR (D6-DMSO, 101 MHz, 25 °C): δ 172.8 (C1), 151.1 (C6), 150.7 (C9), 146.9 (C12), 
139.0 (C3), 131.0 (C4a,b), 129.8 (C11a,b), 123.0 (C10a,b), 122.8 (C5a,b), 40.9 (C2), 35.5 (C13), 
31.5 (Calk), 31.2 (C4), 28.8 (Calk), 22.5 (Calk), 14.4 (C18).  
IR (neat, ATR): ṽ = 3022, 2952, 2926, 2850, 2728, 2636, 1691, 1601, 1497, 1465, 1413, 
1377, 1301, 1249, 1197, 1171, 1153, 1114, 1010, 904, 866, 844, 825, 783, 726, 677.  
HRMS (EI+): m/z calcd. for [C20H24N2O2]: 324.1838, found: 324.1832 ([M-e-]+). 
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4.4.8.4 – N-(4-Hydroxy-3-methoxybenzyl)-2-(4-((4-hexylphenyl)diazenyl)phenyl) 
acetamide (AzCA-2) 
 
N-(4-((4-Hexylphenyl)diazenyl)phenyl)acetic acid (FAAzo-2, 25 mg, 77 µmol, 1.0 equiv.) 
was converted to red solid N-(4-hydroxy-3-methoxybenzyl)-2-(4-((4-hexylphenyl)diazenyl) 
phenyl)acetamide (AzCA-2, 17 mg, 48%) in an analogous manner as described above for 
the preparation of N-(4-hydroxy-3-methoxybenzyl)-4-((4-heptylphenyl)diazenyl)- 
benzamide (AzCA-1). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 1:2): Rf = 0.40.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.88-7.81 (m, 2H, H5a,b, H10a,b, J5,4 ≈ J10,11 ≈ 8.3 Hz), 
7.41 (d, 2H, H4a,b, J4,5 = 8.3 Hz), 7.32 (d, 2H, H11a,b, J11,10 = 8.3 Hz), 6.84-6.80 (m, 1H, H24), 
6.71-6.64 (m, 2H, H25, H21), 5.75 (t, 1H, NH), 5.66 (s, 1H, OH), 4.34 (d, 2H, H19a,b, 
J19,NH = 5.7 Hz), 3.80 (s, 3H, HOMe), 3.67 (s, 2H, H2a,b), 2.68 (t, 2H, H13a,b, J13,14 = 7.7 Hz), 
1.72-1.61 (m, 2H, H14a,b), 1.40-1.23 (m, 6H, H15a,b, H16a,b, H17a,b), 0.89 (t, 3H, H18a,b,c, 
J18.17 = 6.7 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 170.3 (C1), 152.1 (Cazo), 151.0 (Cazo), 147.0 (C3), 
146.8 (C22), 145.2 (C23), 137.6 (C12), 130.2 (2C, Cazo), 130.0 (C20), 129.3 (2C, Cazo), 
123.4 (2C, Cazo), 123.0 (2C, Cazo), 120.7 (2C, Cazo), 114.5 (C24), 110.4 (C25), 56.0 (C26), 
43.8 (C2), 43.8 (C19), 36.0 (C13), 31.8 (C15), 31.4 (C14), 29.1 (C16), 22.7 (C17), 14.2 (C18).  
IR (neat, ATR): ṽ = 3457, 3285, 2953, 2922, 2852, 1648, 1635, 1601, 1518, 1462, 1434, 
1428, 1339, 1276, 1248, 1234, 1194, 1152, 1120, 1039, 1019, 1011, 838, 797, 716, 677.  
HRMS (ESI+): m/z calcd. for [C28H34N3O3]+: 460.2600, found: 460.2592 ([M+H+]+). 
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4.4.8.5 – 3-(4-((4-Pentylphenyl)diazenyl)phenyl)propanoic acid (FAAzo-3) 
 
4-Pentylaniline (1.5 g, 9.2 mmol, 1.5 equiv.) and 4-aminophenylpropionic acid (1.0 g, 
6.1 mmol, 1.0 equiv.)  were converted to red solid 3-(4-((4-pentylphenyl)diazenyl)phenyl)- 
propanoic acid (FAAzo-3, 1.0 g, 27%) in an analogous manner as described above for the 
preparation of 2-(4-((4-hexylphenyl)diazenyl)phenyl)acetic acid (FAAzo-2). Note: all 
reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 10:1): Rf = 0.74.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.87-7.81 (m, 4H, H6a,b, H11a,b), 7.37-7.30 (m, 4H, H5a,b, 
H12a,b, J12,11 ≈ J5,6 ≈ 8.4 Hz), 3.05 (t, 2H, H2a,b, J2,3 = 7.6 Hz), 2.75 (t, 2H, H3a,b, J3,2 = 7.7 Hz), 
2.68 (t, 2H, H14a,b), 1.71-1.62 (m, 2H, H15a,b), 1.40-1.32 (m, 4H, H16a,b, H17a,b), 0.91 (t, 3H, 
H18a,b,c, J18,17 = 6.9 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 178.8 (C1), 151.6 (Cazo), 151.1 (Cazo), 146.6 (Cazo), 
143.2 (Cazo), 129.2 (2C, Cazo), 129.1 (2C, Cazo), 123.1 (2C, Cazo), 122.9 (2C, Cazo), 36.0 (C14), 
35.5 (C2), 31.6 (C3), 31.1 (C16), 30.6 (C15), 22.7 (C17), 14.2 (C18).  
IR (neat, ATR): ṽ = 3026, 2950, 2924, 2853, 2616, 1691, 1599, 1579, 1494, 1431, 1417, 
1358, 1315, 1286, 1217, 1186, 1153, 1105, 1011, 932, 837, 806, 725, 678.  
HRMS (EI+): m/z calcd. for [C20H24N2O2]: 324.1838, found: 324.1831 ([M-e-]+). 
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3-(4-((4-)Pentylphenyl)diazenyl)phenyl)propanoic acid (FAAzo-3, 25 mg, 77 µmol, 
1.0 equiv.)  was converted to red solid N-(4-hydroxy-3-methoxybenzyl)-3-(4-((4-
pentylphenyl)diazenyl)phenyl)propanamide (AzCA-3, 17 mg, 89%) in an analogous 
manner as described above for the preparation of N-(4-hydroxy-3-methoxybenzyl)-4-((4-
heptylphenyl)diazenyl)benzamide (AzCA-1). Note: all reagents and solvents were scaled 
according to molarity. 
 
TLC (CH2Cl2:MeOH:AcOH, 95:5:1): Rf = 0.47.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.78 (m, 4H, H6a,b, H11a,b, J6,5 ≈ J11,12 ≈ 8.3 Hz), 
7.35-7.30 (m, 4H, H5a,b, H12a,b, J5,6 ≈ J12,11 ≈ 8.4 Hz), 6.82 (d, 1H, H22, J22,21 = 7.8 Hz), 
6.71-6.65 (m, 2H, H21, H25), 5.62-5.56 (m, 2H, NH, OH), 4.31 (d, 2H, H19a,b, J19,NH = 5.8 Hz), 
3.80 (s, 3H, H26a,b,c), 3.07 (t, 2H, H3a,b, J3,2 = 7.5 Hz), 2.68 (t, 2H, H14a,b, J14,15 = 8.0 Hz), 
2.53 (t, 2H, H2a,b, J2,3 = 7.4 Hz), 1.70-1.60 (m, 2H, H15a,b), 1.39-1.31 (m, 4H, H16a,b, H17a,b), 
0.90 (t, 3H, H18a,b,c, J18,17 = 6.8 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 171.6 (C1), 151.4 (Cazo), 151.0 (Cazo), 146.8 (C22), 
146.6 (Cazo), 145.2 (C23), 144.0 (Cazo), 130.1 (C20), 129.2 (4C, Cazo), 123.0 (2C, Cazo), 
122.9 (2C, Cazo), 121.0 (C21), 114.5 (C24), 110.7 (C25), 56.0 (C26), 43.8 (C19), 38.3 (C2), 
36.0 (C14), 31.6 (C3), 31.6 (C16), 31.1 (C15), 22.7 (C17), 14.2 (C18).  
IR (neat, ATR): ṽ = 3285, 3052, 2953, 2927, 2855, 1642, 1600, 1513, 1462, 1451, 1429, 
1375, 1272, 1235, 1155, 1123, 1034, 1012, 848, 735, 731.  
HRMS (ESI+): m/z calcd. for [C28H34N3O3]+: 460.2600, found: 460.2591 ([M+H+]+). 
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4-Butylaniline (2.27 g, 15 mmol, 3.0 equiv.) and 4-(4-aminophenyl)butyric acid (0.90 g, 
5.1 mmol, 1.0 equiv.) were converted to red solid 4-(4-((4-butylphenyl)diazenyl)phenyl)- 
butanoic acid (FAAzo-4, 1.49 g, 91%) in an analogous manner as described above for the 
preparation of 2-(4-((4-hexylphenyl)diazenyl)phenyl)acetic acid (FAAzo-2). Note: all 
reagents and solvents were scaled according to molarity. 
 
TLC (CH2Cl2/AcOH, 99:1): Rf = 0.15.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.86-7.81 (m, 4H, H7a,b, H12a,b, J7,6 ≈ J12,13 ≈ 8.4 Hz), 
7.35-7.29 (m, 4H, H6a,b, H13a,b, J6,7 ≈ J13,12 ≈ 8.4 Hz), 2.76 (t, 2H, H4a,b, J4,3 = 7.8 Hz), 2.71 (t, 
2H, H15a,b, J15,16 = 7.8 Hz), 2.43 (t, 2H, H2a,b, J2,3 = 7.3 Hz), 2.08-1.98 (m, 2H, H3a,b), 
1.70-1.61 (m, 2H, H16a,b), 1.44-1.34 (m, 2H, H17a,b), 0.95 (t, 3H, H18a,b,c, J18,17 = 7.3 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 179.6 (C1), 151.3 (C8), 151.0 (C11), 146.4 (C14), 
144.3 (C5), 129.2 (2C, Cazo), 129.1 (2C, Cazo), 122.9 (2C, Cazo), 122.8 (2C, Cazo), 35.6 (C15), 
34.9 (C4), 33.5 (C16), 33.3 (C2), 26.0 (C3), 22.4 (C17), 14.0 (C18).  
IR (neat, ATR): ṽ = 3021, 2950, 2927, 2869, 2853, 2685, 2599, 1689, 1600, 1580, 1497, 
1461, 1434, 1409, 1337, 1279, 1212, 1152, 1113, 1102, 1060, 1024, 1010, 901, 842, 824, 
772, 730, 671.  
HRMS (EI+): m/z calcd. for [C20H24N2O2]: 324.1838, found: 324.1836 ([M-e-]+). 
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4-(4-((4-Butylphenyl)diazenyl)phenyl)butanoic acid (FAAzo-4, 16 mg, 77 µmol, 1.0 equiv.)  
was converted to red solid N-(4-hydroxy-3-methoxybenzyl)-4-(4-((4-butylphenyl)diazenyl) 
phenyl)butanamide (AzCA-4, 20 mg, 87%) in an analogous manner as described above for 
the preparation of N-(4-hydroxy-3-methoxybenzyl)-4-((4-heptylphenyl)diazenyl)- 
benzamide (AzCA-1). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 1:1): Rf = 0.34.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.84-7.78 (m, 4H, H12a,b, H7a,b, J12,13 ≈ J7,6 ≈ 8.4 Hz), 
7.33-7.25 (m, 4H, H6a,b, H13a,b, J6,7 ≈ J13,12 ≈ 8.4 Hz), 6.86 (d, 1H, H24, J24,25 = 8.0 Hz), 
6.80-6.73 (m, 2H, H21, H25), 5.77-5.68 (m, 2H, NH, OH), 4.34 (d, 2H, H19a,b, 
J19,NH = 5.60 Hz), 3.85 (s, 3H, H26), 2.73 (t, 2H, H4a,b, J4,3 = 7.4 Hz), 2.68 (t, 2H, H15a,b, 
J15,16 = 7.6 Hz), 2.21 (t, 2H, H2a,b, J2,3 = 7.6 Hz), 2.08-1.99 (m, 2H, H3a,b), 1.68-1.59 (m, 2H, 
H16a,b), 1.44-1.30 (m, 2H, H17a,b), 0.94 (t, 3H, H18a,b,c, J18,17 = 7.4 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 172.4 (C1), 151.4 (C8), 151.1 (C11), 146.8 (C22), 
146.5 (C14), 145.3 (C23), 144.7 (C5), 130.3 (C20), 129.3 (2C, Cazo), 129.2 (2C, Cazo), 
122.9 (2C, Cazo), 122.9 (2C, Cazo), 121.0 (C21), 114.5 (C24), 110.9 (C25), 56.1 (C26), 
43.7 (C19), 35.9 (C2), 35.7 (C15), 35.1 (C4), 33.6 (C16), 27.0 (C3), 22.5 (C17), 14.1 (C18).  
IR (neat, ATR): ṽ = 3285, 3054, 2953, 2929, 2857, 1643, 1600, 1514, 1462, 1430, 1377, 
1275, 1237, 1155, 1124, 1034, 1013, 845, 736, 677.  
HRMS (EI+): m/z calcd. for [C28H33N3O3]: 459.2522, found: 459.2516 ([M-e-]+). 
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4.4.8.9 – Methyl pent-4-ynoate (1a) 
 
4-Pentynoic acid (0.36 g, 3.6 mmol, 1.0 equiv.) was dissolved in dry MeOH (7.0 mL) and 
benzene (25 mL) under an argon atmosphere. Trimethylsilyldiazomethane (2.4 mL, 0.20 M in 
diethyl ether, 4.7 mmol, 1.3 equiv.) was slowly added at room temperature until the solution 
retained a faint yellow color. The mixture was then titrated with AcOH until a colorless solution 
was obtained and the gas evolution had ceased. The reaction mixture was concentrated under 
reduced pressure (0.25 bar, 40 °C). The resulting oily residue was diluted with diethyl ether 
(50 mL) and the mixture was washed with H2O (2x25 mL). The layers were separated and the 
organic layer was dried over anhydrous Na2SO4. The dried solution was filtered, and the 
filtrate was concentrated under reduced pressure (0.25 bar, 40 °C) to yield methyl pent-4-
ynoate (1a, 0.37 g, 91%) as a volatile colorless liquid.  
 
TLC (hexane/EtOAc, 4:1): Rf = 0.71.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 3.64 (s, 3H, HOMe), 2.51-2.38 (m, 4H, H2a,b, H3a,b), 1.94 (t, 
1H, H5, J5,3 = 2.5 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 172.4 (C1), 82.4 (C4), 69.1 (C5), 51.9 (COMe), 33.1 (C2), 
14.3 (C3). Spectral characteristics matched those previously reported.102 The product still 
contained AcOH but this did not affect the following reaction. 
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4.4.8.10 – Methyl 5-(4-nitrophenyl)pent-4-ynoate (2a)   
 
Methyl 5-(4-nitrophenyl)pent-4-ynoate (2a)  was prepared utilizing a modified method 
described by Sugimoto et al.103 
 
Methyl pent-4-ynoate (1a, 0.40 g, 3.6 mmol, 1.0 equiv.) and 4-iodonitrobenzene (1.1 g, 
4.3 mmol, 1.2 equiv.) were combined in a round-bottomed flask under an argon atmosphere 
and were dissolved in degassed/dry THF (28 mL). NEt3 (1.5 g, 14 mmol, 4.0 equiv.) was then 
added, followed by the addition of CuI (0.12 g, 0.64 mmol, 0.18 equiv.) and (PPh3)2PdCl2 
(0.12 g, 0.18 mmol, 0.050 equiv.) at room temperature. The resulting brown solution was 
heated to 50 °C. After 2 h, the dark red mixture was cooled to room temperature and was 
diluted with EtOAc (50 mL), and washed with saturated aqueous ammonium chloride solution 
(50 mL, then 25 mL), water (25 mL) and then half saturated aqueous NaCl solution (25 mL). 
The organic phase was dried over anhydrous Na2SO4 and the dried solution was filtered. The 
filtrate was concentrated under reduced pressure and after being preadsorbed onto silica gel 
(4.0 g SiO2, loaded from THF), the residue was purified by flash silica gel chromatography 
(0.10 kg SiO2, 10:1 hexane:EtOAc) to yield methyl 5-(4-nitrophenyl)pent-4-ynoate (2a, 
0.42 g, 51%) as an orange solid. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.56.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 8.17-8.13 (m, 2H, H8a,b, J8,7 ≈ 9.0 Hz), 7.53-7.48 (m, 2H, 
H7a,b, J7,8 ≈ 9.0 Hz), 3.73 (s, 3H, HOMe), 2.77 (t, 2H, H2a,b, J2,3 = 7.3 Hz), 2.65 (t, 2H, H3a,b, 
J3,2 = 7.3 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 172.2 (C1), 146.9 (C9), 132.5 (2C, C7a,b), 130.7 (C6), 
123.6 (2C, C8a,b), 94.2 (C4), 79.9 (C5), 52.1 (COMe), 33.1 (C2), 15.6 (C3).  
HRMS (EI+): m/z calcd. for [C12H11NO4]: 233.0688, found: 233.0674 ([M-e-]+). 
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4.4.8.11 – Methyl 5-(4-aminophenyl)pentanoate (3a) 
 
Methyl 5-(4-nitrophenyl)pent-4-ynoate (2a, 0.42 g, 1.8 mmol, 1.0 equiv.) was dissolved in 
2:1 EtOAc:MeOH (v:v, 30 mL total) and this solution was degassed by sparging with argon 
gas. Pd/C (10 wt%, 0.13 g) was added and the suspension was again degassed and placed 
under a hydrogen atmosphere (H2 pressure applied with a balloon). The mixture was stirred 
vigorously at room temperature overnight. Upon completion of the reaction as observed by 
TLC analysis, the mixture was filtered through a pad of celite and the filtrate was concentrated 
under reduced pressure. The residue was purified by flash silica gel chromatography (50 g 
SiO2, 3:1 hexane:EtOAc) to yield 5-(4-aminophenyl)pentanoate (3a, 0.34 g, 1.6 mmol, 92%) 
as an orange oil. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.13.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 6.98-6.93 (m, 2H, H7a,b, J7,8 ≈ 8.3 Hz), 6.64-6.60 (m, 2H, 
H8a,b, J8,7 ≈ 8.3 Hz), 3.66 (s, 3H, HOMe), 3.56 (sbr, NH2), 2.51 (t, 2H, H5a,b, J5,4 = 7.2 Hz), 2.32 (t, 
2H, H2a,b), 1.69-1.54 (m, 4H, H3a,b, H4a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.2 (C1), 144.1 (C9), 132.3 (C6), 129.1 (2C, C7a,b), 
115.3 (2C, C8a,b), 51.5 (COMe), 34.7 (C5), 34.0 (C2), 31.2 (C4), 24.5 (C3).  
HRMS (EI+): m/z calcd. for [C12H17NO2]: 207.1259, found: 207.1238 ([M-e-]+). 
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4.4.8.12 – Methyl 5-(4-((4-propylphenyl)diazenyl)phenyl)pentanoate (4a) 
 
A solution of 4-propylaniline (0.64 g, 4.7 mmol, 3.0 equiv.) in CH2Cl2 (50 mL) was treated with 
Oxone® (3.0 g, 9.6 mmol, 6.0 equiv.) dissolved in H2O (50 mL) and the resulting biphasic 
mixture was stirred rapidly at room temperature overnight. The two phases were then 
separated and the organic phase was washed with H2O (60 mL). The washed organic phase 
was concentrated under reduced pressure to approximately 5 mL volume and this residue 
was then directly purified by flash silica gel chromatography (20 g SiO2, CH2Cl2). The collected 
green fractions were combined and a solution of 5-(4-aminophenyl)pentanoate (3a, 0.33 g, 
1.6 mmol, 1.0 equiv.) in CH2Cl2 (2.0 mL) was added followed by AcOH (25 mL). The CH2Cl2 
was then removed under reduced pressure (0.50 bar, 40 ˚C) and the resulting solution was 
stirred at room temperature for 40 h. Upon complete consumption of 3a as determined by TLC 
analysis, the AcOH was removed under reduced pressure and the residue was azeotroped 
from PhMe (40 mL). The resulting brown oil was purified by flash silica gel chromatography 
(0.12 kg SiO2, gradient: 20:1 to 10:1 pentane:EtOAc) to yield methyl 5-(4-((4-propyl-
phenyl)diazenyl)phenyl)pentanoate (4a, 0.39 g, 74%) as a red oil. 
 
TLC (hexane/EtOAc, 20:1): Rf = 0.73.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.81 (m, 4H, H8a,b, H13a,b, J8,7 ≈ J13,14 ≈ 8.4 Hz), 
7.33-7.29 (m, 4H, H7a,b, H14a,b, J7,8 ≈ J14,13 ≈ 8.4 Hz), 3.67 (s, 3H, HOMe), 2.74-2.64 (m, 4H, 
H5a,b, H16a,b), 2.38-2.32 (m, 2H, H2a,b), 1.75-1.64 (m, 6H, H3a,b, H4a,b, H17a,b), 0.97 (t, 3H, 
H18a,b,c, J18,17 = 7.4 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.1 (C1), 151.3 (CAzo), 151.1 (Cazo), 146.1 (Cazo), 
145.4 (Cazo), 129.3 (2C, Cazo), 129.2 (2C, Cazo), 122.9 (2C, Cazo), 122.8 (2C, Cazo), 51.7 (COMe), 
38.1 (C16), 35.6 (C5), 34.0 (C2), 30.8 (Calk), 24.7 (Calk), 24.6 (Calk), 13.9 (C18).  
HRMS (EI+): m/z calcd. for [C21H26N2O2]: 338.1994, found: 338.1986 ([M-e-]+). 
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4.4.8.13 – 5-(4-((4-Propylphenyl)diazenyl)phenyl)pentanoic acid (FAAzo-5) 
 
Methyl 5-(4-((4-propylphenyl)diazenyl)phenyl)pentanoate (4a, 0.36 g, 1.1 mmol, 
1.0 equiv.) was dissolved in 1:1 MeOH:THF (v:v, 42 mL total). To this solution was added 
aqueous 1 M lithium hydroxide solution (11 mL, 10 equiv.) and the mixture was stirred at room 
temperature for 2 h. Upon consumption of the starting material as observed by TLC analysis, 
the organic solvent was removed under reduced pressure. The resulting solution was acidified 
to pH = 1 with aqueous 2 M hydrochloric acid solution and the aqueous layer was extracted 
with EtOAc (2x30 mL). The combined organic phases were washed with H2O (30 mL), and 
the washed solution was dried over anhydrous Na2SO4. The dried solution was filtered, and 
the filtrate was concentrated under reduced pressure. The residue was purified by flash silica 
gel chromatography (32 g SiO2, 99:1 CH2Cl2:AcOH) to yield 5-(4-((4-propylphenyl)diazenyl) 
phenyl)pentanoic acid (FAAzo-5, 0.33 g, 96%) as a red solid. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.18.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.81 (m, 4H, H8a,b, H13a,b, J8,7 ≈ J13,14 ≈ 8.3 Hz), 
7.33-7.29 (m, 4H, H17a,b, H14a,b, J7,8 ≈ J14,13 ≈ 8.2 Hz), 2.75-2.63 (m, 4H, H5a,b, H16a,b), 2.40 (t, 
2H, H2a,b, J2,3 = 7.0 Hz), 1.76-1.67 (m, 6H, H3a,b, H4a,b, H17a,b), 0.97 (t, 3H, H18a,b,c).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 179.6 (C1), 151.2 (Cazo), 151.0 (Cazo), 146.1 (Cazo), 
141.4   (Cazo), 129.8 (2C, Cazo), 129.2 (2C, Cazo), 122.9 (2C, Cazo), 122.9 (2C, Cazo), 35.9 (C5), 
34.0 (C2), 31.2 (C17), 29.0 (C3), 29.0 (C18), 24.7 (C4), 21.6 (C16).  
IR (neat, ATR): ṽ = 2925, 2856, 1701, 1697, 1693, 1599, 1497, 1462, 1420, 1409, 1303, 
1255, 1200, 1154, 1109, 1090, 1074, 1012, 932, 851, 834, 744, 731, 677.  
HRMS (EI+): m/z calcd. for [C20H24N2O2]: 324.1838, found: 324.1831 ([M-e-]+). 
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4.4.8.14 – N-(4-Hydroxy-3-methoxybenzyl)-5-(4-((4-propylphenyl)diazenyl)phenyl) 
pentanamide (AzCA-5) 
 
5-(4-((4-Propylphenyl)diazenyl)phenyl)pentanoic acid (FAAzo-5, 21 mg, 65 µmol, 
1 equiv.)  was converted to red solid N-(4-hydroxy-3-methoxybenzyl)-5-(4-((4-
propylphenyl)diazenyl)phenyl)pentanamide (AzCA-5, 27 mg, 90%) in an analogous 
manner as described above for the preparation of N-(4-hydroxy-3-methoxybenzyl)-4-((4-
heptylphenyl)diazenyl)benzamide (AzCA-1). Note: all reagents and solvents were scaled 
according to molarity. 
 
TLC (CH2Cl2/AcOH, 99:1): Rf = 0.43.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.84-7.79 (m, 4H, H8a,b, H13a,b, J8,7 ≈ J13,14 ≈ 8.4 Hz), 
7.33-7.24 (m, 4H, H7a,b, H14a,b, J7,8 ≈ J14,13 ≈ 8.4 Hz), 6.85 (d, 1H, H24, J24,25 = 8.0 Hz), 
6.77-6.71 (m, 2H, H21, H25), 5.80 (t, 1H, NH, JNH,19 = 5.8 Hz), 4.33 (d, 2H, H19a,b, 
J19,NH = 5.7 Hz), 3.79 (s, 3H, H26a,b,c), 2.71-2.63 (m, 4H, H5a,b, H16a,b), 2.22 (t, 2H, H2a,b, 
J2,3 = 7.0 Hz), 1.77-1.63 (m, 6H, H3a,b, H4a,b, H17a,b), 0.97 (t, 3H, H18a,b,c, J18,17 = 7.3 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 172.7 (C1), 151.2 (Cazo), 151.1 (Cazo), 146.8 (C22), 
146.2 (Cazo), 145.5 (Cazo), 145.2 (C23), 130.3 (C20), 129.2 (2C, Cazo), 129.1 (2C, Cazo), 
122.9 (2C, Cazo), 122.8 (2C, Cazo), 120.9 (C25), 114.5 (C24), 110.8 (C21), 55.9 (C26), 
43.6 (C19), 38.0 (C16), 36.7 (C2), 35.7 (C5), 31.0 (Calk), 25.5 (Calk), 24.5 (C17), 13.9 (C18).  
IR (neat, ATR): ṽ = 3291, 3054, 2956, 2930, 2859, 1644, 1600, 1515, 1463, 1430, 1376, 
1274, 1236, 1155, 1124, 1035, 1013, 849, 736.  
HRMS (EI+): m/z calcd. for [C28H33N3O3]: 459.2522, found: 459.2507 ([M-e-]+). 
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4.4.8.15 – Methyl hex-5-ynoate (1b) 
 
5-Hexynoic acid (0.10 g, 0.89 mmol, 1.0 equiv.)  was converted to methyl hex-5-ynoate (1b, 
0.12 g, quant.) in an analogous manner as described above for the preparation of methyl 
pent-4-ynoate (1a). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.73.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 3.67 (s, 3H, HOMe), 2.45 (t, 2H, H2a,b, J2,3 = 7.4 Hz), 
2.25 (dt, 2H, H4a,b, J4,3 = 6.7 Hz, J4,6 = 2.7 Hz), 1.96 (t, 1H, H6, J6,4 = 2.7 Hz), 1.84 (quint, 2H, 
H3a,b, J3,2 ≈ J3,4 ≈ 7.4 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.7 (C1), 83.4 (C5), 69.2 (C6), 51.7 (COMe), 32.8 (C2), 
23.7 (C3), 18.0 (C4). Spectral characteristics matched those previously reported104. The 
product still contained AcOH but this did not affect the following reaction. 
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4.4.8.16 – Methyl 6-(4-nitrophenyl)hex-5-ynoate (2b) 
 
 
Methyl hex-5-ynoate (1b, 94 mg, 0.75 mmol, 1.0 equiv.) was converted to methyl 
6-(4-nitrophenyl)hex-5-ynoate (2b, 0.15 g, 0.61 mmol, 82%) in an analogous manner as 
described above for the preparation of methyl 5-(4-nitrophenyl)pent-4-ynoate (2a). Note: 
all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.46.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 8.18-8.14 (m, 2H, H9a,b, J9,8 ≈ 9.0 Hz), 7.53-7.49 (m, 2H, 
H8a,b, J8,9 ≈ 9.0 Hz), 3.69 (s, 3H, HOMe), 2.56-2.49 (m, 4H, H2a,b, H4a,b), 1.96 (quint, 2H, H3a,b, 
J3,2 = J3,4 ≈ 7.2 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.5 (C1), 146.9 (C10), 132.4 (2C, C8a,b), 130.9 (C7), 
123.7 (2C, C9a,b), 95.2 (C5), 80.2 (C6), 51.8 (COMe), 33.0 (C2), 23.7 (C3), 19.2 (C4). 
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4.4.8.17 – Methyl 6-(4-aminophenyl)hexanoate (3b) 
 
 
Methyl 6-(4-nitrophenyl)hex-5-ynoate (2b, 0.12 g, 0.5 mmol, 1 equiv.) was converted to 
methyl 6-(4-aminophenyl)hexanoate (3b, 79 mg, 0.36 mmol, 72%) in an analogous manner 
as described above for the preparation of methyl 5-(4-aminophenyl)pentanoate (3a). Note: 
all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.13.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 6.98-6.93 (m, 2H, H8a,b, J8,9 ≈ 8.5 Hz), 6.64-6.60 (dt, 2H, 
H9a,b, J9,8 ≈ 8.4 Hz), 3.66 (s, 3H, HOMe), 3.55 (sbr, 2H, NH2), 2.50 (t, 2H, H6a,b, J6,5 = 7.6 Hz), 
2.30 (t, 2H, H2a,b, J2,3 = 7.5 Hz), 1.69-1.52 (m, 4H, H3a,b, H5a,b), 1.38-1.28 (m, 2H, H4a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.4 (C1), 144.2 (C10), 132.7 (C7), 129.2 (2C, C8a,b), 
115.3 (2C, C9a,b), 51.6 (COMe), 34.9 (C6), 34.2 (C2), 31.5 (C5), 28.8 (C3), 25.0 (C4).  
HRMS (EI+): m/z calcd. for [C13H19NO2]: 221.1416, found: 221.1408 ([M-e-]+). 
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4.4.8.18 – Methyl 6-(4-((4-ethylphenyl)diazenyl)phenyl)hexanoate (4b) 
 
 
4-Ethylaniline (0.12 g, 0.95 mmol, 3.0 equiv.) and methyl 6-(4-aminophenyl)hexanoate (3b, 
70 mg, 0.32 mmol, 1.0 equiv.) were converted to orange oil methyl 6-(4-((4-ethylphenyl) 
diazenyl)phenyl)hexanoate (4b, 52 mg, 48%) in an analogous manner as described above 
for the preparation of methyl 5-(4-((4-propylphenyl)diazenyl)phenyl) pentanoate (4a). 
Note: all reagents and solvents were scaled according to molarity. 
 
TLC (pentane/EtOAc, 20:1): Rf = 0.24 (trans), 0.10 (cis).  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.80 (m, 4H, H9a,b, H14a,b, J9,8 ≈ J14,15 ≈ 8.4 Hz), 
7.35-7.28 (m, 4H, H8a,b, H15a,b, J8,9 ≈ J15,14 ≈ 8.5 Hz), 3.67 (s, 3H, HOMe), 2.77-2.65 (m, 4H, 
H6a,b, H17a,b), 2.32 (t, 2H, H2a,b), 1.73-1.62 (m, 4H, H3a,b, H5a,b), 1.43-1.34 (m, 2H, H4a,b), 
1.29 (t, 3H, H18a,b,c, J18,17 = 7.6 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.3 (C1), 151.2 (Cazo), 151.1 (Cazo), 147.6 (Cazo), 
145.9 (Cazo), 129.2 (2C, Cazo), 128.7 (2C, Cazo), 122.9 (2C, Cazo), 122.9 (2C, Cazo), 51.7 (COMe), 
35.7 (Calk), 34.1 (C2), 31.1 (Calk), 29.0 (Calk), 28.9 (Calk), 24.9 (Calk), 15.6 (C18).  
HRMS (EI+): m/z calcd. for [C21H26N2O2]: 338.1994, found: 338.1983 ([M-e-]+). 
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4.4.8.19 – 6-(4-((4-Ethylphenyl)diazenyl)phenyl)hexanoic acid (FAAzo-6) 
 
 
Methyl 6-(4-((4-ethylphenyl)diazenyl)phenyl)hexanoate (4b, 45 mg, 0.13 mmol, 1.0 equiv.) 
was converted to red solid 6-(4-((4-ethylphenyl)diazenyl)phenyl)hexanoic acid (FAAzo-6, 
32 mg, 75%) in an analogous manner as described above for the preparation of 
5-(4-((4-propylphenyl)diazenyl)phenyl)pentanoic acid (FAAzo-5). Note: all reagents and 
solvents were scaled according to molarity. 
 
TLC (CH2Cl2:AcOH, 99:1): Rf = 0.22.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.80 (m, 4H, H9a,b, H14a,b, J9,10 ≈ J14,15 ≈ 8.3 Hz), 
7.35-7.28 (m, 4H, H8a,b, H15a,b, J8,9 ≈ J15,14 ≈ 8.4 Hz), 2.77-2.65 (m, 4H, H6a,b, H17a,b), 
2.39-2.33 (t, 2H, H2a,b, J2,3 = 7.4 Hz), 1.73-1.64 (m, 4H, H3a,b, H5a,b), 1.46-1.37 (m, 2H, H4a,b), 
1.29 (t, 3H, H18a,b,c, J18,17 = 7.5 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 179.4 (C1), 151.2 (Cazo), 151.1 (Cazo), 147.7 (Cazo), 
145.8 (Cazo), 129.2 (2C, Cazo), 128.7 (2C, Cazo), 122.9 (2C, Cazo), 122.9 (2C, Cazo), 35.7 (Calk), 
34.0 (C2), 31.0 (Calk), 29.0 (Calk), 28.8 (Calk), 24.6 (Calk), 15.6 (C18).  
IR (neat, ATR): ṽ = 3022, 2956, 2927, 2851, 1692, 1600, 1497, 1466, 1438, 1410, 1355, 
1293, 1249, 1200, 1152, 1056, 1010, 913, 848, 826, 729, 685.  
HRMS (EI+): m/z calcd. for [C20H24N2O2]: 324.1838, found: 324.1838 ([M-e-]+). 
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6-(4-((4-Ethylphenyl)diazenyl)phenyl)hexanoic acid (FAAzo-6, 16 mg, 49 µmol, 1 equiv.)  
was converted to red solid N-(4-hydroxy-3-methoxybenzyl)-6-(4-((4-ethylphenyl)diazenyl) 
phenyl)hexanamide (AzCA-6, 19 mg, 86%) in an analogous manner as described above for 
the preparation of N-(4-hydroxy-3-methoxybenzyl)-4-((4-heptylphenyl)diazenyl)- 
benzamide (AzCA-1). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 1:2): Rf = 0.31.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.79 (m, 4H, H9a,b, H14a,b, J9,8 ≈ J14,15 ≈ 8.3 Hz), 
7.35-7.25 (m, 4H, H8a,b, H15a,b, J8,9 ≈ J15,14 ≈ 8.3 Hz), 6.86 (d, 1H, H24, J24,25 = 8.1 Hz), 
6.81-6.72 (m, 2H, H21, H25), 5.82-5.66 (m, 2H, NH, OH, JNH,19 = 5.3 Hz), 4.33 (d, 2H, H19a,b, 
J19,NH = 5.7 Hz), 3.84 (s, 3H, H26a,b,c), 2.77-2.63 (m, 4H, H6a,b, H17a,b), 2.19 (t, 2H, H2a,b, 
J2,3 = 7.5 Hz), 1.74-1.62 (m, 4H, H5a,b, H3a,b), 1.42-1.32 (m, 2H, H4a,b), 1.28 (t, 3H, H18a,b,c, 
J18,17 = 7.8 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 172.8 (C1), 151.2 (Cazo), 151.1 (Cazo), 147.7 (Cazo), 
146.8 (C22), 145.8 (Cazo), 145.2 (C23), 130.4 (C20), 129.2 (2C, Cazo), 128.6 (2C, Cazo), 
122.9 (2C, Cazo), 122.9 (2C, Cazo), 120.9 (C25), 114.5 (C24), 110.8 (C21), 56.0 (C26), 
43.7 (C19), 36.8 (C2), 35.7 (Calk), 31.1 (Calk), 29.0 (Calk), 28.9 (Calk), 25.7 (Calk), 15.6 (Calk).  
IR (neat, ATR): ṽ = 3291, 3053, 2961, 2930, 2856, 1651, 1645, 1600, 1557, 1539, 1515, 
1546, 1530, 1373, 1274, 1237, 1155, 1124, 1035, 1013, 845, 795, 736.  
HRMS (EI+): m/z calcd. for [C28H33N3O3]: 459.2522, found: 459.2520 ([M-e-]+). 
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4.4.8.21 – Methyl hept-6-ynoate (1c) 
 
6-Heptynoic acid (0.10 g, 0.79 mmol, 1.0 equiv.) was converted to methyl hept-6-ynoate 
(1c, 0.11 g, quant.) in an analogous manner as described above for the preparation of methyl 
pent-4-ynoate (1a). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.71.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 3.65 (s, 3H, HOMe), 2.32 (t, 2H, H2a,b, J2,3 = 7.4 Hz), 
2.19 (dt, 2H, H5a,b, J5,4 = 7.1 Hz, J5,7 = 2.6 Hz), 1.94 (t, 1H, H7, J7,5 = 2.5 Hz), 1.78-1.69 (m, 
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4.4.8.22 – Methyl 7-(4-nitrophenyl)hept-6-ynoate (2c) 
 
Methyl hept-6-ynoate (1c, 96 mg, 0.69 mmol, 1.0 equiv.) was converted to methyl 
7-(4-nitrophenyl)hept-6-ynoate (2c, 0.12 g, 0.47 mmol, 70%) in an analogous manner as 
described above for the preparation of methyl 5-(4-nitrophenyl)pent-4-ynoate (2a). Note: all 
reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.53.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 8.17-8.13 (m, 2H, H10a,b, J10,9 ≈ 8.9 Hz), 7.53-7.49 (m, 
2H, H9a,b, J9,10 ≈ 8.9 Hz), 3.68 (s, 3H, HOMe), 2.48 (t, 2H, H2a,b, J2,3 = 7.0 Hz), 2.38 (t, 2H, 
H5aa,b, J5,4 = 7.3 Hz), 1.85-1.76 (m, 2H, H4a,b), 1.70-1.62 (m, 2H, H3a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.9 (C1), 146.8 (C11), 132.4 (2C, C9a,b), 131.1 (C8), 
123.6 (2C, C10a,b), 95.9 (C6), 79.8 (C7), 51.8 (COMe), 33.6 (C2), 27.9 (C3), 24.3 (C4), 19.5 
(C5). 
HRMS (EI+): m/z calcd. for [C15H17N1O4]: 275.1158, found: 275.1134 ([M-e-]+). 
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4.4.8.23 – Methyl 7-(4-aminophenyl)heptanoate (3c) 
 
Methyl 7-(4-nitrophenyl)hept-6-ynoate (2c, 0.12 g, 0.4 mmol, 1 equiv.) was converted to 
orange oil methyl 7-(4-aminophenyl)heptanoate (3c, 85 mg, 0.36 mmol, 82%) in an 
analogous manner as described above for the preparation of 
methyl 5-(4-aminophenyl)pentanoate (3a). Note: all reagents and solvents were scaled 
according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.12.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 6.99-6.93 (m, 2H, H9a,b, H9,10 ≈ 8.2 Hz), 6.65-6.60 (m, 
2H, H10a,b, J10,9 ≈ 8.3 Hz), 3.66 (s, 3H, HOMe), 3.55 (sbr, NH2), 2.49 (t, 2H, H7a,b, J7,6 = 8.1 Hz), 
2.30 (t, 2H, H2a,b), 1.66-1.50 (m, 4H, H3a,b, H6a,b), 1.39-1.28 (m, 4H, H4a,b, H5a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.4 (C1), 144.2 (C11), 132.9 (C8), 129.2 (2C, C9a,b), 
115.3 (2C, C10a,b), 51.6 (COMe), 35.1 (C7), 34.2 (C2), 31.7 (Calk), 29.1 (Calk), 28.9 (Calk), 
25.0 (Calk).  
HRMS (ESI+): m/z calcd. for [C15H24NO2]+: 250.1807, found: 250.1801 ([M+H+]+). 
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4.4.8.24 – Methyl 7-(4-(p-tolyldiazenyl)phenyl)heptanoate (4c) 
 
 
p-Toluidine (0.10 g, 0.96 mmol, 3.0 equiv.) and methyl 7-(4-aminophenyl)heptanoate 
(3c, 70 mg, 0.32 mmol, 1.0 equiv.) were converted to orange oil methyl 
7-(4-(p-tolyldiazenyl)phenyl)heptanoate (4c, 48 mg, 44%) in an analogous manner as 
described above for the preparation of methyl 5-(4-((4-propylphenyl)diazenyl)phenyl) 
pentanoate (4a). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.74 (trans), 0.55 (cis).  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.84-7.79 (m, 4H, H10a,b, H15a,b), 7.33-7.28 (m, 4H, H9a,b, 
H16a,b, J9,10 ≈ J16,15 ≈ 8.5 Hz), 3.67 (s, 3H, HOMe), 2.68 (t, 2H, H7a,b, J7,6 = 7.5 Hz), 2.43 (s, 3H, 
H18a,b), 2.32-2.27 (m, 2H, H2a,b), 1.71-1.54 (m, 4H, H3a,b, H6a,b), 1.41-1.28 (m, 4H, H4a,b, 
H5a,b). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.4 (C1), 151.1 (Cazo), 151.0 (Cazo), 146.1 (Cazo), 
141.4 (Cazo), 129.8 (2C, Cazo), 129.2 (2C, Cazo), 122.9 (2C, Cazo), 122.9 (2C, Cazo), 51.6 (COMe), 
35.9 (C7), 34.2 (C2), 31.2 (Calk), 29.1 (Calk), 29.0 (Calk), 25.0 (Calk), 21.6 (C18).  
HRMS (EI+): m/z calcd. for [C21H26N2O2]: 338.1994, found: 338.1991 ([M-e-]+). 
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4.4.8.25 – 7-(4-(p-Tolyldiazenyl)phenyl)heptanoic acid (FAAzo-7) 
 
 
Methyl 7-(4-(p-tolyldiazenyl)phenyl)heptanoate (4c, 35 mg, 0.10 mmol, 1 equiv.) was 
converted to red solid 7-(4-(p-tolyldiazenyl)phenyl)heptanoic acid (FAAzo-7, 28 mg, 83%) 
in an analogous manner as described above for the preparation of 5-(4-((4-propylphenyl) 
diazenyl)phenyl)pentanoic acid (FAAzo-5). Note: all reagents and solvents were scaled 
according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.13.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.84-7.79 (m, 4H, H10a,b, H15a,b), 7.32-7.28 (m, 4H, H9a,b, 
H16a,b, J9,10 ≈ J16,15 ≈ 8.3 Hz), 2.68 (t, 2H, H7a,b, J7,6 = 7.6 Hz), 2.43 (s, 3H, H18a,b), 2.35 (t, 2H, 
H2a,b, J2,3 = 7.5 Hz), 1.71-1.58 (m, 4H, H3a,b, H6a,b), 1.42-1.31 (m, 4H, H4a,b, H5a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 179.6 (C1), 151.2 (Cazo), 151.0 (Cazo), 146.1 (Cazo), 
141.4 (Cazo), 129.8 (2C, Cazo), 129.2 (2C, Cazo), 122.9 (2C, Cazo), 122.9 (2C, Cazo), 35.9 (C7), 
34.0 (C2), 31.2 (Calk), 29.0 (Calk), 29.0 (Calk), 24.7 (Calk), 21.6 (C18).  
IR (neat, ATR): ṽ = 2927, 2851, 1720, 1702, 1697, 1693, 1600, 1497, 1465, 1438, 1413, 
1314, 1295, 1280, 1241, 1208, 1152, 1109, 1010, 954, 850, 826, 727.  
HRMS (ESI-): m/z calcd. for [C20H23N2O2]-: 323.1765, found: 323.1762 ([M-H+]-). 
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7-(4-(p-Tolyldiazenyl)phenyl)heptanoic acid (FAAzo-7, 14 mg, 43 µmol, 1.0 equiv.) was 
converted to red solid N-(4-hydroxy-3-methoxybenzyl)-7-(4-(p-tolyldiazenyl)phenyl) 
heptanamide (AzCA-7, 16 mg, 81%) in an analogous manner as described above for the 
preparation of N-(4-hydroxy-3-methoxybenzyl)-4-((4-heptylphenyl)diazenyl)benzamide 
(AzCA-1). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 2:1): Rf = 0.31.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.76-7.71 (m, 4H, H10a,b, H15a,b, J10,9 ≈ J15,16 ≈ 8.4 Hz), 
7.25-7.19 (m, 4H, H9a,b, H16a,b, J9,10 ≈ J16,15 ≈ 8.3 Hz), 6.78 (d, 1H, H24, J24,25 = 8.0 Hz), 
6.73-6.65 (m, 2H, H21, H25), 5.71-5.56 (m, 2H, NH, OH, JNH,19 = 5.3 Hz), 4.26 (d, 2H, H19, 
J19,NH = 5.4 Hz), 3.77 (s, 3H, H26a,b,c), 2.58 (t, 2H, H7a,b, J7,6 = 7.5 Hz), 2.36 (s, 3H, H18a,b,c), 
2.10 (t, 2H, H2a,b, J2,3 = 7.4 Hz), 1.62-1.51 (m, 4H, H3a,b, H6a,b), 1.32-1.24 (m, 4H, H4a,b, H5a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 172.8 (C1), 151.0 (Cazo), 150.9 (Cazo), 146.8 (C22), 
145.9 (Cazo), 145.1 (C23), 141.3 (Cazo), 130.3 (C20), 129.7 (2C, Cazo), 129.1 (2C, CAzo), 
122.7 (4C, CAzo), 120.8 (C25), 114.4 (C24), 110.7 (C21), 55.9 (C26), 43.5 (C19), 36.8 (C2), 
35.8 (C7), 31.1 (Calk), 29.1 (Calk), 28.9 (Calk), 25.7 (Calk), 21.5 (C18).  
IR (neat, ATR): ṽ = 3292, 2927, 2854, 1652, 1645, 1600, 1558, 1539, 1515, 1464, 1456, 
1429, 1373, 1275, 1237, 1155, 1124, 1035, 823, 727.  
HRMS (EI+): m/z calcd. for [C28H33N3O3]: 459.2522, found: 459.2524 ([M-e-]+). 
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4.4.8.27 – Oct-7-ynoic acid (1d) 
 
Oct-7-ynoic acid (1d) was prepared from 7-octyn-1-ol according to a modified procedure 
reported by Reyes et al105. 
 
CrO3 (0.78 g, 7.8 mmol, 1.5 equiv.) was dissolved in H2O (10 mL) and cooled to 0 ˚C. H2SO4 
(96%, 2.4 mL, 45 mmol, 8.7 equiv.) was slowly added and the mixture was allowed to warm 
to room temperature over 10 min. The solution was again cooled to 0 ˚C whereupon 
7-octyn-1-ol (0.65 g, 5.2 mmol, 1.0 equiv.) dissolved in acetone (3.3 mL) was added slowly. 
Upon complete addition of the alcohol, the reaction mixture was allowed to warm to room 
temperature and stirring was continued for 2 h. The reaction mixture was then diluted with 
EtOAc (40 mL) and the phases were separated. The aqueous phase was extracted with 
EtOAc (40 mL) and the combined organic phases were concentrated. The resulting oil was 
purified by flash column chromatography (65 g SiO2, 4:1 hexane:EtOAc to 3:1 hexane:EtOAc) 
to yield oct-7-ynoic acid (1d, 0.34 g, 47%) as a clear, volatile liquid. This product still 
contained CH2Cl2 which was not further removed due to its volatile nature. This did not affect 
the following reaction. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.16.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 10.23 (sbr, 1H, HCOOH), 2.36 (t, 2H, H2a,b, J2,3 = 7.6 Hz), 
2.19 (dt, 2H, H6a,b, J6,5 = 6.9 Hz, J6,8 = 2.8 Hz), 1.98 (t, 1H, H8, J8,6 = 2.8 Hz), 1.69-1.59 (m, 
2H, Halk), 1.58-1.50 (m, 2H, Halk), 1.50-1.40 (m, 2H, H4a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 180.2 (C1), 84.4 (C5), 68.5 (C6), 34.0 (C2), 28.2 (Calk), 
28.2 (Calk), 24.3 (Calk), 18.3 (Calk).  
HRMS (EI+): m/z calcd. for [C8H12O2]+: 140.0837, found: 140.0764 ([M-e-]+). 
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4.4.8.28 – Methyl oct-7-ynoate (2d) 
 
7-Octynoic acid (1d, 0.34 g, 2.4 mmol, 1.0 equiv.) was converted to methyl oct-7-ynoate 
(2d, 0.35 g, 94%) in an analogous manner as described above for the preparation of methyl 
pent-4-ynoate (1a). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.50.  
1H NMR (CDCl3, 400 MHz, 27 °C): δ 3.65 (s, 3H, HOMe), 2.31 (t, 2H, H2a,b, J2,3 = 7.5 Hz), 
2.18 (dt, 2H, H6a,b, J6,5 = 7.0 Hz, J6,8 = 2.7 Hz), 1.93 (t, 1H, H8, J8,6 = 2.7 Hz), 1.67-1.58 (m, 
2H, Halk), 1.56-1.49 (m, 2H, Halk), 1.47-1.39 (m, 2H, H4a,b).  
13C NMR (CDCl3, 101 MHz, 27 °C): δ 174.2 (C1), 84.4 (C5), 68.4 (C6), 51.6 (COMe), 34.0 (C2), 
28.3 (Calk), 28.2 (Calk), 24.5 (Calk), 18.3 (Calk).  
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4.4.8.29 – Methyl 8-(4-nitrophenyl)oct-7-ynoate (3d)  
 
 
Methyl oct-7-ynoate (2d, 350 mg, 2.30 mmol, 1.0 equiv.) was converted to methyl 
8-(4-nitrophenyl)oct-7-ynoate (3d, 430 mg, 69%) in an analogous manner as described 
above for the preparation of methyl 5-(4-nitrophenyl)pent-4-ynoate (2a). Note: all reagents 
and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.59.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 8.13 (d, 2H, H11a,b, J11,10 = 8.8 Hz), 7.49 (d, 2H, H10a,b, 
J10,11 = 8.8 Hz), 3.65 (s, 3H, HOMe), 2.44 (t, 2H, H2a,b, J2,3 = 6.9 Hz), 2.33 (t, 2H, H6a,b, 
J6,5 = 7.4 Hz), 1.72-1.58 (m, 4H, H3a,b, H5a,b), 1.53-1.43 (m, 2H, H4a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.1 (C1), 146.7 (C12), 132.3 (2C, C10a,b), 131.2 (C9), 
123.6 (2C, C11a,b), 96.4 (C7), 79.6 (C8), 51.6 (COMe), 34.0 (C2), 28.5 (Calk), 28.1 (Calk), 
24.5 (Calk), 19.5 (C6).  
HRMS (EI+): m/z calcd. for [C15H17NO4]+: 275.1158, found: 275.1134 ([M-e-]+). 
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4.4.8.30 – Methyl 8-(4-aminophenyl)octanoate (4d) 
 
 
Methyl 8-(4-nitrophenyl)oct-7-ynoate (3d, 43 mg, 0.16 mmol, 1.0 equiv.) was converted to 
orange oil methyl 8-(4-aminophenyl)octanoate (4d, 20 mg, 51%) in an analogous manner 
as described above for the preparation of methyl 5-(4-aminophenyl)pentanoate (3a). 
Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.19.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 6.97-6.95 (m, 2H, H10a,b, J10,11 ≈ 8.5 Hz), 6.64-6.60 (m, 
2H, H11a,b, J11,10 ≈ 8.5 Hz), 3.66 (s, 3H, HOMe), 3.55 (sbr, 2H, NH2), 2.48 (t, 2H, H8a,b, 
J8,7 = 7.4 Hz), 2.29 (t, 2H, H2a,b, J2,3 = 7.5 Hz), 1.65-1.49 (m, 4H, H3a,b, H7a,b), 1.36-1.22 (m, 
6H, H4a,b, H5a,b, H6a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.5 (C1), 144.1 (C12), 133.1 (C9), 129.2 (2C, C10a,b), 
115.3 (2C, C11a,b), 51.6 (COMe), 35.2 (C8), 34.2 (C2), 31.9 (Calk), 29.3 (Calk), 29.2 (Calk), 
29.2 (Calk), 25.1 (Calk).  
HRMS (ESI+): m/z calcd. for [C14H24NO2]+: 250.1807, found: 250.1801 ([M+H+]+). 
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4.4.8.31 – Methyl 8-(4-(phenyldiazenyl)phenyl)octanoate (5d) 
 
 
Methyl 8-(4-aminophenyl)octanoate (4d, 15 mg, 60 µmol, 1.0 equiv.) was dissolved in 
CH2Cl2 (1 mL). Nitrosobenzene (8 mg, 72 µmol, 1.2 equiv.) followed by AcOH (36 mg, 
0.60 mmol, 10 equiv.) were added to this solution and the resulting mixture was stirred at room 
temperature for 7 h. Upon completion of the reaction, the mixture was diluted with EtOAc 
(5 mL), and the organic phase was washed with a saturated aqueous NaHCO3 solution 
(10 mL) and water (2x10 mL). The layers were separated, and the organic phase was dried 
over anhydrous Na2SO4. The dried solution was filtered and the filtrate was then concentrated 
under reduced pressure. The residue was purified by flash column chromatography (5 g SiO2, 
20:1 pentane:EtOAc) to yield methyl 8-(4-(phenyldiazenyl)phenyl)octanoate (5d, 16 mg, 
78%) as an orange oil. 
 
TLC (hexane/EtOAc, 20:1): Rf = 0.36 (trans), 0.10 (cis).  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.92-7.88 (m, 2H, H11a,b, J11,10 ≈ 8.4 Hz), 7.87-7.82 (m, 
2H, H16a,b, J16,17 ≈ 8.4 Hz), 7.54-7.43 (m, 3H, H17a,b, H18), 7.32 (d, 2H, H10a,b, J10,11 = 8.4 Hz), 
3.67 (s, 3H, HOMe), 2.68 (t, 2H, H8a,b, J8,7 = 7.4 Hz), 2.30 (t, 2H, H2a,b, J2,3 = 7.5 Hz), 
1.70-1.50 (m, 4H, H3a,b, H7a,b), 1.41-1.25 (m, 6H, H4a,b, H5a,b, H6a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.4 (C1), 152.9 (Cazo), 151.1 (Cazo), 146.6 (C9), 
130.8 (C18), 129.2 (2C, Cazo), 129.2 (2C, Cazo), 123.0 (2C, Cazo), 122.9 (2C, Cazo), 51.6 (COMe), 
36.0 (C8), 34.2 (C2), 31.4 (Calk), 29.2 (Calk), 29.2 (Calk), 29.2 (Calk), 25.1 (Calk).  
HRMS (ESI+): m/z calcd. for [C21H27N2O2]+: 339.2073, found: 339.2065 ([M+H+]+). 
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4.4.8.32 – 8-(4-(Phenyldiazenyl)phenyl)octanoic acid (FAAzo-8) 
 
 
Methyl 8-(4-(phenyldiazenyl)phenyl)octanoate (5d, 16 mg, 47 µmol, 1 equiv.) was 
converted to red solid 8-(4-(phenyldiazenyl)phenyl)octanoic acid (FAAzo-8, 12 mg, 78%) 
in an analogous manner as described above for the preparation of 5-(4-((4-
propylphenyl)diazenyl)phenyl)pentanoic acid (FAAzo-5). Note: all reagents and solvents 
were scaled according to molarity. 
 
TLC (hexane/EtOAc, 4:1): Rf = 0.13.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.92-7.88 (m, 2H, H11a,b, J11,10 ≈ 8.5 Hz), 7.87-7.82 (m, 
2H, H16a,b, J16,17 ≈ 8.5 Hz), 7.54-7.43 (m, 3H, H17a,b, H18), 7.32 (d, 2H, H10a,b, J10,11 = 8.4 Hz), 
2.68 (t, 2H, H8a,b, J8,7 = 7.5 Hz), 2.35 (t, 2H, H2a,b, J2,3 = 7.4 Hz), 1.70-1.59 (m, 4H, H3a,b, 
H7a,b), 1.41-1.28 (m, 6H, H4a,b, H5a,b, H6a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 179.9 (C1), 152.9 (Cazo), 151.1 (Cazo), 146.5 (C9), 
130.8 (C18), 129.2 (2C, Cazo), 129.2 (2C, Cazo), 123.0 (2C, Cazo), 122.8 (2C, Cazo), 36.0 (C8), 
34.1 (C2), 31.3 (Calk), 29.2 (Calk), 29.2 (Calk), 29.1 (Calk), 24.8 (Calk).  
IR (neat, ATR): ṽ = 3180, 2921, 2848, 1701, 1602, 1486, 1464, 1428, 1409, 1343, 1303, 
1289, 1264, 1226, 1198, 1154, 1088, 1012, 925, 840, 806, 767, 759,  725, 685.  
HRMS (ESI-): m/z calcd. for [C20H23N2O2]-: 323.1765, found: 323.1762 ([M-H+]-). 
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4.4.8.33 – N-(4-Hydroxy-3-methoxybenzyl)-8-(4-(phenyldiazenyl)phenyl) 
octanamide (AzCA-8) 
 
8-(4-(phenyldiazenyl)phenyl)octanoic acid (FAAzo-8, 12 mg, 37 µmol, 1.0 equiv.)  was 
converted to red oil N-(4-hydroxy-3-methoxybenzyl)-8-(4-(phenyldiazenyl)phenyl) 
octanamide (AzCA-8, 15 mg, 88%) in an analogous manner as described above for the 
preparation of N-(4-hydroxy-3-methoxybenzyl)-4-((4-heptylphenyl)diazenyl)benzamide 
(AzCA-1). Note: all reagents and solvents were scaled according to molarity. 
 
TLC (hexane/EtOAc, 1:2): Rf = 0.26.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.92-7.88 (m, 2H, H11a,b), 7.86-7.82 (m, 2H, H16a,b, 
J16,17 ≈ 8.4 Hz), 7.54-7.43 (m, 3H, H17a,b, H18), 7.31 (d, 2H, H10a,b, J10,11 = 8.4 Hz), 
6.88-6.72 (m, 3H, H21, H24, H25), 5.77-5.63 (m, 2H, NH, HOH), 4.34 (d, 2H, H19a,b, 
J19,NH = 5.6 Hz), 3.85 (s, 3H, HOMe), 2.67 (t, 2H, H8a,b, J8,7 = 7.6 Hz), 2.18 (t, 2H, H2a,b, 
J2,3 = 7.5 Hz), 1.70-1.58 (m, 4H, H3a,b, H6a,b), 1.38-1.22 (m, 6H, H4a,b, H5a,b, H6a,b).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.0 (C1), 152.8 (Cazo), 151.1 (Cazo), 146.8 (C22), 
146.5 (C9), 145.2 (C23), 130.8 (C18), 130.5 (C20), 129.2 (2C, Cazo), 129.2 (2C, Cazo), 
123.0 (2C, Cazo), 122.8 (2C, Cazo), 120.9 (C25), 114.5 (C24), 110.8 (C20), 56.0 (COMe), 
43.7 (C19), 36.9 (C2), 36.0 (C8), 31.3 (Calk), 29.3 (Calk), 29.2 (2C, Calk), 25.9 (Calk).  
IR (neat, ATR): ṽ = 3286, 2928, 2853, 1733, 1717, 1699, 1683, 1674, 1652, 1645, 1634, 
1616, 1600, 1557, 1538, 1516, 1464, 1456, 1436, 1418, 1373, 1274, 1153, 1124, 1035, 768, 
688, 667. HRMS (EI+): m/z calcd. for [C28H33N3O3]+: 459.2522, found: 459.2506 ([M-e-]+). 









5 – Photoswitchable diacylglycerols enable optical control of protein kinase C 
This work has been published in Nature Chemical Biology (2016)52. 
 
5.1 – Introduction 
Diacylglycerol (DAG) is not only an integral component of plasma membrane phospholipids, 
but is also known for its role as a second messenger106. Cellular DAG concentrations are 
tightly regulated by enzymes including phospholipase C (PLC), as well as DAG lipases and 
kinases107. The bulk of DAG originates from phosphatidylcholine, or the PLC-mediated 
hydrolysis of phosphoinositides. Rapid changes in DAG levels occur following the extracellular 
stimulation of receptors108. Over 50 different DAGs have been identified in humans109, and the 
length and degree of unsaturation of the lipid chains determines the biophysical and 
pharmacological properties of individual DAG species110.  
 DAGs interact with both transmembrane and soluble proteins, and are known to 
activate TRP cation channels, including TRPC3 and TRPC6111. Importantly, DAG generation 
also triggers the translocation towards the plasma membrane of a number of proteins that 
contain C1 domains112. These small, highly conserved, zinc-binding protein domains were 
originally characterized as the DAG-sensing regulatory elements of the protein kinase C 
(PKC) family113. C1-mediated translocation plays a key role in the activation of various other 
factors, including kinases and nucleotide exchange factors107. DAGs were also reported to 
affect the protein machinery involved in synaptic transmission and exocytosis107,114. Thus, a 
tool which enables reversible control of C1 domain translocation would be widely applicable 
towards the control of intra- and intercellular signaling. 
 Precision pharmacological manipulation of lipid signaling is often difficult due to the 
restricted localization and diffusion of these hydrophobic molecules. Experimentally, the 
activation of C1 domain-containing proteins is usually achieved by addition of bryostatins or 
phorbol-esters, which can be viewed as highly potent DAG mimics115. So far, the greatest 
control over DAG concentrations has been achieved with the photochemical uncaging of 
DAGs, such as caged 1,2-O-dioctanoyl-sn-glycerol (cg-1,2-DOG)116. However, once 
triggered, the activity cannot be switched OFF and the decay of the DAG signal depends on 
its metabolism or diffusion from the cell. Alternatively, chemical dimerizers117,118 or optogenetic 
techniques19 may be employed to modulate the levels of signaling lipids in cells on the addition 
of a small molecule or a flash of light, respectively. While these systems hold great promise 
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for rapid switching within signaling networks, they require recombinant expression of non-
native proteins, and frequently depend on the presence of exogenous co-factors.  
Previously, we prepared a series of photoswitchable FAs, termed FAAzos51, which can 
mimic highly unsaturated FAs such as AA. They are useful modular building blocks for 
synthetic incorporation into more elaborate photolipids. We now report the incorporation of 
the FAAzos into the DAG scaffold. The resulting photoswitchable DAGs, PhoDAGs, allow us 
to mimic the effects of natural DAGs in living cells with unprecedented kinetics and 
reversibility, especially in regards to pattern formation. 
 
5.2 – Results 
5.2.1 – Design and synthesis of photoswitchable DAGs 
The design of the PhoDAGs was guided by our previous work which suggested that the 
azobenzene derivative FAAzo-4 (Fig. 1a), in its cis-configuration, is able to mimic AA51. 
Therefore, we synthesized PhoDAG-1 (1) as a photoswitchable analog of 
2-O-arachidonyl-1-O-stearoyl-sn-glycerol (1,2-SAG) (Fig. 5.1b). PhoDAG-1 was intended to 
be less active with the azobenzene in the trans-form, and become more active upon 
isomerization to the cis-form with UV-A light. The more hydrophilic DAG derivatives, 
PhoDAG-2 (2) and PhoDAG-3 (3), were designed as cell-permeable analogs mimicking 
1,2-O-dioctanoyl-sn-glycerol (1,2-DOG)119, and contain shorter alkyl chains at the sn1 and 
sn2 positions, including the shorter chain azobenzene FAAzo-9 (4) (Fig. 5.2).  
 PhoDAG-1 was synthesized in four steps in 57% overall yield (Fig. 5.3a). When 
handled under ambient lighting conditions, PhoDAG-1 existed predominantly in its thermally 
stable trans-configuration and contained approximately 10% cis-isomer (Fig. 5.3b). On 
irradiation with UV-A light (λ = 350–375 nm), PhoDAG-1 isomerized to its cis-configuration 
(Fig. 5.1c). Thermal back-relaxation of cis-PhoDAG-1 occurred with a τ-value of about 60 h 
in DMSO and 22 h in water, while blue irradiation increased the rate of isomerization from cis 
to trans. As such, PhoDAG-1 behaves as a regular azobenzene, and can be switched over 
many cycles without fatigue (Fig. 5.1d). The remaining PhoDAGs were prepared in an 






Figure 5.1 | Design and synthesis of photoswitchable DAGs. (a) The chemical structures 
of the photoswitchable fatty acid FAAzo-4, 2-O-arachidonyl-1-O-stearoyl-sn-glycerol 
(1,2-SAG) and 1,2-DOG. (b) The chemical structures of photoswitchable DAGs PhoDAG-1 
(1), PhoDAG-2 (2) and PhoDAG-3 (3). (c) The UV-Vis spectra of PhoDAG-1 (25 µM in 
DMSO) in its dark-adapted (black), UV-adapted (gray) and blue-adapted (blue) 
photostationary states. The absorbance at λ = 350 nm was plotted as a function of the 
irradiation wavelength, demonstrating that PhoDAG-1 existed primarily in its trans- and cis-
configurations under blue and UV-A irradiation, respectively. (d) PhoDAG-1 was cycled 
between the two states over many cycles without fatigue. The absorbance at λ = 350 nm was 
plotted over multiple cycles of alternating UV-A and blue irradiation. 
 
  




Figure 5.2 | Synthesis and characterization of a short-chain photoswitchable fatty acid. 
(a) The chemical synthesis of FAAzo-9 (4). (b) UV-Vis spectroscopy showed that FAAzo-9 
(50 µM in DMSO) could be isomerized between its cis- and trans-configurations with UV-A 
and blue light, respectively. Absorption spectra are shown for the dark-adapted (black), 
UV-adapted (grey) and blue-adapted (blue) photostationary states. 
 
Figure 5.3 | Synthesis and characterization of the photoswitchable DAGs. (a) PhoDAG-1 
was synthesized in four steps and 57% overall yield. (b) A representative NMR spectrum of 
PhoDAG-1 (in CDCl3), displaying the aromatic region. Both the trans- and cis-azobenzene 
protons give signals under ambient lighting conditions, where PhoDAG-1 exists as ≈10% the 





5.2.2 – Optical control of C1 domain translocation 
We evaluated the effects of the PhoDAGs in HeLa cells transiently expressing a fluorescent 
C1 domain translocation reporter (C1-GFP)120,121. Before the addition of any compound, 
C1-GFP was evenly distributed within the cytoplasm, and the application of trans-PhoDAG-1 
did not affect its localization (Fig. 5.4a). Illumination with UV-A light (λ = 375 nm) and 
isomerization to cis-PhoDAG-1 rapidly induced the translocation of C1-GFP towards the 
plasma membrane (Fig. 5.4b, Fig. 5.5, Fig. 5.6). After termination of the irradiation, C1-GFP 
diffused back into the cytoplasm, and translocation was again triggered on repeated 
stimulation (Fig. 5.4c). C1-GFP localization could be controlled with a high degree of spatial 
precision, as only cells that were directly irradiated were affected (Fig. 5.7). Shorter UV-A 
pulses triggered a small and transient translocation, while longer periods of irradiation caused 
a larger and more sustained response (Fig. 5.4d), permitting the generation of oscillation 
patterns. After incubation with PhoDAG-1 followed by washing and removal of extracellular 
compound, translocation of C1-GFP was still observed on photoactivation (Fig. 5.8a). The 
magnitude of the translocation induced by cis-PhoDAG-1 was comparable to that triggered 
by the uncaging of 1,2-DOG from its coumarin-caged form, cg-1,2-DOG (Fig. 5.8b-d).  
Interestingly, PhoDAG-2 and PhoDAG-3 did not induce pronounced translocation of 
C1-GFP towards the plasma membrane. Instead, C1-GFP mostly accumulated on the inner 
membranes on PhoDAG application (Fig. 5.9a). We monitored the localization and uptake of 
the PhoDAGs by exploiting the quenching of coumarin fluorescence by the azobenzene. We 
loaded HeLa cells with coumarin-labelled AA (cg-AA) (Fig. 5.9b), which localizes 
predominantly at the inner cellular membranes122. Application of PhoDAG-1 caused a slow 
but small decrease in the observed coumarin fluorescence (<20% of total, τ = 295 s) 
(Fig. 5.4e black, Fig. 5.9c). In comparison, PhoDAG-3 caused a more rapid and significant 
decrease in coumarin fluorescence (>70% in total, τ = 85 s) (Fig. 5.4e gray, Fig. 5.9d). These 
results suggest that PhoDAG-1 internalizes more slowly and remains trapped on the plasma 
membrane, while PhoDAG-3 quickly diffuses and accumulates at inner membranes. UV-A 
irradiation alone did not trigger the translocation of C1-GFP to the plasma membrane 
(Fig. 5.10a). 




Figure 5.4 | PhoDAG-1 enables optical control of C1-GFP translocation and [Ca2+]i in 
HeLa cells. (a) Fluorescence images showed that PhoDAG-1 (150 µM) promotes reversible 
translocation of C1-GFP in HeLa cells towards the plasma membrane only after irradiation 
with λ = 375 nm light. (b) C1-GFP fluorescence intensity was measured across a 
representative cell (white line) loaded with PhoDAG-1 before (left image) and after (right 
image) illumination with λ = 375 nm light. (c) Translocation could be triggered over multiple 
cycles in the presence of PhoDAG-1, and was quantified by plotting the plasma membrane 
to cytoplasm (PM/CP) fluorescence intensity ratio of a representative cell. (d) Patterns of 
C1-GFP translocation were generated by irradiation at λ = 375 nm in the presence of 
PhoDAG-1 (n = 16, 2 experiments). (e) Fluorescence quenching dynamics of coumarin-
labelled AA (cg-AA, 100 µM) localized at the internal cell membranes after application of 
PhoDAG-1 (150 µM, n = 18, 2 experiments, black) or PhoDAG-3 (150 µM, n = 19, 
2 experiments, gray). (f) The TRPC channel blocker SKF-96365 (50 µM) decreased the Ca2+ 
influx on application and photoactivation of PhoDAG-1 (n = 54, 2 experiments, gray) when 
compared to PhoDAG-1 alone (n = 16, 2 experiments, black). [Ca2+]i levels were monitored 
with the R-GECO [Ca2+]i sensor. (g) After incubation with PhoDAG-1 followed by the removal 
of extracellular compound, both cyclopiazonic acid (CPA, 50 µM, n = 64, 4 experiments, 
orange) and NiCl2 (5 mM) combined with a Ca2+-free extracellular buffer (0.1 mM EGTA, 
n = 73, 4 experiments, gray) reduced the Ca2+ response. Error bars were calculated as 





Figure 5.5 | Optical control of C1-GFP translocation. In HeLa cells, PhoDAG-1 (150 µM) 
triggered the translocation of C1-GFP towards the plasma membrane on λ = 375 nm 
irradiation. Scale bar = 20 µM. 
 
 
Figure 5.6 | Quantification of C1-GFP translocation. (a) A representative fluorescence 
image of HeLa cells expressing C1-GFP, detailing the cytoplasm (CP) and plasma membrane 
(PM) sample regions used for translocation quantification. Displayed here is C1-GFP 
fluorescence after the application of PhoDAG-1 (400 µM) and λ = 375 nm irradiation. Scale 
bar = 20 µM. (b) The GFP fluorescence intensities at the plasma membrane and cytoplasm 
of a representative cell after the application of PhoDAG-1 (200 µM). In the main text, C1 
domain translocation is quantified by measuring the ratio of the GFP intensities in the PM and 
CP, and then plotted as the plasma membrane to cytoplasmic (PM/CP) fluorescence ratio. 




Figure 5.7 | PhoDAG-1 enables spatial control of DAG signaling. In HeLa cells expressing 
C1-GFP and R-GECO, PhoDAG-1 (150 µM) activation could be targeted to specific cells. In 
this case, only the left half of the frame (gray bar) was irradiated at λ = 375 nm. In these cells, 
C1 GFP translocated towards the plasma membrane, alongside an increase in [Ca2+]i. The 








Figure 5.8 | Optical control of C1-GFP translocation. (a) HeLa cells expressing C1-GFP 
and R-GECO were incubated PhoDAG-1 (150 µM) followed by washing with buffer to remove 
extracellular compound. Translocation of C1-GFP towards the plasma membrane was 
observed on λ = 375 nm irradiation. An increase in [Ca2+]i was also observed in the same cells 
(n = 12, 2 experiments). (b) The chemical structure of 1,2-DOG being liberated from caged 
1,2-DOG (cg-1,2-DOG) on λ = 375 nm irradiation. (c,d) The uncaging of cg-1,2-DOG 
(100 µM) triggered C1-GFP translocation towards the plasma membrane in HeLa cells. After 
uncaging, the recovery was relatively slow. Shown are (c) fluorescence images of two 
representative cells, and (d) data averaged from multiple cells (n = 25 cells, 1 experiment), 
displayed as the plasma membrane to cytoplasm (PM/CP) fluorescence ratio. Error bars were 
calculated as ±s.e.m. Scale bar = 20 µM. 
 





Figure 5.9 | Lipid chain length determines the localization and activity of the PhoDAGs. 
(a) In HeLa cells, trans-PhoDAG-3 (150 µM) caused translocation of C1-GFP towards internal 
membranes on application. (b) The chemical structure of coumarin-labeled AA (cg-AA), which 
localizes in internal membranes. (c,d) Representative fluorescence images showing the 
localization of cg-AA (100 µM, fire) before (left) and after (right) the addition of (c) PhoDAG-1 
(150 µM) or (d) PhoDAG-3 (150 µM). PhoDAG-3 quenched the coumarin fluorescence more 
quickly than PhoDAG-1. Cell nuclei were stained with DRAQ-5 (green) as a reference. 





Figure 5.10 | PhoDAG-1 affects [Ca2+]i levels in HeLa cells. HeLa cells were transfected 
with C1-GFP and R-GECO. (a) Before the application of PhoDAG-1, UV-A irradiation alone 
did not catalyze C1-GFP translocation. Application of trans-PhoDAG-1 (300 µM) caused an 
increase in [Ca2+]i levels, however no translocation was observed until triggered by 
λ = 375 nm irradiation (n = 6, 1 experiment). Translocation is displayed as the PM/CP 
C1-GFP fluorescence ratio, while [Ca2+]i levels were plotted as the R-GECO fluorescence 
intensity normalized to the baseline fluorescence (F/Fmin). (b) In the presence of PhoDAG-1, 
a small increase in [Ca2+]i was observed on photoactivation, followed by a delayed, larger 
increase. Shown are representative traces from individual cells. (c) The TRPC channel 
inhibitor SKF-96365 (50 µM) slightly decreased the Ca2+ influx after application of 
PhoDAG-3 (150 µM), but not on photoactivation (n = 54, 2 experiments, gray), when 
compared to PhoDAG-3 alone (n = 16, black). Error bars were calculated as ±s.e.m. 
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5.2.3 – PhoDAGs modulate intracellular Ca2+ levels in HeLa cells 
1,2-SAG was previously reported to increase [Ca2+]i levels in HeLa cells via activation of TRPC 
channels116. Using the genetically encoded Ca2+ sensor, R-GECO123, we observed that 
application of trans-PhoDAG-1 stimulated a small rise in [Ca2+]i (Fig. 5.4f). Upon 
isomerization to cis-PhoDAG-1, a much larger [Ca2+]i increase was observed. The TRPC 
channel blocker SKF-96365 suppressed the rise in [Ca2+]i (Fig. 5.4f). After incubation with 
PhoDAG-1 followed by washing and removal of extracellular compound, an increase in [Ca2+]i 
was still observed on photoactivation (Fig. 5.4g, Fig. 5.8a, Fig. 5.10b). Incubation with 
cyclopiazonic acid, which depletes endoplasmic reticulum (ER) Ca2+ stores124, diminished the 
Ca2+ response (Fig. 5.4g, orange). NiCl2 in combination with a Ca2+-free extracellular buffer116 
abolished the Ca2+ signal by preventing the entry of extracellular Ca2+ (Fig. 5.4g, gray). 
Together, these results suggest that cis-PhoDAG-1 promotes Ca2+ influx by activation of 
TRPC3 and/or TRPC6 channels, which in turn triggers Ca2+-induced Ca2+ release from 
intracellular stores. Interestingly, application and photoactivation of PhoDAG-3 only caused a 






5.2.4 – Optical control of protein kinase C 
PKCs are a group of serine/threonine kinases that are involved in cell cycle regulation, 
proliferation, apoptosis and migration108. The PKC family is grouped into three different 
subtypes; conventional, novel and atypical, according to their cofactor requirements as 
determined by the regulatory elements linked to the kinase domain125. These regulatory 
domains allow different PKC isoforms to decode different signals at the plasma membrane, 
such as the generation of DAG.  
Novel PKCs, such as PKCδ, contain two C1 domains that orchestrate their activation 
alongside translocation toward the plasma membrane in a Ca2+-independent fashion126. In 
HeLa cells, PhoDAG-1 triggered translocation of fluorescently labeled PKCδ (PKCδ-RFP) 
towards the plasma membrane following a UV-A flash (Fig. 5.11a). After termination of the 
irradiation, PKCδ-RFP translocated back to the cytosol with a τ-value of ~102 s (Fig. 5.11b). 
Translocation could be repeated over several cycles, however the magnitude of translocation 
often diminished with repeated UV-A flashes of the same duration (Fig. 5.12a). To overcome 
this limitation, we developed a protocol that allowed us to perform many translocation cycles 
without a decrease in efficiency by increasing the irradiation time on each sequential 
photostimulation (Fig. 5.11c). Increasing the interval time between the UV-A pulses did not 
affect the translocation magnitude, suggesting that trans-PhoDAG-1 metabolism was not a 
significant factor (Fig. 5.12b).  
Conventional PKCs, such as PKCα, were also placed under optical control. 
PhoDAG-1 triggered the translocation of PKCα-GFP127 towards the plasma membrane on 
photoactivation (Fig. 5.12c). In contrast to C1-GFP and PKCδ-RFP, PKCα-GFP translocation 
efficiency decreased quickly alongside Ca2+-influx on sequential photostimulations, reflecting 
its known Ca2+-sensitivity125. 
 Although PKC translocation to the plasma membrane is normally associated with its 
activation128, translocation alone is not sufficient to conclude whether PhoDAG-1 can trigger 
PKC phosphorylation. To this end, we utilized the C kinase activity reporter (CKAR)129, which 
displays a decrease in FRET efficiency on phosphorylation (Fig. 5.11d,e). In line with previous 
reports129, the addition of 1,2-DOG (Fig. 5.12d) to HeLa cells expressing CKAR caused a 
5.5% increase in the CFP/YFP fluorescence ratio, while the application of 
phorbol 12-myristate 13-acetate (PMA) (Fig. 5.12e) caused a 4.8% increase. The application 
of trans-PhoDAG-1 did not cause a significant CKAR FRET change. However, a 4.4% 
increase in the CFP/YFP fluorescence ratio was observed on isomerization to cis, 
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corresponding to 80% of the response evoked by 1,2-DOG (Fig. 5.11e). The application of 
trans-PhoDAG-3 also caused a small increase (2.2%) in the CFP/YFP ratio on application, 
and a further 2.0% increase was induced by photoactivation (Fig. 5.12f,g). The overall 
response after the application and photoactivation of PhoDAG-3 was similar to that which was 
evoked by PhoDAG-1 (95%) or 1,2-DOG (76%). Interestingly, this effect was observed even 
in the absence of a clear translocation to the outer plasma membrane, suggesting that PKCδ-
RFP could be activated on internal membranes as well. In all cases, the effect was reversed 
by the application of the broad-spectrum PKC inhibitors Gö-6983 or chelerythrine chloride 
(C-Cl) (Fig. 5.11d,e, Fig. 5.12d–h)130,131.  
 
Figure 5.11 | PhoDAG-1 enables optical control of PKC. (a) Fluorescence images of HeLa 
cells expressing PKCδ-RFP showed that PhoDAG-1 (100 µM) triggered reversible 
translocation of PKCδ-RFP towards the plasma membrane on λ = 375 nm irradiation. Scale 
bar = 20 µM. (b) After photoactivation, PKCδ-RFP redistributed back to the cytoplasm (n = 19, 
2 experiments). Translocation was quantified as the plasma membrane to cytoplasm (PM/CP) 
fluorescence intensity ratio. (c) Oscillations of PKCδ-RFP translocation were generated by 
sequential pulses of UV-A irradiation with increasing length (n = 11 cells, 1 representative 
experiment). (d,e) PKC activation was evaluated in HeLa cells expressing PKCδ-RFP and the 
cytosolic C kinase activation reporter, CKAR129. (d) PhoDAG-1 (300 µM) triggered an 
increase in the cyan/yellow fluorescence emission ratio on isomerization to cis (n = 49, 
3 experiments). (e) Photoactivation of PhoDAG-1 (n = 49, 3 experiments) produced a similar 
FRET change when compared to 1,2-DOG (300 µM, n = 32, 1 experiment) and PMA (5 µM, 
n = 31, 2 experiments). Application of Gö-6983 (10 µM, n = 49, 3 experiments) reversed this 
effect. The Mann-Whitney test was used to determine statistical significance. 





Figure 5.12 | Optical control of PKC. In HeLa cells: (a) PKCδ-RFP translocation efficiency 
induced by PhoDAG-1 (100 µM) decayed over multiple irradiation cycles of the same length 
(28 s pulses at λ = 375 nm, n = 11, 2 experiments). (b) Changing the time between UV-A 
pulses did not affect the magnitude of the translocation. Both the 60 s (n = 13, 1 experiment) 
and 240 s (n = 15, 1 experiment) intervals showed similar efficiencies. (c) PKCα-GFP 
translocated towards the plasma membrane on isomerization to cis-PhoDAG-1 (150 µM) 
(n = 3, 1 experiment). Sequential photostimulations led to diminished efficiency, 
corresponding to a reduced Ca2+ response. [Ca2+]i levels (R-GECO) are displayed as the RFP 
fluorescence intensity and normalized to the baseline fluorescence (F/Fmin). (d,e) As shown 
by the cytosolic C kinase activity reporter (CKAR), the application of (d) 1,2-DOG (300 µM, 
n = 32, 1 experiment) and (e) PMA (5 µM, n = 31, 2 experiments) triggered an increase in the 
CFP/YFP emission ratio, indicating kinase activation. In both cases, the FRET change was 
reversed on addition of the broadband PKC inhibitor Gö-6983 (10 µM). (f,g) PhoDAG-3 
(15 µM) caused an increase in the CFP/YFP emission ratio on application, and a further 
increase on photoactivation. This effect was reversed by the application of C-Cl (100 µM) 
(n = 14, 1 experiment). (h) The CKAR response in HeLa cells was compared between cells 
with (n = 37, 1 experiment, orange) and without (n = 20, 1 experiment, teal) the expression of 
exogenous PKCδ-RFP. Overexpression of PKCδ-RFP increased the CKAR response by 1.2-
fold when compared to endogenous PKC expression only. Error bars were calculated as 
±s.e.m. 
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5.2.5 – Optical control of [Ca2+]i oscillations in β-cells 
In pancreatic β-cells, glucose induces oscillations in [Ca2+]i levels, the frequency of which 
strongly correlate with insulin secretion132. Similarly, DAG levels are known to oscillate in 
β-cells121, implicating a connection between glucose and lipid metabolism. The exact 
mechanism by which DAGs regulate insulin secretion remains elusive, however increased 
DAG levels were reported to terminate [Ca2+]i oscillations in the mouse insulinoma-derived 
β-cell line, MIN6133,134. The addition of trans-PhoDAG-1 did not affect [Ca2+]i oscillations in 
MIN6 cells stimulated by a high glucose concentration (20 mM). Photoactivation with λ = 375 
nm for 3 min caused a rapid decline in both the intensity and frequency of the [Ca2+]i 
oscillations (Fig. 5.13a,b), as well as the overall [Ca2+]i level (Fig. 5.14a). In the majority of 
cells examined, this termination was transient and lasted on average 5 min. PhoDAG-3 
behaved in a similar manner, but was active at a much lower concentration (Fig. 5.13c). 
[Ca2+]i oscillations in β-cells are driven by a dynamic interplay between voltage-gated 
ion channels. DAGs modulate the conductance of L-type voltage-activated Ca2+ channels 
(Cav) in mouse β-cells, and 1,2-DOG is known to inhibit the whole-cell Cav current135. Using 
whole-cell patch clamp electrophysiology in MIN6 cells, we evaluated the effects of PhoDAGs 
on Cav conductance. Photoactivation of PhoDAG-3 with UV-A light triggered a decrease in 
the Cav current (Fig. 5.13d, Fig. 5.14b). This effect could be reversed by irradiation with blue 
light, and could be repeated over several cycles (Fig. 5.13e). Application of diltiazem, which 
blocks L-type Ca2+ channels, diminished the Cav current in a similar fashion (Fig. 5.14c). UV-A 
irradiation alone did not affect the oscillatory behavior (Fig. 5.15) or the Cav current 
(Fig. 5.14c). 
 To compare the responses observed in MIN6 to those of primary β-cells, we cultured 
β-cells from dissociated mouse pancreatic islets. As in MIN6 cells, PhoDAG-3 triggered a 
light-dependent decrease in [Ca2+]i oscillation frequency (Fig. 5.13f) and the whole-cell Cav 
conductance (Fig. 5.13g). Surprisingly, in these cells cis-PhoDAG-1 caused an increase in 
the oscillation frequency and [Ca2+]i level (Fig. 5.13h). Patch clamp experiments revealed that, 
whereas photoactivation of PhoDAG-1 had little effect on Cav conductance (Fig. 5.16a), it 
caused a reduction in the conductance of delayed rectifier voltage-gated K+ channels (Kv) 
(Fig. 5.13i). Ablation of Kv has been shown to increase Ca2+ fluxes in β-cells by extending the 
AP duration15. Similar effects can be also induced by AA, which is known to block Kv2.1 




magnitude of β-cell Cav conductance (Fig. 5.16b), while the addition of AA reduced the Kv 
current (Fig. 5.16c). Neither UV-A nor blue-irradiation alone affected the Cav or Kv currents 
(Fig. 5.16b,c). 
 
Figure 5.13 | Optical control of [Ca2+]i oscillations in MIN6 and dissociated primary 
mouse β-cells. (a-c) [Ca2+]i oscillations in glucose-stimulated (20 mM) MIN6 cells were 
monitored using R-GECO. PhoDAG-1 (300 µM) decreased [Ca2+]i levels on photoactivation 
with λ = 375 nm light, displayed as (a) individual [Ca2+]i traces from four representative cells, 
and (b) a statistical analysis of the oscillation frequency (n = 38, 3 experiments). Bar graphs 
represent the number of high intensity [Ca2+]i oscillations (>50% of highest transient in each 
trace) detected within every 60 s interval. (c) PhoDAG-3 (35 µM) also triggered a decrease 
in glucose-stimulated (20 mM) [Ca2+]i oscillations on photoactivation. (d) Isomerization to 
cis-PhoDAG-3 (35 µM, n = 6) induced a decrease in whole-cell voltage-gated Ca2+ channel 
(Cav) current. (e) This effect was reversed by blue light and could be repeated over several 
cycles (n = 3). (f-i) In dissociated mouse β-cells: (f) cis-PhoDAG-3 (10 µM) caused a decrease 
in glucose-stimulated (11 mM) [Ca2+]i oscillations, corresponding to (g) a reduction in the Cav 
current (15 µM, n = 3). (h) In contrast, cis-PhoDAG-1 (200 µM) led to an increase in the [Ca2+]i 
oscillation frequency. (i) A reduction in the delayed rectifier voltage-activated K+ channel (Kv) 
current was observed on isomerization to cis-PhoDAG-1 (n = 3). Error bars were calculated 
as ±s.e.m. 




Figure 5.14 | Optical control of [Ca2+]i oscillations in MIN6 cells. [Ca2+]i oscillations in 
glucose stimulated (20 mM) MIN6 cells were monitored using R-GECO (a) PhoDAG-1 
(300 µM) caused a decrease in the overall [Ca2+]i level on photoactivation. Data was averaged 
over multiple cells (n = 23, 2 experiments). (b) PhoDAG-3 (35 µM) triggered a decrease in 
the whole-cell voltage activated L-type Ca2+ channel (Cav) current, as shown by voltage ramps 
(−70 to +50 mV over 5 s) from a representative cell. (c) UV-A or blue irradiation alone did not 
affect the Cav current (n = 8), while the application of 1,2-DOG (100 µM, n = 3) and the L-type 
Ca2+ channel blocker diltiazem (500 µM, n = 3) decreased the magnitude of the whole-cell Cav 
current. (d) The application of 1,2-DOG (100 µM) led to a slow and permanent decrease in 






Figure 5.15 | UV-A illumination alone has no effect on MIN6 [Ca2+]i oscillations. [Ca2+]i 
oscillations in glucose-stimulated (20 mM) MIN6 cells were monitored using R-GECO. UV-A 
irradiation alone did not affect the oscillation frequency. Shown are individual [Ca2+]i traces 
from representative cells (left), and a statistical analysis of the oscillation frequency averaged 
over multiple cells (n = 30, one experiment, right). Bar graphs represent the number of 
detected high intensity [Ca2+]i oscillations (>50% of highest transient in each trace) within 




Figure 5.16 |   Electrophysiological studies in dissociated mouse β-cells. In primary 
mouse β-cells: (a) PhoDAG-1 (200 µM) had no effect on the Cav current (n = 5). (b) UV-A or 
blue-irradiation alone did not affect the Cav current (n = 8), while the application of 1,2-DOG 
(15 µM) decreased the magnitude of the Cav current (n = 3). (c) UV-A or blue-irradiation alone 
did not affect the Kv current (n = 4). AA (10 µM) decreased the magnitude of the Kv current 
(n = 4). Error bars were calculated as ±s.e.m. 
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5.2.6 – Optical control of insulin secretion in pancreatic islets  
Islets of Langerhans are endocrine micro-organs comprised of hundreds of β-cells together 
with α-, δ- and pancreatic polypeptide cells137. We therefore examined whether responses in 
intact islets were similar to MIN6 and dissociated β-cells. In contrast to the effects observed 
in dissociated cells, intact mouse pancreatic islets pre-treated with either PhoDAG-1 
(Fig. 5.17a,b) or PhoDAG-3 (Fig. 5.18a,b) responded to illumination with a marked and 
reproducible increase in the glucose-stimulated (11 mM) [Ca2+]i oscillation frequency. These 
results could be mimicked by the application of 1,2-DOG (Fig. 5.17c). Strikingly, islets treated 
with PhoDAG-1 were rendered light-responsive, displaying almost a 3-fold increase in insulin 
secretion (at 16.7 mM glucose) following photoactivation (Fig. 5.17d). UV-A irradiation alone 
did not significantly affect [Ca2+]i oscillation frequency or the amount of insulin secreted 
(Fig. 5.18c,d). These results suggest that photoactivation of the PhoDAGs in intact pancreatic 






Figure 5.17 | Optical control of insulin secretion in intact mouse pancreatic islets. 
Glucose-stimulated (11 mM) [Ca2+]i oscillations in whole mouse pancreatic islets were 
monitored using Fluo-2. (a,b) Photoactivation of PhoDAG-1 (200 µM) triggered an increase 
in the oscillation frequency, displayed as (a) a representative trace from a single islet and 
(b) the average oscillation frequencies for several islets before and after λ = 350 nm irradiation 
(n = 9 recordings from 4 animals). (c) The application of 1,2-DOG (100 µM) led to an increase 
in the oscillation frequency (n = 8 recordings from 4 animals). (d) As determined by an HTRF 
assay, cis-PhoDAG-1 (200 µM) at 16.7 mM glucose led to a 3-fold increase in insulin 
secretion when compared to either trans-PhoDAG-1 or glucose-stimulated conditions 
(16.7 mM) alone. Similar effects were observed with 1,2-DOG (100 µM) (n = 3 assays from 
6 animals). G3 = 3 mM glucose, G16.7 = 16.7 mM glucose. The Mann-Whitney test was used 
to determine statistical significance. ns = not significant, *P<0.05, **P<0.01. Error bars were 
calculated as ±s.e.m. 




Figure 5.18 | Optical control of pancreatic islet activity. [Ca2+]i oscillations in intact mouse 
pancreatic islets were monitored by Fluo-2. (a,b) Photoactivation of PhoDAG-3 (100 µM) 
triggered an increase in the oscillation frequency, displayed as (a) a representative trace from 
a single islet and (b) the average oscillation frequencies for several islets before and after 
λ = 350 nm irradiation (n = 8 recordings from 3 animals). (c,d) UV-A irradiation (λ = 350 nm) 
alone did not affect (c) the speed of the [Ca2+]i oscillations in islets stimulated by 11 mM 
glucose or (d) the insulin secretion stimulated by 16.7 mM glucose (G16.7) (n = 3 experiments 
from 3 animals). The Mann-Whitney test was used to determine statistical significance. 







5.2.7 – Optical control of synaptic transmission 
DAG is known as a regulator of neuronal activity114,138. Multiple downstream effectors of DAG 
signaling have been described139, including the PKC-dependent phosphorylation of Munc18 
and the direct binding of DAG to Munc13 proteins, and have been linked to an increase in 
synaptic transmission140,141. Munc13s function as essential priming factors for synaptic 
vesicles, preparing them for fusion with the plasma membrane at the active zone, thereby 
facilitating the release of neurotransmitters into the synaptic cleft142–144. We found that 
PhoDAG-1 could indeed trigger the translocation of the fluorescent translocation reporter 
Munc13-1-GFP towards the plasma membrane on photoactivation in HeLa cells over multiple 
cycles (Fig. 5.19a). The DAG-insensitive Munc13-1H567K-GFP mutant reporter142 did not 
respond to PhoDAG-1 (Fig. 5.20).  
 We then examined the effects of all three PhoDAGs in primary cultures of mouse 
autaptic hippocampal neurons. In this case, PhoDAG-2 produced the most dramatic and 
reproducible effect on synaptic transmission. Synaptic transmission was measured by 
recording evoked excitatory postsynaptic currents (EPSCs) that were elicited by 
depolarization-induced APs. The initial EPSC amplitude was not affected by the presence of 
trans-PhoDAG-2 when compared to control neurons (Fig. 5.19b). However, on activation with 
λ = 365 nm light (30 s), we observed a prominent increase in the EPSC amplitude 
(Fig. 5.19c,d). This activation was sustained until inactivation with λ = 425 nm light (20 s), 
which triggered a rapid and significant decrease of the EPSC amplitude. This effect was 
absent in control neurons and could be repeated over multiple cycles with little to no decay in 
efficacy. The first activation of PhoDAG-2 led to a 1.19±0.07-fold increase of the EPSC 
amplitude, and was similar in the following two rounds of activation (1.19±0.1 fold and 
1.18±0.07 fold) (Fig. 5.19e). Similarly, the first inactivation led to a 0.80±0.03 fold decrease in 
the EPSC amplitude, and was similar in the two following cycles (0.77±0.03 and 0.76±0.03 
fold, respectively). We did not observe any change in the series resistance of the patch pipette 
during activation or inactivation of PhoDAG-2, which could have generated artifacts mimicking 
changes in the EPSC size (Fig. 5.21). Similarly, PhoDAG-2 affected the frequency of 
spontaneous miniature postsynaptic currents (sEPSCs), pointing to an acute effect on the 
presynaptic release machinery (Fig. 5.19f). An increase in the sEPSC frequency was 
observed during periods of activation, by 1.68±0.3, 1.55±0.4 and 1.62±0.2 fold over three 
rounds. Inactivation led to a decrease in the sEPSC frequency, by 0.65±0.1, 0.82±0.14, and 
0.63±0.06 fold over three inactivation cycles, respectively. PhoDAG-3 produced similar 
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results (Fig. 5.22), however the variability of the response of the neurons to photoactivation 
was larger, and some neurons did not respond consistently during all rounds of 
activation/inactivation. PhoDAG-1 did not yield a consistent effect on synaptic transmission, 
likely due to its limited solubility at these high concentrations during incubation. 
 
 
Figure 5.19 | PhoDAGs enable optical control of Munc13 and synaptic transmission. 
(a) In HeLa cells, PhoDAG-1 (150 µM) triggered reversible translocation of Munc13-1-GFP 
on photoactivation (n = 14, 3 experiments). (b-f) Mouse hippocampal neurons were pre-
incubated with PhoDAG-2 (500 µM, 20–25 min, 37 ˚C) and excitatory post synaptic currents 
(EPSCs) were monitored by whole-cell voltage clamp electrophysiology. (b) trans-PhoDAG-2 
(red, n = 8) did not affect the EPSC amplitude when compared to control neurons (black, 
n = 6). (c) Photoactivation of PhoDAG-2-treated neurons with λ = 365 nm light caused an 
increase in the EPSC amplitude, while deactivation with λ = 425 nm light reversed the effect. 
Shown are two neurons pre-incubated with PhoDAG-2 (red) and two control neurons (black). 
(d) Representative EPSC traces during activation and inactivation. Numbers indicate the 
EPSC number. Black traces are the EPSC before irradiation. (e,f) The normalized change in 
(e) the EPSC amplitude (red = PhoDAG-2, n = 8; black = vehicle, n = 6) and (f) sEPSC 
frequency (red = PhoDAG-2, n = 6; black = vehicle, n = 6) over six rounds of alternating 
activation and inactivation. Values for individual neurons are presented as open circles. 
(g) cis-PhoDAG-3 (1 mM) increased the rate of aldicarb-induced (1 mM) paralysis in 
Caenorhabditis elegans (n = 3 experiments, 20 animals each) when compared to animals 
exposed to trans-PhoDAG-3 (black). The paralysis rate was not affected by UV-A irradiation 
alone (blue, gray). (h) cis-PhoDAG-3 (1 mM) did not affect the rate of levamisole-induced 
(0.1 mM) paralysis in C. elegans (n = 3 experiments, 20 animals each) when compared to 
animals exposed to trans-PhoDAG-3 (black). The paralysis rate was not affected by UV-A 
irradiation alone (blue, gray). A Mann-Whitney test was used to determine statistical 






Figure 5.20 | A C1 domain point mutant abolishes the sensitivity of Munc13-1 to 
PhoDAG-1. In HeLa cells, the DAG-insensitive Munc13-1H567K-GFP mutant translocation 
reporter did not translocate on the application of PhoDAG-1 (150 µM) or after photoactivation 
with λ = 375 nm light, even though an increase in [Ca2+]i levels was observed using R-GECO 
(n = 13, 2 experiments). Error bars were calculated as ±s.e.m. 




Figure 5.21 | PhoDAG-2 does not affect the pipette series resistance in patch-clamp 
experiments. The PhoDAGs are lipid compounds, and therefore might affect the series 
resistance (Rs) of the patch pipette, which could lead to artifacts in the EPSC amplitude. 
Moreover, the compound integrates in the cell membrane where it might lead to changes in 
the cell size or membrane conductance. To exclude these effects, we performed a control 
experiment with PhoDAG-2 and monitored series resistance and membrane capacitance, 
before and after illumination (n represents the number of illumination cycles; DMSO, black, 
for activation n = 9, for inactivation n = 8; PhoDAG-2, red, for activation n = 22, for inactivation 
n = 21). (a) The ratio of the change in the EPSC amplitude was calculated by dividing the 
average amplitude after photoactivation, by that before photoactivation. (b) The ratio of the 
change in EPSC charge was calculated by dividing the average charge after activation by that 
before activation. (c) The ratio of the change in the cell capacitance, a measure of the cell 
body size and conductance, was calculated by dividing the average capacitance after 
activation by that before activation. (d) The ratio of the change in Rs was calculated by dividing 
the average capacitance after activation by that before activation. (e) The ratio of the change 
in EPSC amplitude after inactivation. (f) The ratio of the change in EPSC charge after 
inactivation (g) The ratio of the change in cell capacitance after inactivation. (h) The ratio of 
the change in Rs after inactivation. Error bars were calculated as ±s.e.m. The Mann-Whitney 





   
Figure 5.22 | PhoDAG-3 modulates synaptic transmission in hippocamcal neurons. Wild 
type mouse hippocampal neurons were pre-incubated at 37 ºC in the extracellular recording 
solution containing 500 µM PhoDAG-3 or DMSO (vehicle). The neurons were then whole-cell 
voltage clamped at room temperature and stimulated at 0.2 Hz, and the evoked EPSCs were 
monitored. (a) The initial EPSC amplitudes measured in control neurons (black, n = 12), or in 
neurons where trans-PhoDAG-3 was applied (red, n = 13), were not significantly different. 
(b) The normalized EPSC amplitude is plotted for two neurons preincubated with PhoDAG-3 
(red) and for two control neurons (black) on photostimulation. (c) Example traces of EPSCs 
during activation and inactivation for PhoDAG-3. (d) Activation and inactivation by PhoDAG-3 
could be repeated over several cycles, corresponding to an increase and decrease in the 
EPSC amplitude, respectively (red = PhoDAG-3, n = 13; black = vehicle, n = 12). (e) The 
sEPSC frequency could also be increased by photoactivation with UV-A light, and decreased 
by inactivation with blue light (red = PhoDAG-3, n = 11; black = vehicle, n = 10). Data from 
individual neurons are presented by open circles, summaries are presented as mean ± s.e.m. 
The Mann-Whitney test was used to determine statistical significance. 
ns = not significant P>0.05.  
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5.2.8 – Control of Caenorhabditis elegans synaptic transmission 
Caenorhabditis elegans has been used extensively to study synaptic transmission145. At the 
neuromuscular junction, acetylcholine is released from cholinergic motor neurons and 
activates post-synaptic cholinergic receptors of the body-wall muscles, inducing muscle 
contraction146. This process is terminated by the action of acetylcholinesterase. Sensitivity to 
aldicarb, an acetylcholinesterase inhibitor, is therefore commonly used to study synaptic 
transmission at the neuromuscular junction147. C. elegans become hypersensitive to aldicarb 
under conditions of excess acetylcholine release and display a faster onset of paralysis on 
exposure to the drug. Animals cultivated in the presence of cis-PhoDAG-3 (1 mM) showed a 
faster onset of paralysis induced by aldicarb (1 mM) as compared to animals cultivated only 
with ethanol (vehicle), with or without UV-A irradiation. Animals that were exposed to trans-
PhoDAG-3 showed no aldicarb hypersensitivity (Fig. 5.19g). To exclude post-synaptic effects 
(e.g. a possible PhoDAG-3-induced increase in the sensitivity of nicotinic acetylcholine 
receptors (nAChRs)), we used levamisole, which paralyzes animals due to hyperstimulation 
of muscle-specific nAChRs148,149. Animals grown in the presence of trans- or cis-PhoDAG-3 
showed similar rates of levamisole-induced paralysis when compared to the vehicle controls 
(Fig. 5.19h). These results suggest that PhoDAG-3 affects pre-synaptic transmission via 






5.3 – Discussion 
Here, we have demonstrated that the three PhoDAGs are versatile tools for controlling DAG 
signaling in a variety of experimental settings, and can even be applied in vivo. In all cases, 
the PhoDAGs were more potent in their cis-configuration, which is characterized by an 
increased molecular dipole moment and a more bent orientation150. We hypothesize that these 
changes mimic the transition from a less bent (ex. saturated) fatty acid, to a highly bent acyl 
chain like AA. Effectively, this action mimics an increase in DAG levels on the membrane, 
potentially by making the headgroup more accessible for C1 domain binding. 
The length of each acyl chain is crucial, as hydrophobicity determines the localization 
and site of activity. We envision that PhoDAG-1 could be used as a general tool, by virtue of 
C1-fusion, to translocate other effector proteins towards the plasma membrane in a reversible 
manner. This approach can be extended to other kinases, lipases, or glycosidases, and could 
be invaluable in understanding how plasma membrane localization affects these proteins. 
Although the shorter chain PhoDAGs triggered translocation towards intracellular membranes 
preferentially, we demonstrated that this does not limit their utility in other settings. As 
photochromic ligands, they are applied to cells extracellularly without the need for genetic 
manipulation. Although their activity cannot be genetically targeted to specific organelles, 
activation can still be induced with the spatial precision of light, enabling specific cells or 
organelles to be activated on command. 
As with the metabolic generation of endogenous DAGs, the PhoDAGs stimulate a 
mosaic of effector proteins, similar to the downstream activation of the Gq-pathway. Although 
the small dynamic range of the CKAR sensor might limit our detection of PKC phosphorylation 
to quite low activation levels, our results in more complex systems suggest that the PhoDAGs 
indeed are capable of stimulating the cell in a physiologically relevant manner. In pancreatic 
β-cells, DAG signaling can be manipulated with a degree of precision and reproducibility 
currently unavailable to other chemical tools. These effects likely involve the activation of PKC 
alongside other partners including Munc13, affecting glucose-stimulated [Ca2+]i oscillations 
via effects on Kv/Cav channels, intracellular Ca2+ stores, the SNARE apparatus, granule 
sensitivity and combinations thereof151. Similarly, our experiments in both hippocampal 
neurons and C. elegans suggest that the PhoDAGs increases neurotransmitter release by 
affecting the pre-synaptic release machinery. cis-PhoDAGs likely activate Munc13 or cause 
the phosphorylation of Munc18114,141, promoting vesicle release. Combined, these results 
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demonstrate that the PhoDAGs are useful tools to study the effects of DAG on the exocytosis 
of both hormones and neurotransmitters. 
Most notably, the PhoDAGs revealed the cell and tissue-context of DAG signaling in 
pancreatic β-cells. When PhoDAGs are activated on β-cell inner membranes, an overall 
decrease in the [Ca2+]i oscillation frequency is observed. Conversely, DAG-activation on the 
outer plasma membrane preferentially leads to an increase in oscillation speed. Similar effects 
were also observed for the uncaging of AA on the inner vs outer membranes of MIN6 cells122, 
which is not surprising given the metabolic connection between these two lipids. The divergent 
effects observed between MIN6 and dissociated β-cells highlight the importance of the acyl 
chain length for DAG activity. This may stem from subtle differences in ion channel 
expression, membrane composition, and endogenous DAG levels between immortalized and 
primary cells. In the case of intact islets, a greater amount of extracellular matrix likely 
increases the surface availability of both long- and short-chain PhoDAGs, resulting in a 
reduced effect on the Cav channels. This work highlights the limitations of model cell lines, 
and may explain some of the contrasting reports in the literature on the effects of DAG in 
pancreatic β-cells. 
The PhoDAGs permit control over C1-containg proteins with unmatched 
spatiotemporal precision. They possess the main advantage of caged DAGs, as they can be 
applied to cells in the inactive trans-configuration where they can be switched ON in seconds 
with a light stimulus. Importantly, these small molecule tools stand alone in their ability to 
switch OFF. This characteristic will enable researchers to mimic the natural oscillations 
observed in both DAG levels and PKC activation in a fully time-controlled fashion129. As the 
PhoDAGs require high energy UV-A irradiation to become activated, their use could be 
partially restricted to primary research applications due to the cytotoxicity associated with high 
intensity UV-A light. Future studies will be directed towards preparing “red-shifted” 
PhoDAGs37, or those which can be activated by two-photon irradiation. This will permit the 
use of longer wavelength, and lower energy irradiation for photoactivation. This deeper-
penetrating light will increase the PhoDAGs applicability in more complex intact tissues, and 
as potential therapeutics. 
As a lipid precursor, DAG is incorporated into a collection of more complicated 
glycerolipids that serve as structural components, protein anchors, and signaling molecules. 
We expect that novel photolipids built around the DAG scaffold will emerge as useful tools to 





5.4 – Supporting information 
5.4.1 – List of utilized cDNA constructs 
Name Characterization 
R-GECO123 Red intensiometric [Ca2+]i sensor 
C1-GFP120 Green DAG-sensing translocation probe 
PKCδ-RFP* Protein kinase C δ reporter 
PKCα-GFP127  Protein kinase C α reporter 
CKAR129 Cytosolic C kinase activity reporter 
Munc13-1-GFP142 Munc13-1 translocation reporter 
Munc13-1H567K-GFP142 Munc13-1H567K mutant translocation reporter 
 
*The PKCδ-RFP construct was prepared by exchanging the eGFP from the original 
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5.4.2 – Cell culture 
HeLa Kyoto cells were grown in 1.0 g/L D-glucose DMEM (GIBCO, cat # 31885-023) supplied 
with 10% FBS (GIBCO, cat # 10270-106) and 0.1 mg/mL antibiotic Primocin (Invitrogen, cat 
# ant-pm-1). HeLa cells were first seeded in an 8-well Lab-Tek™ chambered coverslip 
(ThermoScientific # 155411) 24-48 h before transfection at 37 °C and 5% CO2. Transfection 
was carried out with FugeneHD (Promega, cat # E2311) in DMEM free of FBS and antibiotic 
according to the manufacturer's instructions. First, the media was aspirated and the wells were 
charged with DMEM (200 µL per well). A transfection solution containing DMEM (20 µL per 
well), cDNA (300 ng total DNA per well) and FugeneHD (1.5 µL per well) was then added to 
each well of the 8-well Lab-Tek™. Cells were incubated at 37 °C and 5% CO2 for 20−24 h 
before the microscopy experiments were performed. 
 The mouse insulinoma derived cell line, MIN6, used in this study was initially 
developed and provided as a kind gift by Miyazaki et al.153. The cells were grown at 37 °C and 
5% CO2 in high glucose DMEM (41965-039, Life Technologies) supplied with 15% FBS 
(10270098, Lifetechnologies), penicillin-streptomycin (Pen Strep, 100 U/mL, 15140122, 
Lifetechnologies) and β-mercaptoethanol (70 µM, P07-05100, PAN-Biotech) that was always 
added freshly to the cell culture flasks. Cells were seeded in 8-well Lab-Tek™ microscope 
dishes 48–64 h (to reach 50−80% confluence) prior to imaging. For [Ca2+]i imaging, MIN6 cells 
were transfected with cDNA coding for the R-GECO123 [Ca2+]i reporter, and cDNA coding for 
the C1-GFP120 DAG sensor (as a control) usually 24-48 h after seeding. A transfection cocktail 
of C1-GFP (200 ng per well) and R-GECO (200 ng per well) in Opti-MEM (20 µL per well, 
31985-070, Life Technologies) and Lipofectamine2000® transfection reagent (1.5 µL per well, 
11668030, Life Technologies) was added to each well of an 8-well Lab-Tek™ microscope 
dish loaded with 200 µL Opti-MEM (37 °C, immediately before the addition). After 24 h 
incubation at 37 °C and 8.5% CO2, the media was exchanged to culture media, followed by 






5.4.3 – Culture of primary mouse pancreatic islets 
**Note: Culture of mouse pancreatic islets was performed by Dr. David Hodson (IMSR 
Birmingham), and the experimental details are included here for clarity. 
 
Islets were isolated from C57BL6 mice using collagenase digestion, as previously detailed154. 
Briefly, following euthanasia by cervical dislocation, the bile duct was injected with a 
collagenase solution (1 mg/mL) before digestion at 37 °C for 10 min and separation of islets 
using a Histopaque gradient (1.083 and 1.077 g/mL). Islets were cultured for 24-72 h in 
Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal calf serum 
(FCS), 100 U/mL penicillin and 100 µg/mL streptomycin. Islets were dissociated into single 
β-cells using trypsin digestion for 5 min at 37 °C and allowed to attach to poly-L-lysine-coated 
and acid-etched coverslips. All animal work was regulated by the Home Office according to 
the Animals Act 1986 (Scientific Procedures) of the United Kingdom (PPL 70/7349, Dr Isabelle 
Leclerc), as well as EU Directive 2010/63/EU. 
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5.4.4 – Laser scanning confocal microscopy 
The cells were incubated in 250 µL imaging buffer containing (in mM): 115 NaCl, 1.2 CaCl2, 
1.2 MgCl2, 1.2 K2HPO4, 20 HEPES, D-glucose (20 for MIN6, 11 for islets and β-cells unless 
otherwise stated), adjusted to pH 7.4 with NaOH at 37 °C and 5% CO2 for at least 10 min. 
Compounds were first solubilized in DMSO at a concentration of 10 mM. This stock (2-5 µL) 
was then diluted into imaging buffer (50 µL) and added directly to the well containing the cells 
in imaging buffer. 
 Imaging of HeLa, MIN6, or primary rodent pancreatic β-cells was performed cells was 
performed on one of two microscopes: 1) Olympus Fluoview 1200 with a 20x objective, or a 
63x oil objective. GFP excitation was performed with λ = 488 nm laser at low laser power 
(<3%) and emission was collected at λ = 500-550 nm. CFP excitation was performed with a 
λ = 405 nm laser at low laser power and emission was collected at λ = 425-475 nm. For FRET 
experiments, YFP emission was collected at λ = 510-560 nm. RFP/R-GECO excitation was 
performed with a λ = 559 nm laser at low laser power (<3%) and emission was collected at 
λ = 570-670 nm. Compound irradiation at λ = 375 nm was triggered using the quench function 
in the Olympus software. Photoactivation was carried out with λ = 375 nm laser at 100% 
intensity. 2) Zeiss Axiovert M200 coupled to a Yokogawa CSU10 spinning disk head and 10x 
and 20x objectives. Fluo-2 excitation was performed using a solid-state λ = 491 nm laser, and 
emission was collected using a highly sensitive back-illuminated EM-CCD (Hammamatsu 
C9100-13) at λ = 500-550 nm. Photoactivation was carried out using an X-Cite 120 
epifluorescence source and a λ = 350±20 nm band-pass filter. Images were processed with 
Fiji software (http://fiji.sc/Fiji) and the resulting data was analyzed in Microsoft Excel, MATLAB 
and R. The data were then plotted with Igor Pro, Origin and R.   
 
5.4.5 – Quantification of insulin secretion 
Insulin secretion was measured using static incubation of 6-8 islets for 30 min at 37 °C in 
Krebs-HEPES bicarbonate solution containing (in mM): 130 NaCl, 3.6 KCl, 1.5 CaCl2, 
0.5 MgSO4, 0.5 NaH2PO4, 2 NaHCO3, 10 HEPES and 0.1% (wt/vol) bovine serum albumin 
(BSA), pH 7.4155. Treatments were applied as indicated, and photoswitching performed at 
λ = 340±10 nm using a BMG Fluostar Optima platereader. Insulin concentration secreted into 
the supernatant was determined using a homogeneous time-resolved fluorescence (HTRF) 




5.4.6 – Whole-cell electrophysiology in MIN6 and dissociated β-cells 
MIN6 cells (passage 26-33) were cultured as described above at 37 °C and 5% CO2. For cell 
detachment, the medium was removed and the cells were washed with Ca2+-free PBS buffer 
and treated with trypsin for 5 min at 37 °C. The detached cells were diluted in growth medium 
and plated on acid-etched coverslips in a 24-well plate. 50,000 cells were added to each well 
in 500 µL growth medium. The growth medium was exchanged every 48 h, and 
electrophysiological experiments were carried out 2-7 days later.  
Whole cell patch clamp experiments were performed using a standard 
electrophysiology setup equipped with a HEKA Patch Clamp EPC10 USB amplifier and 
PatchMaster software (HEKA Electronik). Micropipettes were generated from “Science 
Products GB200-F-8P with filament” pipettes using a Narishige PC-10 vertical puller. The 
patch pipette resistance varied between 4-7 MΩ. For recording of the Ca2+-channel current156, 
the bath solution contained (in mM): 82 NaCl, 20 tetraethylammonium chloride, 
0.1 tolbutamide, 30 CaCl2, 5 CsCl, 1 MgCl2, 0.1 EGTA, 10 D-glucose, 5 HEPES (adjusted to 
pH 7.4 with NaOH). The intracellular solution contained (in mM): 102 CsCl, 
10 tetraethylammonium chloride, 0.1 tolbutamide, 10 EGTA, 1 MgCl2, 3 Na2ATP, 5 HEPES 
(adjusted to pH 7.4 with CsOH). In voltage clamp mode, voltage steps were applied to the 
cells from the baseline at –70 mV to +50 mV in 10 mV intervals for 0.5 s. All cells had a leak 
current below 15 pA on break-in at –70 mV. For recording of the Kv current, the bath solution 
contained (in mM): 119 NaCl, 2 CaCl2, 4.7 KCl, 10 HEPES, 1.2 MgSO4, 1.2 KH2PO4, 
14.4 D-glucose (adjusted to pH 7.3 with NaOH). The intracellular solution contained (in mM): 
140 KCl, 1 MgCl2, 10 EGTA, 10 HEPES, 5 MgATP (adjusted to pH 7.25 with KOH). The data 
was analyzed in Igor Pro using the Patcher`s Power Tools (MPI Göttingen) plugin. Current 
values were extrapolated and processed in Microscoft Excel, and the results were again 
plotted in Igor Pro. 
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5.4.7 – Electrophysiology in mouse hippocampal neurons 
**Note: Patch-clamp experiments in mouse hippocampal neurons were performed by Dr. Noa 
Lipstein (MPI Göttingen), and the experimental details are included here for clarity. 
 
Microisland cultures of wild type mouse hippocampal neurons were prepared as described157. 
For experiments, a 12-well plate was filled with 480 µL/well of extracellular recording solution 
contained (in mM): 140 NaCl, 2.4 KCl, 10 HEPES, 10 D-glucose, 4 CaCl2, and 4 MgCl2 
(320 mOsmol/L), and 20 µL of a 12.5 M stock solution of PhoDAG-2 or PhoDAG-3 in DMSO 
was added. For controls, 20 µL of DMSO were added. The coverslips containing day in vitro 
14−16 neurons were broken and a piece was moved into one well in the 12-well plate. The 
neurons were incubated at 37 ºC, and 5% CO2 for 10 min with PhoDAG-3 and respective 
controls; or for 20–25 min for PhoDAG-2 and respective controls. Neurons were incubated 
with PhoDAG, and were whole-cell voltage clamped directly post-incubation. EPSCs were 
elicited by depolarization-induced APs at a frequency of 0.2 Hz. For vehicle controls, neurons 
from the same culture were incubated in DMSO for the same time. Beyond these times, we 
did not find a correlation between the length of incubation and the presence of an effect or its 
strength. Longer incubation periods of >1 h resulted in astrocyte death. In the case of 
PhoDAG-2 patching the incubated neurons was usually easier 1 h after the stock solution 
was diluted in the extracellular solution. 3–4 coverslips were subsequently incubated in one 
well where either PhoDAG-2 or PhoDAG-3 was diluted. 
Whole-cell voltage clamp recordings were acquired using the Axon Multiclamp 700B 
amplifier, Digidata 1440A data acquisition system, and the pCLAMP 10 software (Molecular 
Devices). The standard internal solution contained (in mM): 136 KCl, 17.8 HEPES, 1 EGTA, 
4.6 MgCl2, 4 NaATP, 0.3 Na2GTP, 15 creatine phosphate, and 5 U/mL phosphocreatine 
kinase (315–320 mOsmol/liter), pH 7.4. APs were stimulated at 0.2 Hz (by depolarizing the 
cell from –70 to 0 mV for 2 ms) to evoke excitatory post synaptic currents (EPSCs). The 
sEPSCs were derived from the traces where EPSCs were recorded (last 600 ms of a 1 s 
recording) and were recorded without tetrodotoxin (TTX). However, in the autapse-system, 
sEPSCs predominantly represent miniature EPSCs. Light illumination was performed by a 
CoolLED pE-2 lamp that was fixed to the setup. Photoactivation was performed at λ = 365 nm 
(80% strength) and inactivation at λ = 425 nm (40% strength). The normalized responses 
following illumination were calculated by dividing by the averaged response before 




5.4.8 – Aldicarb assay 
**Note: Experiments in Caenorhabditis elegans were performed by Dr. Jatin Nagpal 
(Frankfurt), and the experimental details are included here for clarity. 
 
Caenorhabditis elegans wild-type (N2) strain was cultivated at 20 °C on nematode growth 
medium (NGM) plates seeded with E. coli strain OP50-1158. A 100 mM stock solution of 
PhoDAG-3 was prepared in 100% EtOH. For application to C.elegans, the stock solution was 
diluted to the working concentration of 1 mM PhoDAG-3 using OP50-1 and 200 µL of the 
resulting solution was applied to the NGM plate. For the vehicle control, an equivalent volume 
of 100% EtOH was used instead of the stock solution. L4 stage larvae were picked onto 1 mM 
PhoDAG-3/EtOH NGM plates and left overnight. The young adult hermaphrodites were used 
on the following day for the aldicarb and levamisole-sensitivity assays147,149. The assay was 
performed in the dark, except for the picking and counting of animals which was performed 
under red light. To study aldicarb or levamisole sensitivity, 20 animals were transferred onto 
NGM plates containing 1 mM aldicarb (Sigma) or 0.1 mM tetramisole hydrochloride (Racemic 
form of levamisole, Sigma) and the fraction of animals paralysed was scored every 15 min by 
assessing movement following three gentle touches with a platinum wire. The animals were 
illuminated with UV-A light (λ = 366 nm, 18 µW/mm2) provided by a UV-A lamp (Benda, 
Wiesloch, Germany) for the first 5 min after being placed on the aldicarb/levamsiole plates 
and then subsequently for the last 3 min of each 15 min time interval. The assays were 
performed blinded regarding the absence/presence of PhoDAG-3, and on the same day with 
the same batch of aldicarb or levamisole plates.  
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5.4.9 – Compound synthesis and characterization 












S-2,3-O-Isopropylidene-1-O-stearoyl-sn-glycerol (6) was prepared using a modified 
procedure as previously described by Gaffney et al.159 Spectral characteristics matched those 
previously reported160.  
 
R(-)-2,3-O-Isopropylidene-sn-glycerol (5, 2.85 g, 22.0 mmol, 1.0 equiv.) and 
4-(dimethylamino)pyridine (DMAP, 268 mg, 2.20 mmol, 0.1 equiv.) were dissolved in dry 
CH2Cl2 (75 mL) under an argon atmosphere. To this solution was added dry NEt3 (6.16 mL, 
4.48 g, 44.0 mmol, 2.0 equiv.) and the reaction was cooled to 0 °C. Stearoyl chloride was 
dissolved in dry CH2Cl2 (25 mL) and slowly added to the previously prepared solution. The 
reaction was allowed to slowly warm to room temperature and stirred for 2 h. H2O (28 mL) 
was slowly added and the biphasic solution was stirred rapidly for 10 min. The phases were 
then separated, and the organic phase was washed with aqueous HCl (2 M, 50 mL), followed 
by saturated aqueous NaHCO3 (2x50 mL) and brine (2x50 mL) solutions. The organic phase 
was then dried over anhydrous Na2SO4 and filtered. The filtrate was then concentrated and 
purified by flash silica gel chromatography (150 g SiO2, 20:1 hexane:EtOAc) to yield 
S-2,3-O-isopropylidene-1-O-stearoyl-sn-glycerol (6, 6.99 g, 81%) as an off-white solid. 
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TLC (20:1 hexane:EtOAc): Rf = 0.25.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 4.35-4.28 (m, 1 H, H2G), 4.17 (dd, 1 H, HG1a, J = 11.7, 
4.7 Hz), 4.12-4.05 (m, 2 H, HG1b, HG3a), 3.75 (dd, 1H, H3b, J = 8.4, 6.2 Hz) 2.34 (t, 2 H, 
H2La,b, J = 7.4 Hz), 1.67-1.58 (m, 2 H, H3La,b), 1.43 (s, 3 H, HCH3), 1.37 (s, 3 H, HCH3), 
1.33-1.21 (m, 28 H, Halk), 0.87 (t, 3 H, H8La,b,c, J = 6.5 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.1 (C1S), 109.9 (Ci), 73.8 (CGlycerol), 66.5 (CGlycerol), 
64.6 (CGlycerol), 34.2 (C2S), 32.1 (C3S), 29.9-29.8 (m, Calk, 2xCH3), 29.7 (Calk), 29.6 (Calk), 
29.5 (Calk), 29.4 (Calk), 29.3 (Calk), 26.8 (Calk), 25.5 (Calk), 25.0 (Calk), 22.8 (Calk), 14.3 (C18S). 
HRMS (EI+): m/z calcd. for [C23H43O4]+: 383.3156, found: 383.3172 ([M–CH3–]+). 
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1-O-Stearoyl-3-O-triethylsilyl-sn-glycerol (7) was prepared using a modified procedure as 
previously described by Nadler et al.116 Spectral characteristics matched those previously 
reported. 
 
S-2,3-O-Isopropylidene-1-O-stearoyl-sn-glycerol (6, 500 mg, 1.25 mmol, 1.0 equiv.) was 
dissolved in dry 1,2-dichloroethane (DCE, 20 mL) under an argon atmosphere. 
N,N-Diisopropylethylamine (DIPEA, 1.20 mL, 6.88 mmol), followed by triethylsilyl 
trifluoromethanesulfonate (TESOTf, 496 mg, 0.425 mL, 1.88 mmol, 1.5 equiv.) were added at 
room temperature and the reaction was stirred at 90 °C. After 1 h, a second portion of TESOTf 
(169 mg, 0.145 mL, 0.5 equiv.) was added and the reaction was stirred at 90 °C for 2.5 h. 
Upon consumption of the starting material as determined by TLC, the solution was cooled to 
room temperature, diluted with EtOAc, and then washed with aqueous HCl (0.1 M, 50 mL) 
and brine (50% saturated, 2x50 mL). The organic phase was concentrated under reduced 
pressure and the resulting oil was dissolved in THF (20 mL). To this solution was added an 
aqueous Na2CO3 solution (10%, 10 mL) followed by I2 (610 mg, 2.4 mmol, 1.95 equiv.). The 
solution was stirred rapidly for 2.5 h at room temperature. A further portion of I2 was added 
(300 mg, 1.2 mmol, 1.0 equiv.) and the solution was stirred at room temperature for 1 h. The 
solution was diluted with EtOAc (50 mL) and washed with saturated aqueous 
Na2S2O3 (50 mL), H2O (2x50 mL) and brine (50 mL) solutions. The organic phase was then 
dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced 
pressure and the resulting oil was purified by flash column chromatography (50 g SiO2, 20:1 
hexane:EtOAc) to yield 1-O-stearoyl-3-O-triethylsilyl-sn-glycerol (7, 412 mg, 69%) as a 
colorless liquid. 
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TLC (10:1 hexane:EtOAc): Rf = 0.23.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 4.18 (m, 2 H, H1Ga,b), 3.92-3.82 (m, 1 H, H2G), 3.67 (dd, 
1 H, H3Ga, J = 10.3 Hz, 4.5 Hz), 3.60 (dd, 1 H, H3Gb, J = 10.0 Hz, 5.7 Hz), 2.55 (d, 1 H, OH, 
J = 5.3 Hz), 2.33 (t, 2 H, H2Sa,b, J = 7.6 Hz), 1.66-1.58 (m, 2 H, H3Sa,b), 1.34-1.20 (m, 28 H, 
14xCH2(stearoyl)), 0.96 (t, 9 H, 3xCH3(TES), J = 7.8 Hz), 0.88 (t, 3 H, H18Sa,b,c, J = 6.9 Hz), 0.61 (q, 
6 H, 3xCH2(TES), J = 7.9 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.1 (C1S), 70.2 (C2G), 65.1 (C1G), 63.5 (C3G), 
34.3 (C2S), 32.1 (Calk), 29.9-29.7 (m, Calk), 29.6 (Calk), 29.5 (Calk), 29.4 (Calk), 29.3 (Calk), 
25.1 (C3S), 22.9 (Calk), 14.3 (C18S), 6.8 (3C, 3xCH3(TES)), 4.4 (3C, 3xCH2(TES)).  


















FAAzo-451 (1.08 g, 3.3 mmol, 2.0 equiv.), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
(EDC, 773 mg, 4.38 mmol, 3.0 equiv.) and DMAP (20.2 mg, 166 µmol, 0.1 equiv.) were 
dissolved in dry CH2Cl2 (50 mL) under an argon atmosphere. This solution was stirred at room 
temperature for 15 min. After cooling to 0 °C, a solution of 1-O-stearoyl-3-O-triethylsilyl-sn-
glycerol (7, 787 mg, 1.66 mmol, 1.0 equiv.) in dry CH2Cl2 (30 mL) was slowly added. The 
solution was warmed to room temperature and stirred overnight under an argon atmosphere. 
The solution was then diluted with CH2Cl2 (200 mL) and washed with H2O (2x100 mL) and 
brine (100 mL). The solution was then filtered and the filtrate was concentrated under reduced 
pressure. The resulting red oil was purified by flash silica gel chromatography (170 g SiO2, 
30:1 hexane:EtOAc) to yield 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-
stearoyl-3-O-triethylsilyl-sn-glycerol (8, 944 mg, 72%) as a red oil. 
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TLC (10:1 hexane:EtOAc): Rf = 0.50.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.80 (m, 4 H, H7Aa,b, H12Aa,b), 7.31 (d, 4 H, H6Aa,b, 
H13Aa,b, J = 8.2 Hz), 5.13-5.05 (m, 1 H, H2G), 4.38 (dd, 1 H, H1Ga, J = 12.1 Hz, 3.6 Hz), 
4.17 (dd, 1 H, H1Gb, J = 12.1 Hz, 6.1 Hz), 3.73 (d, 2 H, H3Ga,b, J = 5.3 Hz), 2.73 (t, 2 H, H4Aa,b, 
J = 7.7 Hz), 2.69 (t, 2 H, H15Aa,b, J = 7.8 Hz), 2.37 (t, 2 H, H2Aa,b, J = 7.5 Hz), 2.29 (t, 2 H, 
H2Sa,b, J = 7.6 Hz), 2.00 (quin, 2 H, H3Aa,b, J = 7.4 Hz), 1.69-1.53 (m, 4 H, H3Sa,b, H16Aa,b), 
1.43–1.34 (m, 2 H, H17Aa,b), 1.33-1.21 (m, 28 H, H17Sa,b, 13xCH2(alk)), 0.97-0.85 (m, 15 H, 
H18Aa,b,c, H17Sa,b,c, 3xCH3(TES)), 0.59 (q, 6 H, 3xCH2(TES), J = 8.0 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.7 (C1S), 172.8 (C1A), 151.4 (Cazo), 151.1 (Cazo), 
146.5 (Cazo), 144.6 (Cazo), 129.3 (2 C, Cazo), 129.2 (2 C, Cazo), 123.0 (2 C, Cazo), 122.9 (2 C, 
Cazo), 72.1 (C2G), 62.6 (C3G), 61.3 (C1G), 35.7 (C15A), 35.0 (C4A), 34.3 (C2S), 33.7 (C2A), 
33.6 (C2S), 32.1 (C3S), 29.9-29.7 (m, Calk), 29.6 (Calk), 29.5 (Calk), 29.4 (Calk), 29.3 (Calk), 
26.5 (C3A), 25.1 (C16A), 22.9 (C17S), 22.5 (C17A), 14.3 (C18S), 14.1 (C18A), 6.8 (3 C, 
3xCH3(TES)), 4.4 (3 C, 3xCH2(TES)).  
HRMS (EI+): m/z calcd. for [C20H24N2O2]+: 778.5680, found: 778.5675 ([M–e–]+). 
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glycerol (8, 500 mg, 0.641 mmol, 1.0 equiv.) was first dissolved in CH2Cl2 (5 mL) and added 
to a solution of FeCl2·6H2O (5 mM in 25 mL 3:1 MeOH:CH2Cl2). This solution was stirred at 
room temperature for 30 min. The solution was then diluted with EtOAc (200 mL) and washed 
with H2O (2x200 mL). The organic phase was then dried over Na2SO4. The mixture was 
filtered and the filtrate was concentrated under reduced pressure. The resulting oil was 
purified by flash silica gel chromatography (3:1 hexane:EtOAc) to yield 2-O-(4-(4-((4-
butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-sn-glycerol (PhoDAG-1, 425 mg, 
quant.) as an orange solid. Note: Short reaction time and quick chromatography are essential 
to avoid acyl chain migration. 
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TLC (3:1 hexane:EtOAc): Rf = 0.45 (trans), 0.35 (cis).  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.80 (m, 4 H, H7Aa,b, H12Aa,b), 7.31 (d, 4 H, H6Aa,b, 
H13Aa,b, J = 8.1 Hz), 5.10 (quin, 1 H, H2G, J = 5.1 Hz), 4.34 (dd, 1 H, H3Ga, J = 11.9 Hz, 
4.5 Hz), 4.24 (dd, 1 H, H3Gb, J = 12.0 Hz, 5.8 Hz), 3.73 (t, 2 H, H1Ga,b, J = 5.2 Hz), 2.74 (t, 
2 H, H4Aa,b, J = 7.6 Hz), 2.69 (t, 2 H, H15Aa,b, J = 7.6 Hz), 2.40 (t, 2 H, H2Aa,b, J = 7.3 Hz), 
2.32 (t, 2 H, H2Sa,b, J = 7.5 Hz), 2.06-1.97 (m, 2 H, H3Aa,b), 1.69-1.51 (m, 4 H, H16Aa,b, H3Sa,b), 
1.44-1.32 (m, 2 H, H17Aa,b), 1.34-1.18 (m, 28 H, H17Sa,b, 28xHSalk), 0.94 (t, 3 H, H18Aa,b,c, 
J = 7.1 Hz), 0.88 (t, 3 H, H18Sa,b,c, J = 7.1 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.0 (C1S), 173.1 (C1A), 151.5 (Cazo), 151.1 (Cazo), 
146.5 (Cazo), 144.4 (Cazo), 129.3 (2 C, Cazo), 129.2 (2 C, Cazo), 123.0 (2 C, Cazo), 122.9 (2 C, 
Cazo), 72.4 (C2G), 62.1 (C3G), 61.6 (C1G), 35.7 (C15A), 35.0 (C4A), 34.2 (C2S), 33.6 (C2A), 
33.6 (C3S), 29.9-29.7 (m, Calk), 29.6 (Calk), 29.5 (Calk), 29.4 (Calk), 29.3 (Calk), 26.4 (C3A), 
25.0 (C16A), 22.9 (C17S), 22.5 (C17A), 14.3 (C18S), 14.1 (C18A).  
IR (neat, ATR): ṽ = 3483, 2955, 2917, 2850, 1728, 1711, 1601, 1499, 1472, 1460, 1414, 
1379, 1256, 1235, 1214, 1188, 1173, 1138, 1096, 1068, 1052, 1031, 1012, 962, 888, 832, 
718, 679.  
HRMS (EI+): m/z calcd. for [C20H24N2O2]+: 324.1838, found: 324.1834 ([M–e–]+).  
UV-Vis (25 µM in DMSO): λmax(π-π*) = 340 nm. λmax(n-π*) = 442 nm. 
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5.4.9.5 – S-2,3-O-Isopropylidene-1-O-octanoyl-sn-glycerol (9) 
 
Octanoic acid (490 mg, 3.4 mmol, 1.5 equiv.) was first dissolved in dry CH2Cl2 (10 mL) under 
an argon atmosphere and then NEt3 (0.310 mL, 2.27 mmol, 1 equiv.) and DMAP (27.7 mg, 
0.227 mmol, 0.1 equiv.) were added. The solution was then cooled to 0 °C and then 
N,N'-dicyclohexylcarbodiimide (DCC, 1.171 mg, 5.68 mmol, 2.5 equiv.) was added. This 
mixture was stirred at 0 °C for 30 min and then the R(-)-2,3-O-isopropylidene-sn-glycerol 
(5, 0.280 mL, 2.27 mmol, 1.0 equiv.) was added. The solution was stirred for a further 2 h, 
and then was diluted with CH2Cl2 and washed once with a saturated aqueous NaHCO3  
solution, and twice with H2O. The organic phase was then dried over Na2SO4 and filtered. The 
filtrate was concentrated under reduced pressure and the resulting oil was purified by flash 
silica gel chromatography (30 g SiO2, pre-adsorbed on 1.5 g of SiO2, 40:1 to 10:1 
hexane:EtOAc) to yield S-2,3-O-isopropylidene-1-O-octanoyl-sn-glycerol (9, 537 mg, 
92%) as a colorless oil. 
 
TLC (20:1 hexane:EtOAc): Rf = 0.09.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 4.32-4.24 (m, 1 H, H2G), 4.17-4.09 (m, 1 H, HG1a), 
4.09-4.00 (m, 2 H, HG1b, HG3a), 3.73-3.68 (m, 1H, H3b) 2.31 (t, 2 H, H2La,b, J = 7.3 Hz), 
1.65−1.54 (m, 2 H, H3La,b), 1.40-1.33 (s, 6 H, 2xHCH3), 1.31-1.17 (m, 8 H, Halk), 0.84 (t, 3 H, 
H8La,b,c, J = 6.7 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.7 (C1L), 109.9 (Ci), 73.7 (CGlycerol), 66.4 (CGlycerol), 
66.6 (CGlycerol), 34.2 (C2S), 31.7 (C3S), 29.2 (CCH3), 29.0 (CCH3), 26.8 (Calk), 25.5 (Calk), 25.0 
(Calk), 22.7 (Calk), 14.5 (C18L). 
HRMS (EI+): m/z calcd. for [C13H23O4]+: 243.1591, found: 243.1595 ([M–CH3–]+). 
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5.4.9.6 – 1-O-Octanoyl-3-O-triethylsilyl-sn-glycerol (10) 
 
S-2,3-O-Isopropylidene-1-O-octanoyl-sn-glycerol (9, 453.2 mg, 1.75 mmol, 1.0 equiv.) was 
first dissolved in dry DCE (6 mL) under an argon atmosphere and then dry DIPEA (1.5 mL, 
9.65 mmol , 5.5 equiv.) was added to the solution. The solution was then warmed to 90 °C 
and TESOTf (1.4 mL, 6.13 mmol, 3.5 equiv.) was added and the reaction stirred for 2 h. The 
mixture was then diluted with EtOAc (60 mL) and washed with aqueous HCl (0.1 M, 60 mL) 
and then H2O (2x60 mL). The organic phase was then dried over Na2SO4 and filtered. The 
filtrate was concentrated under reduced pressure. The resulting oil was dissolved in THF 
(8 mL) and then aqueous Na2CO3 (4 mL, 10% w/w) and I2 (1.1 g, 4.4 mmol, 2.5 equiv.) were 
added to the solution. The reaction was stirred for 75 min at room temperature, and was then 
diluted with EtOAc (70 mL) and washed once with saturated aqueous Na2S2O3 (70 mL) and 
H2O (2x70 mL). The organic phase was dried over Na2SO4 and filtered. The filtrate was 
concentrated under reduced pressure and the resulting oil was purified by flash silica gel 
chromatography (60 g SiO2, 20:1→15:1→10:1 hexane:EtOAc) to yield 1-O-octanoyl-3-O-
triethylsilyl-sn-glycerol (10, 211 mg, 36%) as a colourless oil. 
 
TLC (9:1 hexane:EtOAc): Rf = 0.30.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 4.19-4.08 (m, 2 H, H1Ga,b), 3.98-3.87 (m, 1 H, H2G), 
3.63 (dd, 1 H, H3Ga, J1 = 10.5 Hz, J2 = 5.3 Hz), 3.56 (dd, 1 H, H3Gb, J1 = 10.3 Hz, J2 = 5.4 Hz), 
2.69 (d, 1 H, OH, J = 5.4 Hz), 2.34 (t, 2 H, H2a,b, J = 7.5 Hz), 1.67-1.58 (m, 2 H, H3a,b), 
1.34-1.20 (m, 8 H, Halk), 0.96 (t, 9 H, 3xCH3(TES), J = 7.9 Hz), 0.87 (t, 3 H, H8a,b,c, J = 6.9 Hz), 
0.61 (q, 6 H, 3xCH2(TES), J = 7.9 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.1 (C1L), 70.2 (CXG), 65.1, 63.5, 34.3 (C2), 31.8 
(Calk), 29.2 (Calk), 29.1 (Calk), 25.1 (Calk), 22.8 (C7L), 14.2 (C8L), 6.8 (3C, 3xCH3(TES)), 4.4 (3C, 
3xCH2(TES)). 
IR (neat, ATR): ṽ = 3489, 2955, 2929, 2876, 1740, 1458, 1416, 1380, 1239, 1166, 1100, 
1006, 976, 842, 807, 744, 728, 676, 619, 588, 601, 564. 
HRMS (ESI+): m/z calcd. for [C17H37O4Si]+: 333.2461, found: 333.2460 ([M+H+]+). 












FAAzo-451 (136.3 mg, 0.42 mmol, 2.0 equiv.) was dissolved in dry CH2Cl2 (12 mL) under an 
argon atmosphere, and then DMAP (5.13 mg, 0.042 mmol, 0.1 equiv.) and EDC (0.11 mL, 
0.63 mmol, 3.0 equiv.) were added. The solution was stirred at room temperature for 20 min 
and then 1-O-octanoyl-3-O-triethylsilyl-sn-glycerol (10, 68.9 mg, 0.21 mmol, 1.0 equiv.) 
was added. The solution was stirred overnight at room temperature, diluted with CH2Cl2 and 
then washed three times with H2O. The organic phase was dried over Na2SO4, filtered, and 
the filtrate was concentrated under reduced pressure. The resulting dark orange oil was 
purified by flash silica gel chromatography (15 g SiO2, hexane:EtOAc 20:1→10:1) to yield 
2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-triethylsilyl-sn-
glycerol (11, 77.4 mg, 58%) as an orange oil. 
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TLC (3:1 hexane:EtOAc): Rf = 0.48 (trans), 0.30 (cis).  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.87-7.79 (m, 4 H, H7Aa,b, H12Aa,b), 7.31 (d, 4 H, H6Aa,b, 
H13Aa,b, J = 8.7 Hz), 5.14-5.05 (m, 1 H, H2G), 4.42-4.33 (m, 1H, H1Ga), 4.23-4.13 (m, 1 H, 
H1Gb), 3.77-3.69 (m, 2 H, H3Ga,b), 2.78-2.67 (m, 4 H, H4Aa,b, H15Aa,b), 2.37 (t, 2 H, H1Aa,b, 
J = 7.1 Hz), 2.30 (t, 2 H, H2La,b, J = 7.3 Hz), 2.07-1.95 (m, 2 H, H3Aa,b), 1.69-1.52 (m, 4 H, 
H3La,b, H16Aa,b), 1.44-1.33 (m, 2 H, H17Aa,b), 1.33-1.19 (m, 8 H, Halk), 0.99-0.90 (m, 12 H, 
H18Aa,b,c, 3xCH3(TES)), 0.86 (t, 3 H, H8La,b,c), 0.59 (q, 6 H, 3xCH2(TES), J = 8.0 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.6 (C1S), 172.8 (C1A), 151.4 (Cazo), 151.9 (Cazo), 
146.4 (Cazo), 144.6 (Cazo), 129.3 (2 C, Cazo), 129.2 (2 C, Cazo), 123.0 (2 C, Cazo),  122.9 (2 C, 
Cazo), 72.1 (C2G), 62.6 (C3G), 61.3 (C1G), 35.7 (C15A), 35.0 (C4A), 34.3 (C2A), 33.63 (C2A), 
33.59 (C3A), 31.8 (C3L), 29.2 (Calk), 29.1 (Calk), 26.5 (Calk), 25.0 (Calk), 22.7 (Calk), 22.5 (Calk), 
14.2 (C18L), 14.1 (C18A), 6.8 (3 C, 3xCH3(TES)), 4.4 (3 C, 3xCH2(TES)). 
IR (neat, ATR): ṽ = 3028, 2955, 2930, 2874, 2859, 1918, 1739, 1602, 1580, 1498, 1458, 
1416, 1378, 1302, 1240, 1226, 1156, 1145, 1104, 1013, 977, 844, 800, 744, 728, 674, 642, 
618, 601, 571, 564. 
HRMS (ESI+): m/z calcd. for [C37H59N2O5Si]+: 639.4193, found: 639.4142 ([M+H+]+). 
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(PhoDAG-2) was prepared from 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-
octanoyl-3-O-triethylsilyl-sn-glycerol (11, 28.0 mg, 0.044 mmol, 1.0 equiv.) as described 
above in the synthesis of 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-
stearoyl-sn-glycerol (PhoDAG-1). PhoDAG-2 (13.3 mg, 66%) was isolated as an orange 
oil. NOTE: all reactants and reagents were scaled according to molarity. 
 
TLC (2:1 hexane:EtOAc): Rf : 0.39 (trans), 0.28 (cis). 
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.86-7.79 (m, 4 H, H7Aa,b, H12Aa,b), 7.31 (d, 4 H, H6Aa,b, 
H13Aa,b, J = 8.7 Hz), 5.15-5.05 (m, 1 H, H2G), 4.37-4.30 (m, 1H, H3Ga), 4.27-4.20 (m, 1 H, 
H3Gb), 3.76-3.70 (m, 2 H, H1Ga,b), 2.74 (t, 2 H, H4Aa,b, J = 7.5 Hz), 2.69 (t, 2 H, H15Aa,b, 
J = 7.8 Hz), 2.40 (t, 2 H, H2Aa,b, J = 7.5 Hz), 2.36-2.29 (m, 2 H, H2La,b), 2.07-1.97 (m, 3 H, 
H3Aa,b), 1.70-1.50 (m, 4 H, H16Aa,b, HL3a,b), 1.44-1.18 (m, 10 H, Halk), 0.93 (t, 3 H, H18Aa,b,c, 
J = 7.3 Hz), 0.90-0.81 (t, 3 H, H8La,b,c, J = 7.6 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 174.0 (C1L), 173.0 (C1A), 152.8 (Cazo), 151.3 (Cazo), 
146.5 (Cazo),  144.4 (Cazo), 129.3 (2 C, Cazo), 129.2 (2 C, Cazo), 123.9 (2 C, Cazo), 122.9 (2 C, 
Cazo), 72.4 (C2G), 62.1 (C3G), 61.6 (C1G), 35.7 (C15A), 35.0 (C4A), 34.2 (C2L), 33.61 (Calk), 
33.6 (Calk), 31.8 (Calk), 29.2 (Calk), 29.1 (Calk), 26.4 (C3A), 25.0 (C3L), 22.7 (C7L), 22.5 (C17A), 
14.2 (C8L), 14.1 (C18A). 
IR (neat, ATR): ṽ = 3466, 2956, 2929, 2858, 1739, 1602, 1498, 1458, 1417, 1378, 1225, 
1159, 1103, 1051, 1014, 844, 728, 634, 614, 591, 576, 568. 
HRMS (EI+): m/z calcd. for [C31H44N2O5]+: 524.3250, found: 524.3245 ([M–e–]+). 
UV-Vis (50 µM in DMSO): λmax(π–π*) =  340 nm. λmax(n–π*) = 440 nm. 
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5.4.9.9 – 4-(Phenyldiazenyl)phenyl butanoic acid  (FAAzo-9, 4) 
 
4-(4-Aminophenyl)butyric acid (200 mg, 1.12 mmol, 1.0 equiv.) was first dissolved in CH2Cl2 
(20 mL). Nitrosobenzene (143.4 mg, 1.34 mmol, 1.2 equiv.) and AcOH (5 mL) were added, 
and the solution was then stirred at room temperature overnight. The solvents were then 
removed under reduced pressure. The resulting crude residue was purified by flash silica gel 
chromatography (20 g SiO2, 99:1 CH2Cl2:AcOH) to yield 4-(phenyldiazenyl)phenyl butanoic 
acid (FAAzo-9, 4, 320.8 mg, quant.) as an orange solid. 
 
TLC (99:1 CH2Cl2:AcOH): Rf = 0.17. 
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.94-7.82 (m, 4 H, H7a,b, H11a,b), 7.55-7.43 (m, 3 H, 
H13a,b, H14), 7.34 (d, 2 H, H6a,b, J = 4.0 Hz), 2.76 (t, 2 H, H4a,b, J = 7.8 Hz), 2.42 (t, 2 H, H2a,b, 
J = 7.3 Hz), 2.02 (dd, 2 H, H3a,b, J = 7.8, 7.3 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 178.7 (C1), 152.8 (C11), 151.4 (C8), 144.8 (C5), 
131.0 (C14), 129.4-129.2 (4 C, C6a,b, C13a,b), 123.2-122.9 (4 C, C7a,b, C12a,b), 35.0 (C4), 
33.2 (C2), 26.2 (C3). 
IR (neat, ATR): ṽ = 3041, 2944, 1693, 1601, 1500, 1486, 1462, 1439, 1411, 1339, 1303, 
1282, 1252, 1215, 1152, 1106, 1071, 1020, 914, 851, 822, 787, 764, 745, 732, 684, 638, 616, 
577, 561. 
HRMS (EI+): m/z calcd. for [C16H16N2O2]+: 268.1212, found: 268.1206 ([M–e–]+). 
UV-Vis (50 µM in DMSO): λmax(π–π*) =  330 nm. λmax(n–π*) = 425 nm. 
Melting point (°C): 135.5-137.5. 
  










glycerol (12)  
 
4-(Phenyldiazenyl)phenyl butanoic acid (FAAzo-9, 153.4 mg, 0.57 mmol, 2.0 equiv.) was 
dissolved in dry CH2Cl2 (15 mL) under an argon atmosphere. DMAP (3.4 mg, 0.028 mmol, 
0.1 equiv.) and EDC (0.15 mL, 0.84 mmol, 3.0 equiv.) were then added to the solution. The 
mixture was stirred at room temperature for 20 min and then 1-O-octanoyl-3-O-triethylsilyl-
sn-glycerol (10, 95.1 mg, 0.28 mmol, 1.0 equiv.) was added. The solution was stirred 
overnight at room temperature, and was then diluted with CH2Cl2 (100 mL) and washed with 
H2O (3x50 mL). The organic phase was dried over Na2SO4 and then filtered. The filtrate was 
concentrated under reduced pressure. The residue was purified by flash silica gel 
chromatography (20 g SiO2, hexane:EtOAc 20:1→10:1) to yield 2-O-(4-(4-
(phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-triethylsilyl-sn-glycerol (12, 
100 mg, 61%) as an orange oil. 
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TLC (9:1 hexane:EtOAc): Rf =  0.43 (trans),  0.25 (cis).  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.94-7.83 (m, 4 H, H7Aa,b, H12Aa,b), 7.55-7.43 (m, 3 H, 
H14A, H13Aa,b), 7.33 (d, 2 H, H6Aa,b, J = 8.2 Hz), 5.15-5.05 (m, 1 H, H2G), 4.41-4.33 (m, 1H, 
H1Ga), 4.22-4.13 (m, 1 H, H1Gb), 3.78-3.69 (m, 2 H, H3Ga,b), 2.74 (t, 2 H, H4Aa,b, J = 7.2 Hz), 
2.38 (t, 2 H, H2A, J = 7.6 Hz), 2.30 (t, 2 H, H2La,b, J = 7.5 Hz), 2.08-1.96 (m, 2 H, H3Aa,b), 
1.64-1.54 (m, 2 H, H3La,b), 1.34-1.19 (m, 8 H, Halk), 0.94 (t, 9 H, 3xCH3(TES), J = 8.3 Hz), 
0.90-0.82 (t, 3 H, H8La,b,c, J = 6.9 Hz), 0.59 (m, 6 H, 3xCH2(TES), J = 8.2 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.6 (C1L), 172.8 (C1A), 152.8 (Cazo), 151.3 (Cazo), 
145.0 (Cazo), 131.0 (Cazo), 129.3 (2C, Cazo), 129.2 (2 C, Cazo), 123.1 (2 C, Cazo), 122.9 (2 C, 
Cazo), 72.1 (C2G), 62.6 (C3G), 61.3 (C1G), 35.0 (C4A), 34.3 (C2L), 33.6 (C2A), 31.8 (Calk), 
29.2 (Calk), 29.1 (Calk), 26.5 (Calk), 25.0 (Calk), 22.7 (C7L), 14.2 (C8L), 6.8 (3 C, 3xCH3(TES)), 
4.4 (3 C, 3xCH2(TES)). 
IR (neat, ATR): ṽ = 2955, 2930, 2875, 1738, 1603, 1500, 1458, 1415, 1378, 1300, 1240, 
1225, 1144, 1103, 1070, 1004, 847, 797, 743, 727, 688, 638, 616, 598, 563. 
HRMS (ESI+): m/z calcd. for [C33H51N2O5Si]+: 583.3567, found: 583.3567 ([M+H+]+). 
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5.4.9.11 – 2-O-(4-(4-(Phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-sn-glycerol 
(PhoDAG-3, 3) 
 
2-O-(4-(4-(Phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-sn-glycerol (PhoDAG-3) was 
prepared from 2-O-(4-(4-(phenyldiazenyl)phenyl)butanoyl)-1-O-octanoyl-3-O-
triethylsilyl-sn-glycerol (12, 22.0 mg, 0.038 mmol, 1 equiv.) as described above in the 
synthesis of 2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-1-O-stearoyl-sn-
glycerol (PhoDAG-1). PhoDAG-3 (17.7 mg, quant.) was isolated as an orange oil. NOTE: all 
reactants and reagents were scaled according to molarity. 
 
TLC (9:1 hexane:EtOAc): Rf = 0.20 (trans),  0.18 (cis).  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.93-7.83 (m, 4 H, H7Aa,b, H11Aa,b), 7.55–7.43 (m, 3 H, 
H14A, H13Aa,b), 7.33 (d, 2 H, H6Aa,b, J = 8.3 Hz), 5.14-5.04 (q, 1 H, H2G, J = 4.9 Hz), 
4.38-4.29 (m, 1 H, H3Ga), 4.27-4.19 (m, 1 H, H3Gb), 3.78-3.68 (m, 2 H, H1Ga,b), 2.75 (t, 2 H, 
H4Aa,b, J = 7.7 Hz), 2.40 (t, 2 H, H2Aa,b, J = 7.7 Hz), 2.32 (t, 2 H, H2La,b, J = 7.7 Hz), 
2.07-1.96 (m, 2 H, H3Aa,b), 1.65-1.55 (m, 2 H, H3La,b), 1.34-1.20 (m, 8 H, Halk), 0.90-0.82 (t, 
3 H, H8La,b,c, J = 7.1 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.4 (C1L), 173.0 (C1A), 152.8 (Cazo), 151.3 (Cazo), 
144.8 (Cazo), 130.9 (Cazo), 129.3 (2 C, Cazo), 129.2 (2 C, Cazo), 123.2 (2 C, Cazo), 122.9 (2 C, 
Cazo), 72.4 (C2G), 62.1 (C3G), 61.6 (C1G), 35.0 (C4A), 34.2 (C2L), 33.6 (2 C, C2A, C14A), 
31.8 (C6L), 29.2 (Calk), 29.0 (Calk), 26.4 (Calk), 25.0 (Calk), 22.7 (C7A), 14.2 (C8A). 
IR (neat, ATR): ṽ = 3466, 2928, 2857, 1739, 1603, 1458, 1416, 1377, 1224, 1157, 1104, 
1052, 847, 768, 690, 615, 601, 590, 568, 554. 
HRMS (EI+): m/z calcd. for [C27H36N2O5]+: 468.2624, found: 468.2622 ([M–e–]+). 
UV-Vis (50 µM in DMSO): λmax(π–π*) =  325 nm. λmax(n–π*) = 440 nm. 
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6 – Synthesis of photoswitchable glycerophospholipids 
6.1 – Introduction 
Glycerophospholipids are ubiquitous lipid class which possess a polar headgroup containing 
a glycerol unit linked to a phosphate at either the sn-1 or sn-3 positions5,161. Their structures 
are diverse, as the phosphate can be decorated by a variety of polar units, from the simple 
choline to more complex units such as serine, myo-inositols and sugars. The glycerol hydroxyl 
groups can also be linked to many different fatty acyl chains, affording a vast number of 
glycerophospholipids across all types of organisms162. These amphipathic molecules possess 
the ability to self-organize into membranes1,2, and are thus found at all levels of organic life. 
For example, phosphatidylcholines (PCs) have a cylindrical geometry which makes them ideal 
for forming a planar bilayer. Consequently, they are major components of eukaryotic 
membranes, and compose >50% of the total phospholipids present10.  
Glycerophospholipids play more than a structural role, as they are ubiquitously 
involved in cell signaling through several mechanisms163. First, they determine the identity and 
characteristics of the membranes in which transmembrane proteins are folded164–167. Second, 
they serve as first messengers or allosteric modulators for membrane proteins168,169. Finally, 
they are also reservoirs of second messengers, as their receptor-mediated hydrolysis by 
phospholipases releases molecules such as AA, DAG and inositol phosphates170,171. For 
example, phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) is known to directly affect a 
number of proteins including ion channels, GPCRs, and enzymes172–175. On activation of Gαq-
coupled GPCRs, PLC cleaves PI(4,5)P2 into DAG and inositol trisphosphate, which are 
released into the plasma membrane and cytosol, respectively. The generation of these 
second messengers leads to the activation of PKC and a rise in [Ca2+]i, triggering a cellular 
response176. 
Photochemical tools to probe the biophysical and pharmacological properties of 
glycerophospholipids remain limited. However, in recent years a few examples have emerged 
which allow researchers to manipulate glycerophospholipid levels in cells with the 
spatiotemporal precision of light. Caged lipids24, including caged phosphoinositides25,177,178, 
phosphatidic acid26,179, phosphatidyl ethanolamine27, and lysophosphatidic acid180, have 
shown promise in live-cell experiments. In these examples, caged phosphate groups are 
employed to block the compounds activity181. On a flash of light, the native lipid is quickly 




approach relies on metabolism or transport of the active lipid species to turn the process OFF. 
Photoswitchable lipids, however, remain a more novel approach. Interestingly, several 
photoswitchable phosphatidylcholine derivatives were synthesized in the 1980’s and their 
effects in model membrane systems such as monolayers were investigated46–48,75. They were 
synthesized by the esterification of a lyso-phosphatidylcholines with photoswitchable fatty 
acids. However, the lyso-phosphatidylcholine starting materials are quite expensive and no 
reaction scales, yields or characterization were reported in their synthesis. Since their initial 
synthesis and evaluation, their application in controlling cell signaling has remained limited. 
Herein, we describe the syntheses of photoswitchable derivatives  of phosphatidylcholine and 
PI(4,5)P2. We demonstrate that phosphoramidite chemistry is a high-yielding and efficient 
approach to rapidly functionalize existing photoswitchable DAGs into more complex 
glycerophospholipids. 
 
6.2 – Results 
6.2.1 – Synthesis and characterization of a photoswitchable phosphatidylcholine 
We set our sights first on synthesizing a photoswitchable phosphatidylcholine derivative. For 
more sophisticated and modern applications, a versatile synthesis must be devised to allow 
for the preparation of significant amounts of the photoswitchable lipid. We recognized that 
PhoDAG-152 could serve as the backbone for a photoswitchable phosphatidylcholine 
derivative, now called azo-PC. Therefore, an optimized synthetic route was developed which 
utilized phosphoramidite chemistry to attach the phosphocholine headgroup to PhoDAG-1 
(Fig. 6.1a). A 1H-tetrazole-mediated coupling of PhoDAG-1 with bis-(9H-fluoren-9-ylmethyl)-
N,N-diisopropylamidophosphite181, a 9-fluorenylmethyl (Fm)-protected phosphoramidite, 
afforded 13 in high yield. From this phosphoramidite, a sequence of three sequential reactions 
was optimized to complete the phosphocholine headgroup. A 1H-tetrazole-mediated coupling 
between 13 and choline p-toluenesulfonate was immediatley followed by oxidation to the 
phosphate with peracetic acid (AcOOH). A final Fm-deprotection under basic conditions 
afforded azo-PC in an excellent yield of 89% over the three steps. Similar to PhoDAG-1 and 
the rest of the FAAzos, azo-PC behaved as a regular azobenzene which could be isomerized 
between its cis- and trans-states with UV-A and blue light, respectively (Fig. 6.1b). 




Figure 6.1 | Synthesis and characterization of a photoswitchable phosphatidylcholine. 
(a) The photoswitchable phosphatidylcholine, azo-PC, was prepared from PhoDAG-1 in 4 
steps and high yield using phosphoramidite chemistry. azo-PC could be isomerized between 
its cis and trans-configurations by UV-A and blue light, respectively. (b) UV-Vis spectra of 
azo-PC (40 µM in PBS) in its dark- (black), UV- (gray), and blue-adapted (blue) states. The 







6.2.2 – Design and synthesis of cell-permeable, photoswitchable PI(4,5)P2 
Given our success using phosphoramidite chemistry to modify the polar headgroup of 
PhoDAG-1, we set our sights on the preparation of a photoswitchable derivative of PI(4,5)P2, 
which could also be built around the PhoDAG scaffold. However, we recognized that PI(4,5)P2 
is a negatively charged glycerophospholipid, and this could inhibit its ability to reach the inner 
leaflet of the plasma membrane where it normally exerts its effects. To circumvent this, we 
designed a “pro-lipid” with esterase-labile protecting groups to mask the charged and polar 
functional groups of the phosphoinositol headgroup (Fig. 6.2). The three free hydroxyl groups 
would be masked by butanoyl (Bt) protecting groups, while the negatively charged phosphates 
would be masked by acetoxymethyl (Am)-esters. These protecting groups have been used 
before to prepare cell-permeant phosphoinositides and phosphates177. This fully-protected 
phosphoinositide, apo-azo-PIP2, would therefore be neutral, and more likely to cross the cell 
membrane. Once inside the cell, intracellular esterases can remove both the butanoyl and 
Am-ester protecting groups25. The resulting negatively charged photoswitchable azo-PIP2 
would remain trapped inside the cell, where it would exert its effects on effector proteins.  
 
Figure 6.2 | Design of a cell-permeable, photoswitchable PI(4,5)P2. The chemical structure 
of apo-azo-PIP2, which is a masked derivative of the photoswitchable phosphoinositide, 
azo-PIP2. Once inside the cell, the butanoyl and acetoxymethyl ester protecting groups can 
be cleaved by intracellular esterases, affording the photoswitchable phosphoinositide 
azo-PIP2, which would remain trapped inside the cell. 
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We synthesized apo-azo-PIP2 in high yield using phosphoramidite chemistry like that 
described above for azo-PC (Fig. 6.3). A 1H-tetrazole-mediated coupling between 
phosphoramidite 13 and the protected myo-inositol RM-317 (unpublished building block from 
Prof. Carsten Schultz and Dr. Rainer Müller, EMBL Heidelberg), followed by a sequential 
oxidation with AcOOH afforded the Fm-protected, phosphoinositide 14 in 78% yield over two 
steps. Fm-deprotection and acetoxy-methylation using bromomethylacetate then afforded 
apo-azo-PIP2 in 72% yield. This four-step sequence generated this complex protected 
glycerophospholipid in very high yield (56% over 4 steps), further demonstrating the versatility 
of phosphoramidite chemistry in the synthesis of complex glycerophospholipids. 
 
Figure 6.3 | Synthesis of a cell-permeable photoswitchable PI(4,5)P2. A cell permeable 
and photoswitchable derivative of PI(4,5)P2 was synthesized using phosphoramidite 






6.3 – Discussion 
In this chapter, we have expanded the scope of photoswitchable lipids into the 
glycerophospholipid class. We demonstrated that phosphoramidite chemistry is a versatile 
and high-yielding approach to attach various polar headgroups to pre-existing 
photoswitchable DAGs. We could install both a simple phosphocholine headgroup and a 
complex protected phosphoinositide in high yields, and on a comparably large scale. Given 
the success of this synthetic approach, we envision that phosphoramidite chemistry could also 
be used to prepare even more photoswitchable glycerophospholipids, for example 
phosphatidylserine or phosphatidic acid derivatives. 
 Studies using both compounds are currently underway in our lab and the labs of our 
collaborators. azo-PC is being used in collaborations with Prof. Dr. Thomas Bein (LMU 
Munich), Prof. Dr. Theobald Lohmüller (LMU Munich), Prof. Dr. Bert Nickel (LMU Munich), 
Prof. Dr. Joachim Heberle and Prof. Dr. Petra Schwille (MPI Martinsried). A detailed 
discussion of this work is not within the scope of this thesis; however, we have demonstrated 
that azo-PC can be incorporated into a variety of artificial membrane systems such 
monolayers and vesicles. For example, giant phospholipid vesicles consisting of 100% 
azo-PC can be prepared. Isomerization between the trans- and cis-forms allows us to control 
the fluidity of these vesicles and in turn manipulate their shape and structure (unpublished 
work from the Lohmüller lab). Further investigations utilizing azo-PC to control artificial 
membrane systems are currently ongoing. Similarly, the evaluation of apo-azo-PIP2 and its 
ability to control cell signaling is still underway in collaboration with Prof. Dr. Carsten Schultz 
(OHSU, EMBL Heidelberg). These efforts remain in the preliminary stage, and will not be 
discussed further in this thesis. However, given the wide range of physiological processes 
with which PI(4,5)P2 is involved175, there are a large number of potential systems which this 
tool could be applied to. 
 In summary, we anticipate that both azo-PC and apo-azo-PIP2 will be broadly 
applicable to studying the roles of their parent compounds in membrane biophysics and cell 
signaling. Similarly, novel glycerophospholipids synthesized using this phosphoramidite 
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6.4 – Supporting information 
6.4.1 – Compound synthesis and characterization 
6.4.1.1 – 2-O-(4-(4-((4-Butylphenyl)diazenyl)phenyl)butanoyl)-3-bis-(9H-fluoren-9-





(PhoDAG-1, 1) was prepared as previously described52. PhoDAG-1 (1, 408 mg, 0.614 mmol, 
1.0 equiv.) was suspended in 1H-tetrazole solution (1.4 mL, 0.45 M in MeCN, 1.0 equiv.) and 
the solvent was removed under reduced pressure. The residue was then dissolved in PhMe 
(5 mL) and the solvent was again removed under reduced pressure. bis-(9H-fluoren-9-
ylmethyl)-N,N-diisopropylamidophosphite181 (262 mg, 0.614 mmol, 1.0 equiv.) was dissolved 
in dry CH2Cl2 (5 mL) under argon and then added to the PhoDAG-1/1H-tetrazole residue 
under an argon atmosphere at 0 °C.  The solution was slowly warmed to room temperature 
and stirred for 2 h. A solution of NEt3 in cyclohexane (2% v/v, 5 mL) was then added, and the 
CH2Cl2 was removed under reduced pressure. The solution was directly purified by column 
chromatography under argon (50 g SiO2, deactivated first with 10% NEt3 in cyclohexane, then 
eluent 1% NEt3 in cyclohexane) and the product was collected in argon-filled test tubes. The 
solvent was then removed under reduced pressure to yield a 1:1 P-diastereomeric mixture of 
2-O-(4-(4-((4-butylphenyl)diazenyl)phenyl)butanoyl)-3-bis-(9H-fluoren-9-ylmethyl)-N,N-
diisopropyl-amidophosphite)-1-O-stearoyl-sn-glycerol (13, 542 mg, 89%) as an orange 
oil. Note: the product was always kept under an argon atmosphere and in the presence of 
NEt3 to avoid oxidation and decomposition. 
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TLC (9:1 cyclohexane:EtOAc): Rf = 0.90.  
31P NMR (CDCl3, 162 MHz, 25 °C): δ  148.2, 148.1. 
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.85-7.78 (m, 4 H, H7Aa,b, H12Aa,b), 7.74 (d, 2 H, 2HFm, 
J = 7.5 Hz), 7.66 (d, 1 H, HFm, J = 7.5 Hz), 7.62 (d, 1 H, HFm, J = 7.5 Hz), 7.37 (t, 2 H, 2HFm, 
J = 7.3 Hz), 7.33-7.26 (m, 6 H, H6Aa,b, H13Aa,b, 2HFm), 5.25-5.17 (m, 1 H, H2G), 4.40-4.33 (m, 
1 H, HFm), 4.22-4.14 (m, 2 H, H1Ga,b), 4.04-3.96 (m, 1 H, H3Ga), 3.84-3.72 (m, 2 H, 2HFm), 
3.72-3.65 (m, 1 H, H3Gb), 3.65-3.53 (m, 2 H, 2HCH(iPr)), 2.69 (t, 4 H, H4Aa,b, H15Aa,b, 
J = 7.8 Hz), 2.34 (t, 2 H, H2Aa,b, J = 7.2 Hz), 2.29 (t, 2 H, H2Sa,b, J = 7.6 Hz), 1.96 (q, 2 H, 
H3Aa,b), 1.70-1.53 (m, 4 H, H16Aa,b, H3Sa,b), 1.42-1.34 (m, 2 H, H17Aa,b), 1.33-1.21 (m, 28 H, 
H17Sa,b, 28xHSalk), 1.18-1.11 (m, 12 H, 12HNiPr(CH3)), 0.95 (t, 3 H, H18Aa,b,c, J = 7.4 Hz), 0.88 (t, 
3 H, H18Sa,b,c, J = 7.1 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.5, 172.7, 151.4, 151.1, 146.4, 145.0, 144.64, 
144.62, 141.5, 141.4, 129.3, 129.2, 127.62, 127.58, 127.04, 127.02, 126.97, 125.6, 125.3, 
123.0, 122.9, 120.0, 119.9, 71.3, 71.2, 66.4, 66.3, 66.2, 66.1, 62.6, 61.8, 61.7, 49.3, 49.2, 
43.3, 43.2, 35.7, 35.0, 34.3, 33.7, 33.6, 32.1, 29.9, 29.84, 29.81, 29.6, 29.5, 29.4, 29.3, 27.1, 
26.5, 25.1, 24.84, 24.77, 24.73, 24.66, 22.9, 22.5, 14.3, 14.1. 
IR (neat, ATR): ṽ = 2962, 2925, 2855, 1742, 1603, 1498, 1451, 1417, 1396, 1364, 1302, 
1200, 1184, 1156, 1102, 1071, 1025, 976, 886, 848, 758, 739. 
HRMS (ESI+): m/z calcd. for [C62H89N3O6P]+: 990.6489, found: 990.6519 ([M+H+]+). 
  



















Choline p-toluenesulfonate (85 mg, 0.19 mmol, 1.5 equiv.) and a 1H-tetrazole solution 
(1.41 mL, 0.45 M in MeCN, 5.0 equiv.) were combined and the solvent was removed under 
reduced pressure. The residue was then dissolved in dry CH2Cl2 (12 mL) and dry MeCN 
(12 mL) under an argon atmosphere. 2-O-(4-(4-((4-Butylphenyl)diazenyl)phenyl)-
butanoyl)-3-bis-(9H-fluoren-9-ylmethyl)-N,N-diisopropylamidophosphite)-1-O-stearoyl-
sn-glycerol (13, 126 mg, 0.127 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (12 mL), added 
to the choline solution and stirred for 30 min at room temperature. After consumption of 13, 
the solution was cooled to −10 °C and peracetic acid (AcOOH, 19 µL, 30% in AcOH, 
0.25 mmol, 2.0 equiv.) was then added. Stirring was continued and the solution was let warm 
to room temperature. After 40 min or completion of the reaction as shown by TLC, the solvent 
was removed under reduced pressure. The residue was then dissolved in MeCN (12 mL), and 
EtNMe2 (12 mL) was added. The solution was then stirred for 1 h at room temperature. The 
solvent was then removed under reduced pressure, and the residue was purified by flash 
column chromatography (50 g SiO2, 75:25:4 CHCl3:MeOH:H2O) to afford 2-O-(4-(4-((4-
butylphenyl)diazenyl)phenyl)butanoyl)-3-1-O-stearoyl-sn-glycero-3-phosphocholine 
(azo-PC, 94 mg, 89%) as an orange oil. 
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TLC (75:25:4 CHCl3:MeOH:H2O): Rf = 0.2.  
31P NMR (CDCl3, 162 MHz, 25 °C): δ 0.92.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.88-7.84 (m, 4 H, H7Aa,b, H12Aa,b), 7.30 (d, 4 H, H6Aa,b, 
H13Aa,b, J = 7.9 Hz), 5.27-5.19 (m, 1 H, H2G), 4.39 (dd, 1 H, H3Ga, J = 12.2, 2.9 Hz), 4.30  (br, 
2 H, H1Ca,b), 4.13 (dd, 1 H, H3Gb, J = 12.1, 7.3 Hz), 3.96 (t, 2 H, H1Ga,b, J = 5.9 Hz), 3.78  (br, 
2 H, H2Ca,b), 3.32 (s, 9 H, 3xCH3), 2.74-2.63 (m, 4 H, H4Aa,b, H15Aa,b), 2.36 (t, 2 H, H2Aa,b, 
J = 7.7 Hz), 2.25 (t, 2 H, H2Sa,b, J = 7.8 Hz), 2.00-1.91 (m, 2 H, H3Aa,b), 1.68-1.58 (m, 2 H, 
H16Aa,b), 1.58-1.49 (m, 2 H, H3Sa,b), 1.43-1.32 (m, 2 H, H17Aa,b), 1.28-1.18 (m, 28 H, H17Sa,b, 
26xHSalk), 0.93 (t, 3 H, H18Aa,b,c, J = 7.4 Hz), 0.87 (t, 3 H, H18Sa,b,c, J = 7.0 Hz). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.7 (C1S), 172.9 (C1A), 151.4 (Cazo), 151.0 (Cazo), 
146.6 (Cazo), 144.6 (Cazo), 143.4, 129.3 (2 C, Cazo), 129.2 (2 C, Cazo), 123.0 (2 C, Cazo), 
122.9 (2 C, Cazo), 70.8, 66.5, 63.9, 62.9, 59.6, 54.6 (3 C, 3xCH3), 46.7, 35.7, 35.0, 34.2 (C2S), 
33.7 (C2A), 33.6, 32.1, 29.9, 29.8, 29.7, 29.5, 29.5, 29.3, 26.5 (C3A), 25.0 (C16A), 22.8, 
22.5 (C17A), 21.4, 19.0, 14.3 (C18S), 14.1 (C18A). 
IR (neat, ATR): ṽ = 2954, 2923, 2853, 1739, 1603, 1462, 1377, 1238, 1180, 1122, 1090, 
1066, 1034, 1012, 969, 816, 721, 682. 
HRMS (ESI+): m/z calcd. for [C46H77N3O8P]+: 830.5448, found: 830.5445 ([M+H+]+).  
 
 






















stearoyl-sn-glycero)phosphoryl-myo-inositol (14) - (P-diastereomeric mixture) 
 
RM-317 was obtained from Prof. Dr. Carsten Schultz and Dr. Rainer Müller (OHSU, EMBL 
Heidelberg). RM-317 (0.20 g, 0.16 mmol, 1.0 equiv.) was azeotroped twice from MeCN 
(2 mL). A 1H-tetrazole solution (1.7 mL, 0.45 M in MeCN, 0.77 mmol, 4.9 equiv.) was then 
added, and the solvent was removed under reduced pressure. 2-O-(4-(4-((4-
Butylphenyl)diazenyl)phenyl)butanoyl)-3-bis-(9H-fluoren-9-ylmethyl)-N,N-diisopropyl-
amidophosphite)-1-O-stearoyl-sn-glycerol (13, 187 mg, 0.189 mmol, 1.2 equiv.) was 
dissolved in dry CH2Cl2, and this solution was then added to the RM-317 mixture under an 
argon atmosphere at room temperature. The solution was then stirred at room temperature 
for 3 h, diluted with dry CH2Cl2 (15 mL) and cooled to −20 °C. AcOOH (42 µL, 30% in AcOH, 
0.25 mmol, 1.6 equiv.) was then added and the solution was let warm slowly to room 
temperature and stirred for 2h. The reaction was monitored by observing consumption of the 
phosphite by 31P NMR. AcOOH (30% in AcOH) was then added at room temperature in 
aliquots (15 µL) every 30 min until the phosphite was consumed (in this case, 2 further AcOOH 
aliquots were added). After completion of the oxidation, the solvents were removed under 
reduced pressure. The residue was purified by flash column chromatography (50 g SiO2, 
gradient eluent 5:2 cyclohexane:EtOAc  2:1 cyclohexane:EtOAc) and then preparative 
HPLC (C18, gradient 20% EtOAc in MeOH  to 35% EtOAc in MeOH) to afford a 1:1 
P-diastereomeric mixture of 2,3,6-O,O,O-tris(butyryl)-4,5-O,O-bis(9H-fluoren-9-ylmethyl) 
diphosphoryl-1-O-(9H-fluoren-9-ylmethyl)-(2’-O-(4’-(4’-((4’-butylphenyl)diazenyl)-
phenyl)butanoyl)-1’-O-stearoyl-sn-glycero)phosphoryl-myo-inositol  (14, 268 mg, 78%) 
as an orange oil. 
TLC (5:2 cyclohexane:EtOAc): Rf = 0.2.  
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31P NMR (CDCl3, 162 MHz, 25 °C) δ  −1.55, −2.04, −2.06, −2.21, −2.59.  
1H NMR (CDCl3, 400 MHz, 25 °C): δ 7.76-7.70 (m, 6 H), 7.65-7.58 (m, 5 H), 7.58-7.44 (m, 
7 H), 7.40 (dd, 2 H, J = 7.5, 3.0 Hz), 7.37-6.98 (m, 26 H), 6.97-6.80 (m, 2 H), 5.57 (t, 1 H, 
J = 2.8 Hz), 5.42 (t, 1 H, J = 9.9 Hz), 5.19-5.09 (m, 1 H), 5.01-4.93 (m, 1 H), 4.80-4.71 (m, 
1 H), 4.48-4.36 (m, 2 H), 4.35-4.24 (m, 4 H), 4.23-4.14 (m, 4 H), 4.11-3.86 (m, 15 H), 
2.72-2.46 (m, 4 H), 2.33-2.22 (m, 6 H), 2.17-2.10 (m, 2 H), 2.09-1.79 (m, 4 H), 1.71-1.61 (m, 
2 H), 1.60-1.48 (m, 4 H), 1.48-1.33 (m, 4 H), 1.33-1.15 (m, 26 H), 0.95 (t, 3 H, J = 7.4 Hz), 
0.92-0.83 (m, 6 H), 0.81-0.73 (m, 6 H). 
13C NMR (CDCl3, 101 MHz, 25 °C): δ 173.23, 173.20, 172.9, 172.8, 172.4, 172.3, 172.2, 
172.1, 151.3, 151.1, 146.4, 144.5, 144.4, 143.3, 143.2, 143.00, 142.95, 142.90, 142.87, 
142.72, 142.65, 141.7, 141.60, 141.57, 141.54, 141.50, 141.46, 141.31, 141.29, 141.2, 129.2, 
129.1, 128.69, 128.66, 128.3, 128.2, 128.1, 128.02, 127.97, 127.9, 127.8, 127.5, 127.4, 127.3, 
127.2, 127.1, 127.0, 125.5, 125.4, 125.3, 125.2, 125.13, 125.05, 124.99, 124.9, 123.0, 122.9, 
120.9, 120.8, 120.5, 120.43, 120.35, 120.3, 120.2, 120.09, 120.06, 120.02, 119.98, 119.9, 
76.3, 73.1, 72.9, 69.92, 69.86, 69.6, 69.54, 69.47, 68.4, 68.3, 66.1, 65.9, 61.6, 48., 48.0, 47.9, 
47.84, 47.76, 35.9, 35.8, 35.70, 35.66, 35.5, 35.3, 35.1, 34.9, 34.6, 34.0, 33.5, 33.4, 33.3, 
32.0, 29.80, 29.76, 29.7, 29.6, 29.5, 29.4, 29.2, 26.2, 24.9, 22.8, 22.4, 22.4, 18.6, 18.5, 17.9, 
17.7, 17.5, 14.2, 14.04, 14.00, 13.7, 13.62, 13.59, 13.56, 13.5. 
IR (neat, ATR): ṽ = 3042, 2957, 2925, 2854, 1745, 1603, 1581, 1498, 1478, 1450, 1415, 
1379, 1276, 1246, 1154, 1103, 1075, 1012, 989, 942, 908, 868, 841, 784, 756, 738, 727, 668. 
HRMS (ESI+): m/z calcd. for [C129H147N22O2]2+: 1084.4829, found: 1084.4849 ([M+2H+]2+). 

















inositol pentakis(acetoxymethyl) ester (apo-azo-PIP2) - (P-diastereomeric mixture) 
 
A solution of 2,3,6-O,O,O-tris(butyryl)-4,5-O,O-bis(9H-fluoren-9-ylmethyl)diphosphoryl-
1-O-(9H-fluoren-9-ylmethyl)-(2’-O-(4’-(4’-((4’-butylphenyl)diazenyl)phenyl)butanoyl)-1’-
O-stearoyl-sn-glycero)phosphoryl-myo-inositol  (14, 160 mg, 73.8 µmol, 1.0 equiv.) in 
CH2Cl2 was concentrated from MeCN (2 mL) and dried under vacuum for 30 min. The orange 
foam was then dissolved in MeCN (3 mL) and EtNMe2 (3 mL) under an argon atmosphere 
and stirred for 30 min. The volatiles were then removed under reduced pressure and the 
resulting orange oil was dissolved in MeCN (2 mL) and again concentrated under reduced 
pressure. The resulting oil was dissolved in dry MeCN (3 mL) under an argon atmosphere, 
and to this solution was added sequentially DIPEA (450 µL, 2.58 mmol, 35 equiv.) and 
bromomethylacetate (167 µL, 1.7 mmol, 23.1 equiv.). The solution was stirred for 22 h at room 
temperature and then PhMe (8 mL) was added and the volatiles were removed under reduced 
pressure. The resulting orange oil was purified by preparative HPLC (C18, 8:2 MeCN:TBME) 
to yield 2,3,6-O,O,O-tris-(butyryl)-4,5-O,O-bis(phosphoryl)-1-O-(2’-O-(4’-(4’-((4’-
butylphenyl)diazenyl)phenyl)butanoyl)-1’-O-stearoyl-sn-glycero)-phosphoryl-myo-
inositol pentakis(acetoxymethyl) ester (apo-azo-PIP2, 88 mg, 72%) as an orange oil. 
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31P NMR (C6D6, 162 MHz, 25 °C): δ −2.17, −3.04, −4.25, −4.29, −4.56, −4.61. 
1H NMR (C6D6, 400 MHz, 25 °C): δ 8.06 (d, 4 H, J = 8.1 Hz), 7.17-7.12 (m, 2 H), 7.08 (d, 2 H, 
J = 8.2 Hz), 6.13-6.09 (m, 1 H), 6.05-5.96 (m, 1 H), 5.93-5.75 (m, 4 H), 5.75-5.39 (m, 8 H), 
5.22-5.09 (m, 2 H), 5.08-4.99 (m, 1 H), 4.56-4.19 (m, 4 H), 2.90-2.69 (m, 2 H), 2.57-2.47 (m, 
2 H), 2.45-2.12 (m, 8 H), 2.09-2.00 (m, 2 H), 1.99-1.83 (m, 5 H), 1.82-1.63 (m, 16 H), 
1.62-1.48 (m, 4 H), 1.47-1.37 (m, 4 H), 1.35-1.15 (m, 28 H), 1.15-1.06 (m, 3 H), 0.90 (t, 6 H, 
J = 6.8 Hz), 0.86-0.77 (m, 6 H). 
13C NMR (C6D6, 101 MHz, 25 °C): δ 173.2, 173.1, 173.0, 172.9, 172.5, 172.4, 172.42, 172.39, 
169.3, 169.2, 169.1, 168.99, 168.97, 168.9, 151.9, 151.7, 146.3, 145.14, 145.10, 129.6, 129.4, 
123.5, 123.4, 121.1, 83.6, 83.5, 83.44, 83.39, 83.13, 83.09, 83.05, 83.0, 77.3, 77.1, 73.7, 
70.23, 70.16, 70.1, 69.9, 69.2, 69.0, 68.9, 68.8, 66.7, 66.6, 62.2, 62.0, 36.1, 36.0, 35.93, 
35.90, 35.78, 35.76, 35.7, 35.07, 35.06, 34.2, 34.1, 33.64, 33.58, 33.5, 32.4, 30.2, 30.2, 30.2, 
30.0, 29.9, 29.8, 29.54, 29.52, 26.6, 26.5, 25.2, 23.1, 22.6, 22.5, 20.4, 20.31, 20.29, 20.2, 
18.81, 18.76, 18.4, 18.30, 18.28, 14.4, 14.11, 14.08, 14.0, 13.9, 13.8, 13.58, 13.56. 
IR (neat, ATR): ṽ = 2927, 2856, 1753, 1751, 1602, 1465, 1418, 1371, 1289, 1217, 1156, 
1086, 1080, 1008, 970, 870, 827. 
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7 – Optical control of arachidonate signalling in pancreatic β-cells 
7.1 – Introduction 
Although minimalistic in structure and most often viewed as subunits of more complex lipids, 
FAs can have profound effects on cell signaling183–186. Free FAs most often consist of a long, 
unbranched carbon chain attached to a carboxyl headgroup, which is negatively charged at 
physiological pH13. They are amphiphilic molecules with diverse structures that vary in the 
chain length and the level of unsaturation. As a unique example, AA is a 20 carbon FA with 
four non-conjugated cis double bonds that affects a variety of transmembrane signaling 
proteins including GPCRs such as the Free Fatty Acid Receptor 1, also called GPR40122.  This 
GPCR responds to long-chain FAs187, and stimulates a rise in [Ca2+]i through the activation of 
PLC via Gαq14,188,189. Various ion channels, including many K+ channels, are also affected by 
AA183,190,191, demonstrating its complex pharmacology and vital role within the cell. 
Pancreatic β-cells secrete insulin in response to stimulation by glucose (glucose-
stimulated insulin secretion, GSIS). When extracellular glucose levels increase, glucose 
enters β-cells through glucose transporters (GLUT2), where it is metabolized to ATP. The 
rising cytosolic ATP/ADP ratio leads to the closure of ATP-sensitive K+ channels (KATP) in the 
plasma membrane, resulting in membrane depolarization (Fig. 7.1). This induces opening of 
Cav, and increases the [Ca2+]i concentration, triggering exocytosis of insulin secretory 
granules. Subsequent activation of Kv and Ca2+-sensitive voltage-dependent K+ channels 
leads to repolarization of the membrane, resulting in reduced Ca2+-entry through Cav 
channels, and termination of insulin secretion. Usually, glucose stimulation in β-cells does not 
induce a single cycle of membrane depolarization-repolarization, but membrane potential 
oscillations that drive corresponding oscillations in [Ca2+]i levels. The amplitude and the 
frequency of these oscillations are dependent on the interplay between K+ and Ca2+ channel 
activity, and strongly correlate with the amount of insulin secreted132,135. Under physiological 
conditions, GSIS is determined not only by glucose metabolism (triggering pathway) but is 
also complemented by the action of messengers which activate GPCRs which further 
potentiate insulin secretion (amplifying pathway)192. For example, GPR40 activation is known 
to intensify GSIS and modulate blood glucose levels187,193. Given its specific localization in 
insulin-secreting cells, synthetic orthosteric and allosteric GPR40 agonists such as 
Gw-9508194,195 and TAK-875196,197 have received significant attention as potential treatments 




summarized as a failure of pancreatic β-cells to properly compensate when faced with insulin 
resistance200. A phase III clinical trial for TAK-875 was recently terminated due to off-target 
effects and toxicity concerns201. Notably, the effects of GPR40 activation on insulin secretion 
remain elusive due to conflicting results in different experimental settings195,202. As such, tools 
which could enable precise control over GPR40 signaling may be useful to understand its 
effect on β-cell function, and could even lead to the development of novel therapeutics203. 
 
Figure 7.1 | Glucose-stimulated insulin secretion from pancreatic β-cells. Upon uptake 
into the pancreatic β-cell, glucose is metabolized into ATP. The rising ATP/ADP ratio inhibits 
KATP which causes membrane depolarization and the opening of Cav. The resulting increased 
[Ca2+]i triggers the fusion of secretory granules and the release of insulin. Kv channels work to 
repolarize the cell, generating oscillations in [Ca2+]i. GPR40 stimulation also leads to increased 
[Ca2+]i, further potentiating GSIS. 
 
Previous studies in our labs have focused on the development of photoswitchable anti-
diabetics such as sulfonylureas and incretins, and have already placed pancreatic β-cell 
function under the precise spatiotemporal control of light204–208. Complementary to this 
approach, we showed that a set of photoswitchable FAs, called FAAzos, can be used as 
modular building blocks for incorporation into photoswitchable lipids such as DAG51–53, which 
also affect β-cell [Ca2+]i activity and insulin secretion. These results suggested that the FAAzos 
can mimic highly unsaturated FAs like AA when conjugated to other polar headgroups. 
However, the pharmacology of the FAAzos alone remains largely unexplored. Given the 
sensitivity of GPR40 to unsaturated FAs, we hypothesized that the FAAzos themselves could 
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enable optical control of this GPCR. As β-cell activity is known to be regulated by GPR40 and 
several AA-sensitive K+ channels, we envisioned they could serve as the perfect model 
system to evaluate the activity of the FAAzos. Herein, we describe our approach towards to 
the optical control of FA signaling in the β-cell. We demonstrate that the FAAzos can mimic 
AA at several different protein targets, enabling photopharmacological control of β-cell 
function via a new mechanism. 
 
7.2 – Results 
7.2.1 – Design and synthesis of photoswitchable arachidonate mimics 
Although GPR40 is known to be activated by long-chain FAs such as arachidonic and linoleic 
acid14, various aromat-containing carboxylic acids such as Gw-9508 are known to produce a 
similar effect185 (Fig. 7.2a). Therefore, we reasoned that a photoswitchable FA such as 
FAAzo-4 could act as GPR40 agonists as well (Fig. 7.2b). We also recognized that the 
benzyl-aniline moiety of Gw-9508 could be easily substituted by a diazene, and would afford 
a photoswitchable ligand with little disturbance to the overall size and structure of the drug. 
Therefore, we synthesized the “azolog” of Gw-950835, FAAzo-10, using the Mills reaction in 
two steps and 45% overall yield (Fig. 7.2c). Like FAAzo-4, FAAzo-10 behaved as a regular 
azobenzene and could be isomerized between its thermally stable trans-form to the cis-form 
with UV-A light (Fig. 7.2d). The process could be reversed on irradiation with blue light, and 





Figure 7.2 | Design and synthesis of photoswitchable GPR40 agonists. (a) The chemical 
structures of Gw-9508 and AA. (b) Chemical formula and crystal structure of the 
photoswitchable fatty acid FAAzo-4. (c) Chemical synthesis of FAAzo-10, the azolog of 
Gw-9508. (d) The UV-Vis spectra of FAAzo-10 in its dark-adapted (black), UV-adapted (gray) 
and blue-adapted (blue) states (20 µM in PBS).  
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7.2.2 – Photolipids enable optical control of GRP40 in HeLa cells 
Using the genetically encoded fluorescent [Ca2+]i reporter R-GECO123, we first characterized 
the effects on GPR40 in HeLa cells with confocal fluorescence microscopy. When transfected 
with GPR40, a portion of cells displayed spontaneous [Ca2+]i oscillations without the addition 
of any external stimuli (Fig. 7.3a). Gw-9508 induced a GPR40-dependent increase in the rate 
and intensity of [Ca2+]i oscillations that was not affected by UV-irradiation (Fig. 7.3b, 
Fig. 7.4a). In cells without GPR40, no response was observed (Fig. 7.4b,c). Complementary 
to this result, we discovered that both FAAzo-4 (Fig. 7.3c, Fig. 7.4d) and FAAzo-10 
(Fig. 7.3d,e) enabled optical control of [Ca2+]i levels in HeLa cells expressing GPR40. In both 
cases, the trans-form stimulated an increase in [Ca2+]i. On isomerization to cis with λ = 375 nm 
irradiation, a sharp decrease in the [Ca2+]i level was observed. For both compounds, after 
termination of the irradiation the effect was reversed and an increase in [Ca2+]i levels was 
observed. FAAzo-10 was more potent and active at a much lower concentration when 
compared to FAAzo-4 (Fig. 7.4e). In control cells lacking GPR40, spontaneous [Ca2+]i 
oscillations were not observed, and neither FAAzo-10 nor FAAzo-4 affected [Ca2+]i levels 
(Fig. 7.4f-h). In all cells, histamine (HIS, 10 µM) was used as a positive control and triggered 
a large increase in [Ca2+]i levels on application, independent of GPR40 expression (Fig. 7.4). 
To investigate the downstream effects of GPR40 activation, we expressed the fluorescent 
DAG reporter C1-GFP, which translocates to the plasma membrane in response to increased 
DAG-levels following PLC activation120. trans-FAAzo-10 triggered C1-GFP translocation 
towards the plasma membrane, which could be reversed following isomerization to 
cis-FAAzo-10 (Figure 7.3f). This effect could be repeated over many cycles, demonstrating 






Figure 7.3 | Optical control of GPR40 in HeLa cells. In HeLa cells expressing GPR40, 
C1-GFP and the [Ca2+]i reporter R-GECO: (a) Spontaneous oscillations of [Ca2+]i levels were 
observed without the addition of any compound. (b) Gw-9508 (200 nM) caused an increase 
in [Ca2+]i levels that was not affected by λ = 375 nm irradiation. HIS (10 mM) application 
caused an increase in [Ca2+]i (n = 179 cells from two experiments). (c) trans-FAAzo-4 (25 µM) 
increased [Ca2+]i levels, and isomerization to cis-FAAzo-4 reversed this effect. 
(d,e) FAAzo-10 (200 nM) also behaved as a photoswitchable GPR40 agonist that was more 
potent in the trans-form. Displayed as (d) individual [Ca2+]i traces from representative cells 
and (e) the average [Ca2+]i level for many cells (n = 157 cells from two experiments). (f) The 
fluorescent DAG sensor C1-GFP translocated to the plasma membrane alongside the 
increase in [Ca2+]i when stimulated by trans-FAAzo-10 (20 µM, n = 10 cells from one 
representative experiment). Translocation (black) is displayed as the plasma membrane to 








Figure 7.4 | Optical control of GPR40 in HeLa cells. [Ca2+]i in HeLa cells was monitored 
using R-GECO. (a) When co-transfected with GPR40, application of Gw-9508 (200 nM) 
caused an increase in the [Ca2+]i and oscillation frequency. This was not affected by 
λ = 375 nm irradiation. (b,c) Without GPR40, Gw-9508 (up to 20 µM) did not affect [Ca2+]i 
levels. Displayed as (b) an average of many cells (n = 65 cells from one experiment) and 
(c) individual traces from representative cells. HIS (10 mM) was used as a positive control 
and caused an increase in [Ca2+]i. (d) When co-transfected with GPR40, trans-FAAzo-4 
(25 µM) triggered an increase in [Ca2+]i, while isomerization to cis-FAAzo-4 reversed this 
effect (n = 170 cells from two experiments). (e) At 200 nM, FAAzo-10 (n = 153 cells from two 
experiments) was active on GPR40 while FAAzo-4 (n = 211 cells from two experiments) was 
not. (f-h) In cells lacking GPR40, neither (f) FAAzo-4 (25 µM) nor (g,h) FAAzo-10 (200 nM) 
significantly affected [Ca2+]i levels. Displayed as (f,h) representative traces from induvial cells 
and (g) the average [Ca2+]i level from many cells (n = 159 cells from two experiments). HIS 





7.2.3 – Optical control of K+ channel activity in β-cells 
We used whole-cell electrophysiology in dissociated mouse β-cells to examine the effect of 
our photoswitchable ligands on Kv channel conductance, a major determinant of the [Ca2+]i 
oscillation frequency. Like AA, which is known to inactivate Kv15,52,136 channels in β-cells, 
trans-FAAzo-10 reduced channel conductance in the IV-curve in the dark or under blue light 
(Fig. 7.5a). On isomerization to cis-FAAzo-10, Kv channel activity was restored to a 
comparable level as the vehicle controls (Fig. 7.5b). Application of Gw-9508 reduced channel 
conductance to a comparable level (Fig. 7.5b). Advantageously, FAAzo-10 could be switched 
ON and OFF over several cycles, effectively replicating washin and washout of Gw-9508, 
using only a light stimulus (Fig. 7.5c). Voltage ramps were then acquired under varying 
irradiation wavelengths between λ = 350-450 nm. This action spectrum demonstrated that Kv 
activity could be precisely tuned by changing the irradiation wavelength (Fig. 7.5d,e). FAAzo-
4 (50 µM) behaved in a similar fashion, and reversibly inactivated Kv more strongly in the 
trans-configuration (Fig. 7.6).  
 Gw-9508 was previously shown to potentiate KATP channels in mouse β-cells194. 
Similarly, AA is known to affect KATP channels in other cell types, however contradicting 
activities have been observed under different experimental conditions209. We first measured 
the whole-cell KATP current from mouse β-cells without extracellular glucose. IV-curves were 
measured between −110 to −50 mV to exclude any effect of the Kv channels. After dialysis of 
the cytoplasm with intracellular buffer, the KATP current increased to a steady state 
(Fig. 7.7a,b). In line with previous reports, Gw-9508 increased the KATP conductance further, 
and AA acted in a similar fashion (Fig. 7.7a,b). Interestingly, trans-FAAzo-10 behaved 
differently, and reduced the KATP conductance, while isomerization to cis- reversed the effect 
entirely (Fig. 7.7a,c). Like the effects observed on the Kv channels, FAAzo-10 activity at KATP 
could be fine-tuned by altering the irradiation wavelength (Fig. 7.7d). Under blue irradiation 
the KATP current was reduced, while the blockade was reversed under UV-A irradiation. UV-A 
or blue irradiation alone did not affect the KATP current (Fig. 7.7e). 
  




Figure 7.5 | Optical control of β-cell Kv channel activity with FAAzo-10. The whole-cell Kv 
channel current in dissociated wt mouse β-cells was measured using electrophysiology. (a) 
An IV-plot revealed that in the dark and under blue light, trans-FAAzo-10 (20 µM) reduced the 
whole-cell Kv current (n = 7 cells from 3 animals). Isomerization to cis-FAAzo-10 with UV-A 
light reversed this effect comparable to (b) the vehicle control (n = 6 cells from 3 animals). 
Gw-9508 (50 µM) reduced the Kv conductance to a similar degree (n = 8 cells from 2 animals). 
(c) FAAzo-10 could be activated and inactivated over several cycles with irradiation, 
producing a similar effect to Gw-9508 washin and washout. Shown are IV-steps from −70 to 
+80 mV from representative cells. (d,e) An action spectrum between λ = 350-450 nm showed 
that Kv activity could be fine-tuned by changing the irradiation wavelength. Shown are 
(d) sequential voltage ramps (−70 to +80 mV) from a representative cell and (e) the 
normalized (to I350nm) current under each λ (n = 3 cells from 2 animals). Error bars were 






Figure 7.6 | Optical control of β-cell voltage activated K+ channel activity with FAAzo-4. 
The whole-cell Kv channel current in dissociated wt mouse β-cells was measured using 
electrophysiology. (a) An IV-plot revealed that in the dark (black) under blue (blue) irradiation, 
trans-FAAzo-4 (50 µM) reduced the whole-cell Kv current (n = 6 cells from 2 animals). 
Isomerization to cis-FAAzo-4 with UV-A light (gray) reversed this effect comparable to the 
vehicle control (red) (n = 6 cells from 3 animals). (b) An action spectrum between 
λ = 350-450 nm demonstrates that Kv activity could be fine-tuned with the irradiation 
wavelength. Shown are sequential voltage ramps (−70 to +80 mV) from a representative cell. 
(c) Isomerization of FAAzo-4 between its trans- and cis- forms could reversibly inactivate and 
activate Kv channels over several cycles. Shown are overlaid sequential IV-steps from −70 to 
+80 mV from a representative cell. Error bars were calculated as ±s.e.m. 
  





Figure 7.7 | Optical control of β-cell KATP channels. The whole-cell KATP current from 
dissociated mouse β-cells was measured between −110 to −50 mV. (a-c) After dialysis of the 
cytoplasm with the pipette solution, the KATP current developed to a steady state 
(black = before, n = 21 cells; green = after, n = 20 cells; both from 2 animals). Application of 
Gw-9508 (20 µM, red, n = 9 cells from 2 animals) and AA (20 µM, orange, n = 4 cells from 
1 animal) increased KATP conductance. In contrast, the application of trans-FAAzo-10 (20 µM, 
blue) decreased the KATP current, while isomerization to cis-FAAzo-10 (gray) reversed this 
effect (n = 7 cells from 2 animals). Data is displayed as (a) the % KATP current (at −110 mV) 
for multiple cells, normalized to the KATP open (green) state and (b,c) the full IV relationship 
between −110 to −50 mV.  (d) In the presence of FAAzo-10, an action spectrum between λ = 
350-450 nm revealed that KATP was inhibited the most under blue irradiation. Irradiation with 
UV-A light prevented FAAzo-10 from blocking the KATP current. Displayed as the normalized 
photocurrent for multiple cells (n = 3 cells from one animal, normalized to I350nm(−110 mV)). (e) 
UV-A and blue irradiation alone did not affect the KATP current, displayed as sequential voltage 
ramps under alternating UV-A and blue light from a representative cell. ns = P>0.05, *P<0.05. 






7.2.4 – Optical control of [Ca2+]i oscillations in pancreatic islets 
Finally, we evaluated our photoswitchable ligands for their effects on intact pancreatic islets. 
We used the small-molecule [Ca2+]i indicator Fluo-8 to monitor [Ca2+]i oscillations stimulated 
by a high glucose concentration (11 mM). Similar to the application of Gw-9508 (Fig. 7.8a,b) 
or AA (Fig. 7.8c), application of trans-FAAzo-10 caused a marked increase in the [Ca2+]i 
oscillation frequency (Fig. 7.8d). In line with our previous results, isomerization to 
cis-FAAzo-10 with λ = 365 nm irradiation reversed this effect entirely (Fig. 7.8e). Lower 
concentrations of FAAzo-10 did not affect oscillation frequency in either configuration 
(Fig. 7.8f). FAAzo-4 behaved in an analogous manner, and reversibly stimulated [Ca2+]i 
oscillations in the trans- configuration (Fig. 7.8g,h). To exclude imaging artefacts, in particular 
fluorescence quenching, the cells were treated with a methyl ester FAAzo-derivative, 
FAAzo-5(OMe), which possesses an azobenzene photoswitch with similar spectral 
characteristics to both FAAzo-10 and FAAzo-451. FAAzo-5(OMe) did not affect the [Ca2+]i 
oscillations in either configuration (data not shown), as methyl esterification of the acid group 
abolished compound activity. As was previously demonstrated52, UV-irradiation alone did not 
affect oscillatory behavior. We then compared the effects of FAAzo-10 and Gw-9508 on 
insulin secretion. At 3 mM glucose, Gw-9508 stimulated an increase in insulin secretion 
(Fig. 7.8i). However, application of FAAzo-10 in either the trans- or cis- forms did not affect 
secretion levels. Further experiments at different glucose concentrations are required to verify 
this effect, however these results suggest that insulin secretion is not only determined by the 
[Ca2+]i oscillation frequency, or that other targets may in fact be affected by the FAAzos as 
well. 
  





Figure 7.8 | FAAzo-10 enables optical control of [Ca2+]i oscillations in pancreatic islets. 
[Ca2+]i oscillations were stimulated by a high glucose concentration (11 mM) and monitored in 
intact mouse islets using the fluorescent [Ca2+]i indicator Fluo-8. (a,b) The application of 
Gw-9508 (50 µM) caused an increase in the [Ca2+]i oscillation frequency. Displayed as (a) a 
representative trace from a single islet and (b) the oscillation frequency averaged over multiple 
islets (n = 6 islets). (c) Similarly, AA (50 µM) caused an increase in [Ca2+]i. (d,e) The 
application of trans-FAAzo-10 also caused a marked increase in the oscillation frequency. 
Isomerization to cis-FAAzo-10 with λ = 365 nm irradiation reversed this effect. Results are 
displayed as (d) a representative trace from a single islet and (e) the average oscillation 
frequency from multiple islets (n = 5 islets). (f) FAAzo-10 enabled optical control of β-cell 
[Ca2+]i oscillations at 20 µM, but not at 2.5 µM (n = 4-5 islets). (g,h) Application of 
trans-FAAzo-4 also increased [Ca2+]i oscillations, while isomerization to cis-FAAzo-4 
reversed this effect. Displayed as (g) a representative trace from a single islet and (h) the 
oscillation frequency averaged over multiple islets in the presence of cis-FAAzo-4 (50 µM, 
n = 8 islets) and AA (50 µM, n = 6 islets). (i) At low glucose levels (3 mM), Gw-9508 stimulated 
insulin secretion, but FAAzo-10 did not (n = 3). *P<0.05 and **P<0.01, Student’s t-test or 







7.3 – Discussion 
In summary, this work demonstrates the utility of the FAAzos for manipulating lipid 
signaling in cells. Both FAAzo-4 and FAAzo-10 can mimic AA signaling in a time-controlled 
manner. Although previous studies involving the FAAzos conjugated to different polar 
headgroups have all afforded cis-active compounds51,52, we found the opposite in this case. 
Both mimicked the activities of their parent compounds, AA and Gw-9508, with the greatest 
efficacy in trans-form. As such, they behave as a dark-active AA that can be quickly switched 
OFF and ON again with UV-A and blue irradiation, respectively. 
Like AA, these photoswitchable molecules exhibit complex polypharmacology at 
different targets. They affect GPR40, KATP and Kv channels, all of which are known to regulate 
[Ca2+]i oscillations and GSIS in pancreatic β-cells. Accordingly, we could stimulate 
glucose-stimulated [Ca2+]i oscillations in mouse islets on application of either compound in the 
trans-form, while isomerization to cis- reduced the effect. However, these results did not 
translate to the optical control of insulin secretion, which was unaffected by FAAzo-10 in either 
the trans or cis-configurations. A potential explanation is the activation of parallel, non-light-
responsive targets, whose activation may counteract any increase in secretion stimulated by 
the trans-ligand at GPR40 or Kv, or KATP. Nevertheless, we showed that GPR40 agonists like 
Gw-9508 behave similarly to AA when applied to β-cells, and that their combined effects on 
GPR40, Kv, and KATP regulate the intensity and frequency of the [Ca2+]i oscillations. This 
complex polypharmacology could also contribute to the varied effects observed using GPR40 
agonists in primary vs. model cell lines, as channel expression likely varies between the 
different cell-types, as was previously alluded to using the PhoDAGs52. Moreover, FAs have 
been shown to alter insulin secretion via non-ionic pathways (e.g. by acting directly upon the 
exocytotic machinery through DAG generation) and this could have differential contributions 
depending on the exact cell-system employed.   
Drugs targeting GPR40 for the treatment of T2DM previously received great attention 
due to the specific localization of the receptor to pancreatic β-cells. Unfortunately, these drugs 
failed due to adverse side-effects associated with treatment, including liver toxicity. This work 
demonstrates that GPR40 agonists can have off-target effects on β-cell K+ channels, and this 
could be limiting for drug development targeting GPR40. As such, novel molecules must be 
synthesized to achieve greater specificity towards GPR40 and limit off-target effects. This 
effort would not only lead to the development of more efficacious photoswitchable ligands, but 
could even lead to the development of novel therapeutics for T2DM. 
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7.4 – Supporting information 
7.4.1 – Cell culture 
HeLa Kyoto cells were grown in 1.0 g/L D-glucose DMEM (GIBCO, cat # 31885-023) supplied 
with 10% FBS (GIBCO, cat # 10270-106) and 0.1 mg/mL antibiotic Primocin (Invitrogen, cat 
#ant-pm-1). HeLa cells were first seeded in an 8-well Lab-Tek™ chambered coverslip 
(ThermoScientific #155411) 24-48 h before transfection at 37 °C and 5% CO2. Transfection 
was carried out with FugeneHD (Promega, cat # E2311) in DMEM free of FBS and antibiotics 
according to the manufacturer's instructions. First, the media was aspirated and the wells were 
charged with DMEM media (200 µL per well). A transfection solution containing DMEM (20 µL 
per well), cDNA (300 ng total DNA per well) and FugeneHD (1.5 µL per well) was then added 
to each well of the 8-well Lab-Tek™. The cells were incubated at 37 °C and 5% CO2 for 
20-24 h before the microscopy experiments were performed.  
  
7.4.2 – Culture of primary mouse pancreatic islets 
**Note: Culture of mouse pancreatic islets was performed by Dr. David Hodson and Nick Fine 
(IMSR Birmingham), and the experimental details are included here for clarity. 
 
Islets were isolated from C57BL6 and CD1 mice using collagenase digestion, as previously 
detailed154. Briefly, following euthanasia by cervical dislocation, the bile duct was injected with 
a collagenase solution (1 mg/mL) before digestion at 37 °C for 10 min and separation of islets 
using a Histopaque gradient (1.083 and 1.077 g/mL). Islets were cultured for 24-72 h in RPMI 
medium supplemented with 10% FCS, 100 U/mL penicillin and 100 µg/mL streptomycin. All 
animal work was regulated by the Home Office according to the Animals Act 1986 (Scientific 






7.4.3 – List of utilized cDNA constructs 
Name Characterization 
R-GECO123 red intensiometric [Ca2+]i sensor 
hGPR40 (FFAR1)* human free fatty acid receptor 1 
C1-GFP120 green fluorescent DAG-sensing translocation probe 
*This cDNA clone was obtained from the cDNA Resource Center (www.cdna.org). 
 
7.4.4 – Laser scanning confocal microscopy 
Imaging of HeLa cells was performed on an Olympus Fluoroview 1200 with a 20x objective, 
or a 63x oil objective. C1-GFP excitation was performed with λ = 488 nm laser at low laser 
power (<3%) and emission was collected at λ = 500-550 nm. R-GECO excitation was 
performed with a λ = 559 nm laser at low laser power (<3%) and emission was collected at 
λ = 570-670 nm. Compound activation was triggered using the quench function in the 
Olympus software. Photoactivation was carried out with a λ = 375 nm laser at 100% intensity. 
The cells were incubated in imaging buffer (250 µL, containing in mM: 115 NaCl, 1.2 CaCl2, 
1.2 MgCl2, 1.2 K2HPO4, 20 HEPES, 20 D-glucose) at 37 °C and 5% CO2 for at least 10 min. 
Compounds were first solubilized in DMSO at a concentration of 10 mM. This stock was then 
diluted into imaging buffer (50 µL) and then added directly to the well containing the cells and 
imaging buffer. 
Imaging of primary rodent pancreatic β-cells was performed on a Zeiss Axiovert M200 
coupled to a Yokogawa CSU10 spinning disk head and 10x and 20x objectives. Fluo-8 
excitation was performed using a solid-state λ = 491 nm laser, and emission was collected 
using a highly sensitive back-illuminated EM-CCD (Hammamatsu C9100-13) at 
λ = 500-550 nm. Photoactivation was carried out using an X-Cite 120 epifluorescence source 
and a λ = 350±20 nm band-pass filter. Islets were imaged in a HEPES-bicarbonate buffer 
containing (in mM): 120 NaCl, 4.8 KCl, 24 NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2, 
1.2 MgCl2 and 11 D-glucose. Images were processed with Fiji software (http://fiji.sc/Fiji) and 
the resulting data was analyzed in Microsoft Excel, MATLAB and R. The data were then 
plotted with Igor Pro, Origin and R.  **Note: [Ca2+]i imaging of mouse pancreatic islets was 
performed by Dr. David Hodson and Nick Fine (IMSR Birmingham), and the experimental 
details are included here for clarity. 
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7.4.5 – Whole-cell electrophysiology in dissociated mouse β-cells 
Two days after culture, primary mouse islets were dissociated into single β-cells using trypsin 
digestion for 5 min at 37 °C and allowed to attach to poly-L-lysine-coated and acid-etched 
coverslips overnight in RPMI medium supplemented with 10% FCS, 100 U/mL penicillin and 
100 µg/mL streptomycin at 37 °C and 5% CO2. Whole cell patch clamp experiments were 
performed the next day using a standard electrophysiology setup equipped with a HEKA Patch 
Clamp EPC10 USB amplifier and PatchMaster software (HEKA Electronik). Micropipettes 
were generated from “Science Products GB200-F-8P with filament” pipettes using a Narishige 
PC-10 vertical puller. The patch pipette resistance varied between 4-8 MΩ.  
For recording of the Kv current, the bath solution contained (in mM): 119 NaCl, 2 CaCl2, 
4.7 KCl, 10 HEPES, 1.2 MgSO4, 1.2 KH2PO4, 14.4 D-glucose (adjusted to pH 7.3 with NaOH). 
The intracellular solution contained (in mM): 140 KCl, 1 MgCl2, 10 EGTA, 10 HEPES, 
5 MgATP (adjusted to pH 7.25 with KOH). In voltage clamp mode, voltage steps (500 ms) 
were applied to the cells from the baseline at –70 mV to +80 mV in 10 mV intervals. The 
resulting current was averaged between the 400-470 ms range of each voltage step and 
plotted as a function of the holding potential 
For measurement of the KATP current, the bath solution contained (in mM): 116 NaCl, 
3 KCl, 4 CaCl2, 3 MgCl2, 25 HEPES (adjusted to pH 7.4 with NaOH). The intracellular solution 
contained (in mM): 130 K-gluconate, 10 KCl, 10 NaCl, 3 MgCl2, 4 EGTA, 10 HEPES, 0.3 
MgATP (adjusted to pH 7.2 with KOH). In voltage clamp mode, voltage steps (500 ms) were 
applied to the cells from the baseline at −110 mV to −50 mV in 10 mV intervals. The resulting 
current was averaged between the 100-450 ms range of the voltage step and plotted as a 
function of the holding potential. 
All cells had a leak current below 15 pA on break-in at –70 mV. And recordings were 
corrected for the liquid junction potential. The data was analyzed in Igor Pro using the 
Patcher`s Power Tools (MPI Göttingen) plugin. Current values were extrapolated and 
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7.4.6 – Compound synthesis and characterization 
7.4.6.1 – 3-(4-((3-Phenoxyphenyl)diazenyl)phenyl)propanoic acid (FAAzo-10) 
 
3-phenoxyaniline (112 mg, 0.600 mmol, 2.0 equiv.) was dissolved in CH2Cl2 (25 mL), and then 
an aqueous solution (25 mL) of Oxone® (372 mg, 1.20 mmol, 4.0 equiv.) was added. The 
biphasic mixture was stirred rapidly overnight. The phases were then separated and the 
organic phase was washed with H2O (2x30 mL), dried over anhydrous Na2SO4 and filtered. 
The filtrate was concentrated under reduced pressure and the residue was purified by flash 
silica gel chromatography (10 g SiO2, CH2Cl2). The fractions containing the green 1-nitroso-
3-phenoxybenzene were pooled and 3-(4-aminophenyl)propionic acid (50 mg, 0.30 mmol, 
1.0 equiv.) was added alongside AcOH (20 mL). The solution was again stirred overnight at 
room temperature. The solvents were removed under reduced pressure and the crude residue 
was purified by flash silica gel chromatography (10 g SiO2, 7:3 hexane:EtOAc with 1% AcOH) 
to yield 3-(4-((3-phenoxyphenyl)diazenyl)phenyl)propanoic acid (FAAzo-10, 46.7 mg, 
45%) as an orange solid. 
 
TLC (70:30:1 hexane:EtOAc:AcOH): Rf = 0.5 (trans), 0.36 (cis). 
1H NMR (CDCl3, 400 MHz, 25 °C): δ 11.33 (bs, 1 H, HCOOH), 7.85 (d, 2 H, H6a,b, J = 8.0 Hz), 
7.68 (d, 1 H, H15, J = 7.8 Hz), 7.56 (s, 1 H, H11), 7.48 (t, 1 H, H14, J = 8.0 Hz), 7.41-7.33 (m, 
4 H, H5a,b, H19a,b), 7.18-7.14 (m, 2 H, H13, H20), 7.10 (d, 2 H, H18a,b, J = 8.0 Hz), 3.04 (t, 2 H, 
H3a,b,  J = 7.8 Hz), 2.74 (t, 2 H, H2a,b, J = 7.6 Hz).  
13C NMR (CDCl3, 101 MHz, 25 °C): δ 179.1 (C1), 158.2 (CAzo), 156.9 (CAzo), 154.2 (CAzo), 
151.3 (CAzo), 143.8 (C4), 130.2 (C14), 130.0 (2 C, C19a,b), 129.2 (2 C, C5a,b), 123.8 (C20), 
123.3 (2 C, C6a,b), 121.2 (C13), 119.3 (2 C, C18a,b), 118.6 (C15), 112.1 (C11), 35.4 (C2), 30.5 (C3). 
IR (neat, ATR): ṽ (cm-1) = 3038, 2924, 2623, 1694, 1602, 1586, 1488, 1437, 1417, 1314, 
1277, 1253, 1215, 1166, 1150, 1104, 1072, 1022, 963, 943, 916, 899, 865, 838, 792, 779, 
749, 680. 
HRMS (ESI+): m/z calcd. for [C21H19N2O3]+: 347.1396, found: 347.1390 ([M+H+]+). 
UV-Vis (50 µM in DMSO): λmax(π-π*) = 330 nm. λmax(n-π*) = 430 nm. 
Melting point (°C): 129.8-132.0. 
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7.4.7 – Crystallographic data 
7.4.7.1 – 4-(((4-Butylphenyl)diazenyl)phenyl)butanoic acid (FAAzo-4) 
 
Figure 7.10 | FAAzo-4 unit cell. Displacement ellipsoids are drawn at the 30% probability 
level. 
 
Net formula = C20H24N2O2 
Mw = 324.41 g/mol 
Monoclinic, P21/c 
Diffractometer:  Bruker D8Venture 
a (Å) = 33.5257(16) 
b (Å) = 4.6215(2) 
c (Å) = 11.3999(6) 
α (°) = 90 
β (°) = 99.154(2) 
γ (°) = 90 
V (Å3) = 1743.79(15) 
Z = 4 
Dx (g cm−3) = 1.236 
µ (mm-1)= 0.080  
T (K) = 100 
Crystal size (mm) = 0.100 × 0.100 × 0.030 
Absorption correction: multi-scan 
Transmission factor range = 0.8615-
0.9585 
Reflections measured = 16414 
Rint = 0.0319 
Mean σ(I) (I) = 0.0304 
θ range = 3.077-26.45 
Observed reflections = 2643 
x, y (weighting scheme) = 0.0435, 0.4645 
Hydrogen refinement:  mixed 
Reflections in refinement = 3570 
Parameters = 279 
Restraints = 0 
R(Fobs) = 0.0380 
Rw(F2) = 0.0989 
S = 1.018 
Shift/errormax = 0.001 
Max electron density (e Å−3) = 0.187 





8 – Optical control of lipid rafts with photoswitchable ceramides 
This work has been published in the Journal of the American Chemical Society (2016)53. 
 
8.1 – Introduction 
The plasma membrane is not simply a two-dimensional fluid mosaic, but can be laterally 
organized through the assembly of dynamic lipid domains, the so-called lipid rafts210. These 
segregated domains are thought to permit the two-dimensional organization of membrane 
components, including both signaling molecules and proteins, leading to the modulation of 
signaling processes within the plane of the membrane12,211–213. Lipid rafts are structurally and 
dynamically distinct from the bulk of the lipid bilayer213. They are enriched in specific lipid 
species such as cholesterol (Chol) and sphingolipids214,215. Moreover, their physical state is 
more similar to a liquid-ordered (Lo) phase, in contrast to the rest of the plasma membrane, 
which is assumed to be mainly in the liquid-disordered (Ld) phase. While the most abundant 
sphingolipid in the plasma membrane is sphingomyelin (SM), in recent years the neutral 
sphingolipid ceramide (Cer) has received great attention for its effects on membrane 
structure216–221. This ubiquitous sphingolipid is often considered a second messenger, and is 
best known for its role in triggering apoptosis, cell-proliferation and cell-cycle arrest217,222. 
Defects in Cer metabolism are involved in various disease states223. In most healthy cells, Cer 
concentrations are quite low and tightly regulated. However, its generation via the hydrolysis 
of SM by sphingomyelinase is stimulated by a variety of cell stress signals or other external 
factors. This can lead to an overall Cer concentration of 10-20% within the membrane, which 
has a significant effect on the membrane structure217,224. Although structurally similar to DAG, 
ceramides possess an elevated melting temperature and are known to rigidify lipid 
membranes225,226. Recent studies in model membrane systems have shown that Cer can 
trigger the formation of ordered gel-like platforms, and this process is known to be dependent 
on the length and saturation of its N-acyl chain227–229. 
Currently, chemical tools used to manipulate lipid membranes have failed to address the 
features of lipid raft and sphingolipid dynamics. For this, a tighter control of individual 
membrane components must be achieved than with what is currently available230. Over the 
past decades, the emergence of photochemical tools has allowed researchers to translate a 
light stimulus into a cellular response, with the high degree of spatiotemporal precision 
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associated with light34. Caged lipids24, whose activities are masked with a photo-labile 
protecting group, have already proven themselves useful to study lipid signaling at the cellular 
level231,232. In terms of in vitro applications, caged ceramides have been shown to modulate 
lipid domain structure in phase-separated bilayers28; yet the effects observed were quite slow 
and naturally irreversible, as uncaging is a one-shot process. 
An alternative approach utilizes photoswitchable small molecules, such as azobenzene 
derivatives, to translate optical stimuli into a reversible cellular response. This technique has 
placed a variety of cellular machinery, including ion channels, GPCR’s and enzymes, under 
the control of light35. The behavior of photoswitchable azobenzene-modified lipids has been 
evaluated in model membrane systems before, most notably to explore membrane 
permeability and surface pressure45–47. Photoswitchable amphiphiles have also been used to 
enable reversible control the lipid domain structure in giant unilamellar vesicles49,50. However, 
in those studies the photoswitch was incorporated into the polar headgroup of the amphiphile, 
while the membrane-embedded portion remained unaffected by light. 
Recently, we developed a series of photoswitchable fatty acids, the FAAzos, which 
contain an azobenzene photoswitch along the length of the aliphatic chain51. The FAAzos can 
be used as modular building blocks for the construction of more complex photoswitchable 
lipids, now coined photolipids52. Here, we report the incorporation of the FAAzos into the Cer 
scaffold, which has allowed us to produce, for the first time, a set of intrinsically 
photoswitchable ceramides, ACes. This approach enables dynamic control over the curvature 
of the N-acyl chain, while still retaining the integrity of the Cer headgroup. Here, we investigate 
the biophysical properties of this novel class of photolipids within lipid raft-mimicking 
membrane models using atomic force (AFM) and fluorescence microscopy. In summary, the 








8.2 – Results 
8.2.1 – Synthesis of photoswitchable ceramides 
We designed and synthesized three photoswitchable ceramides, ACes (Fig. 8.1a,b), which 
are composed of a sphingosine backbone N-acylated with one of the FAAzos. ACe-1-3 differ 
in the position of the azobenzene photoswitch from the near to the distal end of the chain, with 
the diazene unit representing the ∆9, ∆6 and ∆12 positions, respectively. ACe-1 was prepared 
in one step by amide coupling between FAAzo-447,51 and D-erythro-sphingosine in 70% yield 
(Fig. 8.1c). To investigate the photoswitching behavior in a lipid environment, we incorporated 
ACe-1 into small unilamellar vesicles (SUVs) (Fig. 8.1d). In the dark at room temperature, 
ACe-1 existed primarily in the thermally stable trans-configuration. Irradiation with UV-A light 
(λ = 350-380 nm) triggered isomerization to the cis-configuration (Fig. 8.1e). On termination 
of the irradiation, ACe-1 relaxed spontaneously back to the trans-form with a τ-value of 39 h, 
and this effect could be reversed by irradiation with blue light. Photoswitching could be 
repeated over many cycles without fatigue (Fig. 8.1f). The average size of the SUVs was 
66±2 nm, and was not affected by UV-A or blue irradiation, suggesting that the SUVs were 
stable on photoswitching. ACe-2 and ACe-3 were prepared in an analogous fashion by 
coupling with FAAzo-1 and FAAzo-7, respectively, and possessed similar spectral 
characteristics when compared to ACe-1 (Fig. 8.2). As such, the ACes can be described as 
a classical azobenzenes, whose physical orientation can be reversibly modulated by 
irradiation with UV-A/blue light. 




Figure 8.1 | Design and synthesis of photoswitchable ceramides. (a) The chemical 
structure of C18-ceramide (C18-Cer). (b) The chemical structures of photoswitchable 
ceramides, ACe-1-3. (c) D-erythro-sphingosine was converted to the photoswitchable Cer, 
ACe-1, by peptide coupling with FAAzo-4. ACe-1 isomerized between its cis- and trans-
configurations on UV-A (λ = 365 nm) and blue (λ = 470 nm) irradiation, respectively. 
(d-f) SUVs containing ACe-1 (150 µM lipid mixture composed of DOPC:Chol:SM:ACe-1 
10:6.7:7:3 mol ratio).  were analyzed using UV-Vis. (d) The spectra of dark- (black), UV- (gray) 
and blue-adapted (blue) ACe-1. The black trace is superimposed under the blue line. 
(e) ACe-1 could be isomerized to its cis-configuration with UV-A light (λ = 350-380 nm). 
(f) This effect could be reversed with blue light (λ = 470 nm), and could be repeated over 





Figure 8.2 | Synthesis of photoswitchable ceramides. The chemical syntheses of 
photoswitchable ceramides (a) ACe-2 and (b) ACe-3. Both compounds were prepared in high 
yield via an amide coupling between D-erythro-sphingosine and the photoswitchable FAs 
FAAzo-1 and FAAzo-7, respectively. (c) The UV-Vis spectra of dark- (black), UV- (gray) and 
blue-adapted (blue) ACe-1 (50 µM in DMSO). ACe-2 and ACe-3 possessed nearly identical 
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8.2.2 – Confocal fluorescence microscopy of supported lipid bilayers 
In our previous studies, the effect of different ceramides in Ld-Lo phase separated supported 
lipid bilayers (SLBs) composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), Chol, 
and C18-SM was investigated233,234. Despite the influence of the solid support235,236, SLBs 
provide us with a practical advantage to study both the spatial and topographical properties 
of such membranes. Using a similar approach, we prepared lipid mixtures containing molar 
ratios of 10:6.7:X:Y DOPC:Chol:SM:ACe (with 0.1 mol% ATTO655-DOPE for fluorescence 
detection), and varied the SM:ACe (X:Y) molar ratio between 9:1, 7:3, 5:5, 2.5:7.5 and 0:10 
for all 3 ACes. After deposition of these lipid mixtures on a flat mica surface237, we analyzed 
the resulting SLBs using confocal fluorescence microscopy. We discovered that all three ACes 
formed ordered domains in the 9:1 and 7:3 SM:ACe ratios at room temperature, observed as 
a decrease in fluorescence intensity in regions of the SLB (Fig. 8.3a). However, at the 5:5 
ratio, a difference was observed between the three compounds. The ACe-1 SLB again formed 
large ordered domains, whereas ACe-2 prevented the formation of distinguishable domains, 
and ACe-3 formed a bilayer with many small domains of a different structure than the ACe-1 
SLB. For SM:ACe ratios of 2.5:7.5 and 0:10, where minimal or no SM is present, a 






Figure 8.3 | Optical control of ordered lipid domains in supported lipid bilayers (SLBs). 
(a) Confocal fluorescence images of SLBs containing a quaternary mix of 
DOPC:Chol:SM:ACe (10:6.7:X:Y mol ratio with 0.1 mol% ATTO655-DOPE). SLBs with 
SM:ACe X:Y ratios of 9:1, 7:3 and 5:5 are presented for all three ACes. (b) Using AFM, we 
showed that the ordered (Lo) domains were approximately 0.7-1.1 nm higher than the 
disordered (Ld) phase in the 7:3 SM:ACe-1 mixture. (c) Representative AFM images of the 
7:3 SM:ACe-1 mixture showed that isomerization to cis-ACe-1 with λ = 365 nm irradiation 
triggered the formation of Ld lakes within the Lo domains. Scale bars = 5 μm. 
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8.2.3 – Isomerization to cis-ACe-1 triggers a fluidification of ordered domains  
Correlated fluorescence and AFM images in contact mode at room temperature of the 
7:3 SM:ACe-1 mixture confirmed that we had indeed produced a two phase mixture 
containing a liquid ordered (Lo) domain, which rested approximately 0.7-1.1 nm above the 
liquid disordered (Ld) phase (Fig 8.3b). Similarly, the 9:1 and 5:5 SM:ACe-1 mixtures 
possessed identical height profiles. By measuring the depth of holes found within the SLB, we 
determined a total SLB thickness of 6-7 nm. On irradiation with UV-A light (λ = 365 nm, 10 s), 
a fluidification of the Lo domains was observed and small Ld domains (from here-on called 
“lakes”, for the sake of clarity) appeared inside the Lo domains (Fig. 8.3c). The size of the 
lakes formed within the Lo domains was proportional to the amount of ACe-1 present in the 
lipid mixture (Fig. 8.4). In the 9:1 SM:ACe-1 mixture, only small fluid domains were observed 
1 min after UV-A irradiation. After 5 min they had entirely disappeared, presumably via lateral 
diffusion of lipids into the nearby Ld phase. In contrast, many fluid lakes were formed in the 
7:3 and 5:5 SM:ACe-1 mixtures on UV-A irradiation, and after 5 min most of them had fused 
to even larger, stable Ld lakes within the Lo domains. In control experiments using C18-Cer, 
we observed sphingolipid-rich Lo domains that appeared approximately 0.7-1.1 nm above the 
DOPC-rich liquid disordered (Ld) phase (Fig. 8.5a); and Cer enriched gel-like platforms234 that 
were 0.4-1.0 nm higher than the Lo phase (Fig. 8.5b). As expected, the control SLBs 
containing C18-Cer were not sensitive to UV-A irradiation (Fig. 8.5c). Interestingly, in the case 
of ACe-1 we were never able to observe the presence of a higher so phase; indicating that 
the formation of such rigid domains may be hindered by the bulkiness of the azobenzene 
moiety. Using instead a ternary DOPC:SM:ACe-1 mixture (10:7:3 mol ratio) lacking Chol, we 
could demonstrate that ACe-1 allows the formation of so gel-domains (Fig. 8.6), similar to 
what was reported for C16-Cer239. Analogous to our results in the quaternary mixture, on 
irradiation with UV-A light, a shrinkage of the so domains was observed, as well as small 








Figure 8.4 | ACe-1 induces a concentration-dependent fluidification within the ordered 
Lo domains on isomerization to cis. SLBs consisting of DOPC:Chol:SM:ACe-1 
(10:6.7:X:Y mol ratio) were analyzed using contact mode atomic force microscopy (AFM). The 
SM:ACe-1 X:Y ratio was varied between 9:1, 7:3 and 5:5. Immediately after irradiation with 
UV-A light (λ = 365 nm), small Ld lakes were observed within the Lo domains.  In the 7:3 and 
5:5 SM:ACe-1 mixtures, those lakes fused together into larger Ld domains and persisted more 
than 5 min after irradiation. In the 9:1 SM:ACe-1 mixture, the Ld lakes had disappeared 5 min 
after irradiation. Scale bars = 2 µm. 
 
 




Figure 8.5 | UV-A irradiation does not affect SLBs containing C18-Cer. SLBs consisting 
of a of DOPC:Chol:SM:C18-Cer (10:6.7:7:3 mol ratio) were analyzed by contact mode AFM, 
displayed is a representative SLB. (a) Immediately after deposition, a two-domain Ld-Lo phase-
separated SLB was observed. (b) More than 4 h after deposition, a higher Cer-rich gel phase 
(so) appeared inside the Lo domains. (c) Irradiation with UV-A light (λ = 365 nm, 10 s) did not 






Figure 8.6 | ACe-1 controls domain structure in a ternary lipid mixture. (a) Fluorescence 
microscopy revealed the presence of gel-like domains in a ternary lipid mixture containing 
10:7:3 DOPC:SM:ACe-1 (with 0.1 mol% ATTO655-DOPE) in the presence of trans-ACe-1. 
(b,c) Using AFM, we observed a fluidification of the so domains on λ = 365 nm irradiation, as 
they shrunk slightly in size. Small holes were also observed within the domain on 
isomerization to cis. This effect could be reversed with λ = 470 nm irradiation. (d) The so 
domains rested approximately 1.5-2.0 nm higher than the Ld domain, displayed as a profile 
sampled across the white line in b. Scale bars: a = 20 µm, b = 5 µm, c = 300 nm. 
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8.2.4 – Dynamic control of raft fluidification and rigidification  
We next utilized high-speed AFM in intermittent-contact mode (AC mode), which allowed us 
to acquire images of SLBs (quaternary mixtures) at much higher frame rates to facilitate the 
observation of domain dynamics on photo-isomerization. In the 5:5 SM:ACe-1 lipid mixture, 
we were again able to observe the formation of Ld lakes within the Lo phase on isomerization 
of ACe-1 from trans to cis (Fig. 8.7a left). Immediately after irradiation, the newly formed 
domains were very small and mobile. They laterally diffused towards the Ld phase, or fused 
together into larger lakes in an effort to reduce surface tension. After equilibration in cis, 
isomerization back to trans-ACe-1 with blue light (λ = 470 nm) revealed the immediate 
formation of small Lo rafts within the fluid Ld phase (Fig. 8.7a right, Fig. 8.7b). The islands 
were quite small and rested approximately 1.0-1.5 nm higher than the Ld phase (Fig. 8.7c). 
This height difference is in close agreement with the value obtained for the bilayers under 
low-speed AFM in contact mode. The small ordered domains quickly disappeared within the 
first 30 s after blue irradiation, likely due to lipid diffusion into nearby pre-existing Lo domains. 
By analyzing the fraction of Ld phase compared to Lo phase (Ld/Lo ratio), we showed that the 
fraction of Ld increased on UV-A irradiation, while the fraction of Lo increased to similar levels 
as in the dark-adapted state on blue irradiation (Fig. 8.7a). This effect could be repeated over 
several cycles (Fig. 8.7d), and demonstrates a change in the phase distribution of ACe-1 
within the SLB on isomerization. This effect could also be observed under fluorescence 
microscopy, confirming that the fluidification was not an artefact caused by the AFM tip 
(Fig. 8.7e, Fig. 8.8). In this case, the dark Lo domains became smaller, brighter and less 
defined on isomerization to cis-ACe-1. On isomerization back to trans-ACe-1, the domain 
structure was slowly restored as the dye diffused out of the ordered domains. For the 7:3 
SM:ACe-1 mixture, the formation of Lo islands within the fluid Ld matrix was also observed on 
isomerization back to trans-ACe-1, however this effect was less prominent when compared 








Figure 8.7 | ACe-1 permits reversible remodeling of lipid domains. SLBs containing a 
DOPC:Chol:SM:ACe-1 (10:6.7:5:5 mol ratio) lipid mixture were prepared and analyzed using 
high-speed AFM (AC mode). (a,b) On isomerization to cis-ACe-1, a fluidification inside the Lo 
domains was observed as fluid Ld lakes formed within them. On isomerization back to 
trans-ACe-1 with λ = 470 nm blue light, rigidification was observed within the Ld phase as 
small Lo islands appeared. (c) Representative height profiles of the membrane (regions 
marked with white lines in a) after irradiation with λ = 365 nm and λ = 470 nm light. 
(d) Fluidification and rigidification could be repeated over multiple cycles, observed as an 
increase and decrease in the Ld phase. (e) Using fluorescence confocal microscopy, we could 
also observe reversible alterations in the SLB domain structure on UV-A/blue irradiation, with 
an increased Ld/Lo ratio in the cis-form. Scale bars: a,e = 1 µm, b = 500 nm. 
 





Figure 8.8 | ACe-1 enables optical control of SLB structure. Confocal fluorescence 
microscopy of an SLB composed of a DOPC:Chol:SM:ACe-1 (10:6.7:5:5 mol ratio with 0.1% 
ATTO655-DOPE) revealed Lo domains (dark) within a fluid Ld phase (bright). (a,b) On 
isomerization to cis-ACe-1 with λ = 365 nm irradiation (15 s) the dark Lo domains shrunk and 
became less defined. On isomerization back to trans ACe-1 with λ = 470 nm irradiation (15 s), 
the dark Lo domains slowly took shape as the dye diffused back into the fluid domains. Scale 






Figure 8.9 | Ordered domains are formed on isomerization from cis- to trans-ACe-1. 
SLBs consisting of DOPC:Chol:SM:ACe-1 (10:6.7:X:Y mol ratio) were analyzed using contact 
mode AFM. On isomerization to cis, Ld lakes formed within the Lo domains of the SLB. On 
blue irradiation and isomerization back to trans-ACe-1, Lo islands were immediately observed 
within the Ld phase. This effect could be repeated over multiple cycles. In the 5:5 SM:ACe-1 
mixture, both holes and islands were more pronounced when compared to the 7:3 SM:ACe-1 
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8.2.5 – ACe-2 and ACe-3 affect domain structure on isomerization 
Next, we used high-speed AFM to examine different SLB mixtures containing ACe-2 and 
ACe-3 to probe the structure activity relationship between the position of the N-acyl 
azobenzene moiety and the lipid domain structure. In the 7:3 SM:ACe-2 mixture, only very 
small and transient Ld lakes were formed inside the Lo domains on isomerization to cis-ACe-2, 
while the Lo domains themselves shrunk slightly in size (Fig. 8.10a). Irradiation with blue light 
reversed this effect, as shown by the Ld/Lo ratio. In comparison, photoswitching of ACe-3 had 
a greater effect on the SLB structure. In the 7:3 SM:ACe-3 mixture, large Ld lakes were 
observed inside the Lo domains on isomerization to cis-ACe-3, affording a large increase in 
the Ld/Lo ratio (Fig. 8.10b). On isomerization back to trans with blue light, Lo islands could be 
observed within the Ld phase, and the ordered domains again grew to their original size. 
In the 5:5 SM:ACe mixtures, a stark difference was observed between ACe-2 and 
ACe-3. In agreement with our fluorescence microscopy data, the ACe-2 mixture formed only 
a flat fluid phase without domains that was not affected by UV-A irradiation (Fig. 8.11). In the 
case of ACe-3, however, an inversion of the phases was observed. The SLB consisted 
primarily of a Lo phase, with smaller embedded Ld domains (Fig. 8.10c). Similar to the other 
lipid mixtures here described, the Lo phase rested 1.0-1.5 nm higher than the Ld domains 
(Fig. 8.10d). On isomerization to cis-ACe-3, the Ld domains grew dramatically as the fraction 
of Lo decreased (Fig. 8.10c,e). Isomerization back to trans-ACe-3 with blue light reversed this 
effect, and this behavior could be repeated over multiple cycles. These results suggest that 
ACe-3 associates itself much more strongly within the Lo domains when compared to ACe-2, 
and consequently a larger difference in raft structure is induced on photoisomerization. It is 
likely that the location of the azobenzene unit within ACe-2, due to its proximity to the 
headgroup, interferes with the hydrogen bonding between the Cer headgroup and SM. This 
decreases its presence within the Lo domains, and thus inhibits its efficacy in modulating the 
architecture of the SLB. In this case, ACe-2 behaves more like a short-chain Cer derivative234, 
affecting the miscibility and translational order of the Lo domains217,240. In contrast, the 
azobenzene moiety of ACe-3 is quite far from the headgroup, which permits its incorporation 
into the Lo lipid rafts in the trans-configuration, and thus ACe-3 behaves more like a long-
chain Cer234. However, photo-isomerization to cis-ACe-3, mimics a bend in the N-acyl chain, 
and disrupts its interactions within the rigid domains. Consequently, this effect triggers ACe 






Figure 8.10 | ACe-2 and ACe-3 enable optical control of ordered lipid domains. SLBs 
containing DOPC:Chol:SM:ACe lipid mixtures (10:6.7:X:Y mol ratio) were analyzed by high-
speed AFM (AC mode). (a) In the 7:3 SM:ACe-2 mixture, the size of the Lo domains shrunk 
on isomerization to cis-ACe-2. Very few Ld lakes were observed within the Lo domains. On 
isomerization back to trans-ACe-2, the Lo domains grew to their original size. (b) In the 
7:3 SM:ACe-3 mixture, isomerization had a greater effect on the raft structure, as large Ld 
lakes and Lo islands were observed on UV-A and blue irradiation, respectively. (c) For the 5:5 
SM:ACe-3 mixture, an inversion of the Ld-Lo phases was observed. As before, UV-A irradiation 
significantly increased the amount of the Ld phase, while blue irradiation reversed this effect. 
(d,e) Representative height profiles of the same membrane region (marked with white line) 
(d) before and (e) after irradiation with λ = 365 nm light. After shining UV-A light, Ld lakes 
resting approximately 1.0-1.5 nm below the Lo phase can be observed. Scale bars = 1 µm. 




Figure 8.11 | Lipid bilayers containing a 5:5 SM:ACe-2 ratio do not form ordered 
domains. DOPC:Chol:SM:ACe-2 (10:6.7:5:5 mol ratio) lipid mixtures were analyzed by high-
speed AFM and representative AFM images are displayed. Only a single fluid phase was 
observed, and the SLB was not affected by λ = 365 nm irradiation. Scale bars = 2 µm (top) or 






8.3 – Discussion 
In conclusion, we demonstrated that ACes in their trans-configuration can function similar to 
Cer in raft-mimicking SLBs. Insertion of the hydrophobic azobenzene into the Cer N-acyl chain 
does not inhibit its interaction with Lo domains. Isomerization from the trans- to cis-
configuration induces a conformational change in the fatty acid structure from a less bent 
(similar to saturated C18:0), to more bent acyl chain (similar to unsaturated C18:1), 
respectively; allowing us to locally and effectively control the degree of lipid saturation within 
the bilayer. This result is in accordance with previous studies utilizing the FAAzos51, where we 
demonstrated that they can mimic long and saturated fatty acids in their trans-form, whereas 
they resemble more highly bent fatty acids like arachidonic acid in their cis-form. Similar to a 
previous report investigating the behavior of the unsaturated C18:1-Cer241, the bent cis-ACes 
are presumably less soluble within the rigid Lo domains, and therefore prefer to be localized 
within the fluid phase. 
The dynamic manipulation of membrane structure through fluctuations in Cer 
concentration is thought to be crucial for many biological processes224, potentially through the 
lateral segregation of lipids within the plane of the membrane. In vitro, we were able to observe 
the dynamic formation of small transient ordered domains, alongside the growth of existing 
ones, on isomerization of the ACes from cis to trans. As such, the ACes may provide 
biophysical insights on the requirements necessary to form rigid domains in the membrane 
on the generation of Cer. Effectively, the ACes permit cycling between ceramides with 
different biophysical characteristics, enabling dynamic and reversible control over the domain 
structure within model membranes. This characteristic is not shared with other photochemical 
tools like caged lipids. We hypothesize that the ACes may become useful to study the role of 
Cer production in the initiation of apoptosis or other signaling cascades. Furthermore, this 
work demonstrates the utility of the FAAzos as modular building blocks that can be used to 
construct more elaborate photoswitchable sphingolipids. As such, these tools will enable 
dynamic control over cell membranes, alongside the proteins with which they interact. 
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8.4 – Supporting information 
8.4.1 – Supported lipid bilayer formation 
N-Stearoyl-D-erythro-sphingosine (C18-Cer), N-stearoyl-D-erythro-sphingosyl-
phosphorylcholine (C18-SM, or simply SM), 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) and cholesterol (Chol) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 
Supported lipid bilayers (SLBs) were prepared by deposition and fusion of small unilamellar 
vesicles (SUVs) as described elsewhere237. SUVs composed of DOPC:Chol:SM:C18-Cer and 
DOPC:Chol:SM:ACe, containing additional 0.1 mol% ATTO655-DOPE (ATTO Technology 
GmbH, Siegen, Germany), were obtained through bath sonication of multilamellar vesicles. 
SUV suspensions (1 mM total lipid concentration diluted in a 10 mM HEPES, 150 mM NaCl, 
pH 7.4 buffer) were deposited in the presence of 2 mM CaCl2 on freshly-cleaved mica 
previously glued to glass coverslips. The samples were incubated for 30 min at 65 °C, rinsed 
with buffer and were then allowed to cool slowly to room temperature for at least 1 h. 
SUV size (z-average) was measured at a total 66.7 µM lipid concentration via dynamic 
light scattering, utilizing a Malvern Zetasizer Nano ZSP (Malvern, Worcestershire, UK) with 
Hellma SUPRASIL precision quartz cuvettes (10 mm light path). 
 
8.4.2 – Combined atomic force and confocal microscopy 
Combined atomic force and confocal microscopy was performed on a JPK Instruments 
Nanowizard III BioAFM and Nanowizard Ultra (Berlin, Germany) mounted on a Zeiss LSM510 
Meta laser scanning confocal microscope (Jena, Germany). Contact-mode AFM imaging was 
performed with the Nanowizard III head, using uncoated silicon cantilevers CSC38 from 
MikroMasch (Tallinn, Estonia) with typical spring constants of 0.01-0.2 N/m. The scan rate 
was typically set between 2-10 Hz. High-speed AFM in AC mode was done with the 
Nanowizard Ultra head, utilizing USC-F0.3-k0.3 ultra-short cantilevers from Nanoworld 
(Neuchâtel, Switzerland) with typical stiffness of 0.3 N/m. The cantilever oscillation was tuned 
to a frequency of 100-150 kHz and the amplitude kept below 10 nm. Scan rate was set to 25-
150 Hz. For both modes, images were acquired with a typical 256×256-pixel resolution. All 
measurements were performed at room temperature. The force applied on the sample was 
minimized by continuously adjusting the set point and gain during imaging. Height, error, 




was analyzed using JPK data processing software Version 5.1.4 (JPK Instruments) and 
Gwyddion Version 2.30 (Czech Metrology Institute).  
 For the confocal measurements, a λ = 633 nm He-Ne laser (to excite the 0.1 mol% 
ATTO655-DOPE added to the lipid mixtures) and a 40× NA 1.2 UV-VIS-IR C Apochromat 
water-immersion objective were used. All measurements were performed at room 
temperature. Images were typically acquired with a 512×512-pixel resolution at a scan rate of 
3.2 µs per pixel and using a 1 Airy pinhole. Images were further processed with Fiji software 
(http://fiji.sc/Fiji) and the resulting data was analyzed in Microsoft Excel. The data was then 
plotted using Igor Pro.   
 
8.4.3 – Compound switching on supported lipid bilayers 
Compound switching for combined atomic force and confocal microscopy was achieved using 
a CoolLED pE-2 LED light source (Andover, United Kingdom) for illumination at λ = 365, 425 
and 470 nm. The lightsource was operated at a maximum of 80% power. The light beam was 
guided by a fiber-optic cable directly through the objective of the microscope via a collimator 
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A solution of 4-(((4-butylphenyl)diazenyl)phenyl)butanoic acid (FAAzo-4, 20 mg, 62 µmol, 
1.0 equiv.)  and O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU, 
20 mg, 62 µmol, 1.0 equiv.) in EtOAc (3.0 mL) was treated with NEt3 (25 mg, 4.0 equiv.) under 
an argon atmosphere at room temperature. After 1 h, D-erythro-sphingosine (24 mg, 
0.078 mmol, 1.25 equiv.) was added and stirring was continued at room temperature for 4 h. 
The solution was then diluted with EtOAc (30 mL) and washed with aqueous NaHCO3 
(2x20 mL) and brine (2x20 mL, 50% saturated) solutions. The phases were separated and 
the organic solvents were removed under reduced pressure. The residue was then purified 
by flash silica gel chromatography (3.0 g SiO2, 3:1 EtOAc:hexane) to yield N-(4-(((4-
butylphenyl)diazenyl)-phenyl)butanamide)-(2S,3R)-2-aminooctadec-4-ene-1,3-diol 
(ACe-1, 26 mg, 70%) as an orange oil. 
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TLC (EtOAc:hexane, 4:1): Rf = 0.39.  
1H NMR (CDCl3, 400 MHz, 25 ˚C): δ 7.81 (d, 4 H, H7Aa,b, H12Aa,b, J = 8.1 Hz), 7.33-7.28 (m, 
4 H, H6Aa,b, H13Aa,b), 6.33 (d, 1 H, NH, J = 7.4 Hz), 5.80-5.71 (m, 1 H, H5S), 5.50 (dd, 1 H, 
H4S, J = 15.4, 6.3 Hz), 4.29-4.25 (m, 1 H, H3S), 3.95-3.86 (m, 2 H, H2S, H1Sa), 3.67 (dd, 
1 H, H1Sb, J = 10.9, 3.1 Hz), 3.12 (sbrd, 2 H, 2xOH), 2.76-2.50 (m, 4 H, H4Aa,b, H15Aa,b), 
2.29-2.17 (m, 2 H, H2Aa,b), 2.07-1.96 (m, 4 H, H6Sa,b, H3Aa,b), 1.69-1.50 (m, 2 H, H16Aa,b), 
1.44-1.66 (m, 24 H, Halk), 0.94 (t, 3 H, H18Aa,b,c, J = 7.4 Hz), 0.90-0.85 (m, 3 H, H18Sa,b,c). 
13C NMR (CDCl3, 101 MHz, 25 ˚C): δ 173.4 (C1A), 151.4 (Cazo), 151.0 (Cazo), 146.5 (Cazo), 
144.6 (Cazo), 134.3 (C5S), 129.3 (2 C, Cazo), 129.2 (2 C, Cazo), 128.8 (C4S), 123.0 (2 C, Cazo), 
122.9 (2 C, Cazo), 74.6 (C3S), 62.5 (C1S), 54.5 (C2S), 35.9 (C2A), 35.7 (Calk), 35.1 (Calk), 
33.6 (C16A), 32.4 (C6S), 32.1 (Calk), 29.83 (2C, Calk), 29.80 (Calk), 29.77 (Calk), 29.6 (Calk), 
29.5 (Calk), 29.4 (Calk), 29.3 (Calk), 27.0 (Calk), 22.8 (Calk), 22.5 (Calk), 14.3 (C18A), 14.1 (C18S). 
IR (neat, ATR): ṽ = 3291, 2954, 2918, 2849, 1640, 1602, 1548, 1497, 1466, 1454, 1435, 
1417, 1377, 1284, 1224, 1199, 1155, 1107, 1070, 1036, 1013, 982, 959, 914, 850, 839, 721. 
HRMS (EI): m/z calcd. for [C28H33N3O3]: 605.4556, found: 605.4563 ([M-e-]+). 
UV-Vis (50 µM in DMSO): λmax(π-π*) = 340 nm. λmax(n-π*) = 435 nm. 
  













(ACe-2) was prepared from 4-((4-heptylphenyl)diazenyl)benzoic acid (FAAzo-1, 25 mg, 
0.078 mmol, 1 equiv.) as described above in the synthesis of N-(4-(((4-butylphenyl)-
diazenyl)phenyl)butanamide)-(2S,3R)-2-aminooctadec-4-ene-1,3-diol (ACe-1). ACe-2 
(43 mg, 92%) was isolated as an orange oil. NOTE: all reactants and reagents were scaled 
according to molarity. 
 
TLC (EtOAc:hexane 9:1): Rf = 0.31.  
1H NMR (THF, 400 MHz, 25 ˚C): δ 8.01 (d, 2 H, Hazo, J = 8.3 Hz), 7.91 (d, 2 H, Hazo, J = 8.2 Hz), 
7.86 (d, 2 H, Hazo, J = 8.1 Hz), 7.49 (d, 1 H, NH, J = 8.2 Hz), 7.36 (d, 2 H, Hazo, J = 8.1 Hz), 
5.77-5.67 (m, 1 H, H5S), 5.59 (dd, 1 H, H4S, J = 15.6, 6.3 Hz), 4.39 (d, 1 H, OH(3), J = 5.0 Hz), 
4.26 (q, 1 H, H3S, J = 5.5 Hz), 4.08-4.00 (m, 1 H, H2S), 3.97 (t, 1 H, OH(1), J = 5.5 Hz), 
3.91-3.84 (m, 1 H, H1Sa), 3.75-3.68 (m, 1 H, H1Sb), 2.70 (t, 2 H, H12A, J = 7.9 Hz), 
2.06-1.96 (m, 2 H, H6Sa,b), 1.72-1.63 (m, 2 H, H13Aa,b), 1.40-1.20 (m, 30 Halk), 0.94-0.82 (m, 
6 H, H18Aa,b,c, H18Sa,b,c). 
13C NMR (CDCl3, 101 MHz, 25 ˚C): δ 166.7 (C1A), 154.9 (Cazo), 151.9 (Cazo), 148.0 (Cazo), 
138.2 (Cazo), 132.5 (2 C, C4S, C5S), 130.0 (2 C, Cazo), 129.2 (2 C, Cazo), 123.9 (2 C, Cazo), 
123.2 (2 C, Cazo), 73.8 (C3S), 62.2 (C1S), 57.3 (C2S), 36.7 (C12A), 33.3 (C6S), 32.9 (Calk), 
32.8 (Calk), 32.3 (C13A), 30.8 (Calk), 30.72 (Calk), 30.67 (Calk), 30.65 (Calk), 30.61 (Calk), 
30.5 (Calk), 30.4 (Calk), 30.3 (Calk), 30.22 (Calk), 30.19 (Calk), 23.63 (Calk), 23.60 (Calk), 
14.53 (C18), 14.51 (C18). 
IR (neat, ATR): ṽ = 3677, 3634, 3301, 2955, 2850, 1634, 1604, 1575, 1539, 1493, 1466, 
1414, 1341, 1300, 1259, 1222, 1154, 1101, 1047, 1012, 965, 858, 821, 770, 721. 
HRMS (EI+): m/z calcd. for [C38H60N3O3]+: 606.4635, found: 606.4636 ([M-e-]+). 
UV-Vis (50 µM in DMSO): λmax(π-π*) = 340 nm. λmax(n-π*) = 435 nm. 













(ACe-3) was prepared from 7-(4-(p-tolyldiazenyl)phenyl)heptanoic acid (FAAzo-7, 9.0 mg, 
0.028 mmol, 1.0 equiv.) as described above in the synthesis of N-(4-(((4-
butylphenyl)diazenyl)phenyl)butanamide)-(2S,3R)-2-aminooctadec-4-ene-1,3-diol 
(ACe-1). ACe-3 (16.5 mg, 97%) was isolated as an orange solid. NOTE: all reactants and 
reagents were scaled according to molarity. 
 
TLC (9:1 EtOAc:hexane): Rf = 0.41. 
1H NMR (CDCl3, 400 MHz, 25 ˚C): δ 7.84–7.78 (m, 4 H, H10a,b, H15Aa,b), 7.33-7.28 (m, 4 H, 
H9Aa,b, H16Aa,b), 6.25 (d, 1 H, NH, J = 7.4 Hz), 5.82-5.71 (m, 1 H, H5S), 5.52 (dd, 1 H, H4S, 
J = 15.5, 6.3 Hz), 4.33-4.27 (m, 1 H, H3S), 3.98-3.86 (m, 2 H, H2S, H1Sa), 3.68 (dd, 1 H, 
H15A, J = 11.2, 3.2 Hz), 2.79 (s(br), 2 H, 2xOH), 2.67 (t, 2 H, H7Aa,b, J = 7.5 Hz), 2.43 (s, 3 H, 
H18Aa,b,c), 2.22 (t, 2 H, H2Aa,b, J = 7.6 Hz), 2.08-2.00 (m, 2 H, H6Sa,b), 1.71-1.59 (m, 4 H, 
H6Aa,b, H3Aa,b), 1.43-1.18 (m, 26 H, Halk), 0.87 (t, 3 H, H18Sa,b,c, J = 7.2 Hz). 
13C NMR (CDCl3, 100 MHz, 25 ˚C): δ 173.9 (Cazo), 151.1 (Cazo), 151.0 (Cazo), 146.1 (Cazo), 
141.4 (Cazo), 143.4 (Cazo), 134.4 (C5S), 129.9 (2C, Cazo), 129.2 (2C, Cazo), 128.9 (C4S), 
122.9 (4C, Cazo), 74.9 (C3S), 62.6 (C1S), 54.5 (C2S), 36.8 (C2A), 35.9 (C7A), 32.4 (C6S), 
32.1 (Calk), 31.2 (Calk), 29.85 (Calk), 29.84 (Calk), 29.82 (Calk), 29.81 (Calk), 29.77 (Calk), 
29.64 (Calk), 29.51 (Calk), 29.37 (Calk), 29.25 (Calk), 29.19 (Calk), 29.01 (Calk), 25.7 (Calk), 
22.9 (Calk), 21.7 (C18A), 14.2 (C18S). 
IR (neat, ATR): ṽ = 3564, 3294, 2919, 2850, 1634, 1603, 1539, 1466, 1359, 1155, 1104, 
1012, 963, 855, 721. 
HRMS (ESI+): m/z calcd. for [C38H59N3O3]+: 605.4635, found: 606.4635 ([M+H+]+). 
UV-Vis (50 µM in DMSO): λmax(π−π*) = 340 nm. λmax(n−π*) = 435 nm. 
Melting point (˚C): 103-105. 
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9.1 – Abbreviations  
1,2-DOG – 1,2-dioctanoyl-sn-glycerol 
5-HT – serotonin 
AA – arachidonic acid 
AC – intermittent contact (AFM mode) 
ACe – azo-ceramide 
AcOOH – peracetic acid 
AFM – atomic force microscopy 
Am – acetoxymethyl (protecting group) 
AP – action potential 
ATP – adenosine 5’-triphosphate 
ATR – attenuated total reflectance 
a.u. – arbitrary units 
AzCA – azo-capsaicin 
BK – bradykinin 
Bn – benzyl 
BSA – bovine serum albumin 
Bt – butyryl (protecting group) 
[Ca2+]i – intracellular Ca2+ concentration 
CAP – capsaicin 
Cav – L-type voltage-activated Ca2+ 
channel 
C-Cl – chelerythrine chloride 
cDNA – complementary deoxyribonucleic 
acid 
Cer – ceramide 
cg – caged 
Chol – cholesterol 
CKAR – C kinase activity reporter 
CM-H – C-fiber nociceptor 
CPZ – capsazepine 
DAG – diacylglycerol 
DCC – N,N'-dicyclohexylcarbodiimide 
DCE – 1,2-dichloroethane 
DIPEA – N,N-diisopropylethylamine 
DNA – deoxyribonucleic acid 
DOPC – 1,2-dioleoyl-sn-glycero-3- 
    phosphocholine 
DOPE – 1,2-dioleoyl-sn-glycero-3- 
    phosphoethanolamine 
DMAP – 4-dimethylaminopyridine 
DMEM – Dulbecco’s modified eagle 
 medium 
DMSO – dimethyl sulfoxide 
DRG – dorsal root ganglion 
EDC – 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide 
EGTA – ethylene glycol-bis(β-aminoethyl 
ether)-N,N,N',N'-tetraacetic acid 
EI – electron ionization 
EPSC – excitatory postsynaptic current 
ESI – electrospray ionization 
FA – fatty acid 
FAAzo – photoswitchable fatty acid 
FBS – fetal bovine serum 
FCS – fetal calf serum 
Fm – 9-fluorenylmethyl (protecting group) 
FRET – Förster resonance energy transfer 
GFP – green fluorescent protein 
GPCR – G protein-coupled receptor  
GSIS – glucose-stimulated insulin 
secretion 
 
9 − Appendix 
254 
 
HEPES – 4-(2-hydroxyethyl)-1- 
 piperazineethanesulfonic acid 
HIS – histamine 
Hi-K+ – high potassium 
HRMS – high-resolution mass 
spectrometry 
HTRF – homogeneous time-resolved 
 fluorescence 
IR – infrared (spectroscopy) 
iPr – isopropyl 
KATP – ATP-sensitive K+ channel 
Kv − delayed rectifier voltage-gated K+ 
channel 
Ld – liquid disordered (domain) 
Lo – liquid ordered (domain) 
MeCN – acetonitrile 
NGM – nematode growth medium 
NMR – nuclear magnetic resonance 
(spectroscopy) 
ns – not significant 
osc – oscillation 
PBS – phosphate-buffered saline 
PC – phosphatidylcholine 
PCL – photochromic ligand 
PhMe – toluene 
PhoDAG – photoswitchable diacylglycerol 
PI(4,5)P2 – phosphatidylinositol 4,5- 
bisphosphate 
PLC – phospholipase C 
PMA – phorbol 12-myristate 13-acetate 
PKC – protein kinase C 
PM/CP – plasma membrane to cytoplasm 
(translocation quantification ratio) 
PTL – photoswitched tethered ligand 
RFP – red fluorescent protein 
RPMI – Roswell Park Memorial Institute 
(medium) 
SAG – 1-O-stearoyl-2-O-arachidonoyl-sn- 
 glycerol 
sEPSC – spontaneous miniature 
postsynaptic current 
SLB – supported lipid bilayer 
SM – sphingomyelin 
so – gel-like (domain) 
SUV – small unilamellar vesicle 
TBME – tert-butyl methyl ether 
TBTU – O-(benzotriazol-1-yl)-N,N,N′,N′- 
 tetramethyluronium  
tetrafluoroborate 
TES – triethylsilyl (protecting group) 
TESOTf – triethylsilyl 
trifluoromethanesulfonate 
THF – tetrahydrofuran 
TLC – thin layer chromatography 
TRP – transient receptor potential 
UV-Vis – ultraviolet-visible (spectroscopy) 






9.2 – General synthetic methods and spectroscopic characterization 
All reagents and solvents were purchased from commercial sources (Sigma-Aldrich, TCI 
Europe N.V., Strem Chemicals, etc.) and were used without further purification unless 
otherwise noted. Tetrahydrofuran (THF) was distilled under a N2 atmosphere from 
Na/benzophenone prior to use. Triethylamine (NEt3), was distilled under a N2 atmosphere 
from CaH2 prior to use. Further dry solvents such as ethyl acetate (EtOAc), benzene (PhH), 
dichloromethane (CH2Cl2), toluene (PhMe), ethanol (EtOH) and methanol (MeOH) were 
purchased from Acros Organics as "extra dry" reagents and used as received. Solvents were 
degassed by sparging the freshly distilled solvent with argon gas in a Schlenk flask under 
ultra-sonication using a Bandelin Sonorex RK510H ultra-sonic bath for 20 min prior to use. 
Reactions were monitored by TLC on pre-coated, Merck Silica gel 60 F254 glass-backed plates 
and the chromatograms were first visualized by UV irradiation at λ = 254 nm, followed by 
staining with aqueous ninhydrin, anisaldehyde or ceric ammonium molybdate solution (CAM), 
and finally gentle heating with a heat gun. Flash silica gel chromatography was performed 
using silica gel (SiO2, particle size 40-63 µm) purchased from Merck. 
 UV-Vis spectra were recorded using a Varian Cary 50 Bio UV-Visible 
Spectrophotometer with Helma SUPRASIL precision cuvettes (10 mm light path). Switching 
was achieved using a Polychrome V (Till Photonics) monochromator (intensity vs. wavelength 
screen, Fig. 9.1). The illumination was controlled using PolyCon3.1 software and the light was 
guided through a fiber-optic cable with the tip pointed directly into the top of the sample 
cuvette. 
All NMR spectra were measured on a BRUKER Avance III HD 400 (equipped with a 
CryoProbeΤΜ). Multiplicities in the following experimental procedures are abbreviated as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, 
hept = heptet, br = broad, m = multiplet. 1H chemical shifts are expressed in parts per million 
(ppm, δ scale) and are referenced to the residual protium in the NMR solvent (CDCl3: δ = 7.26, 
D6-DMSO: δ = 2.50, THF-d8: δ = 3.58, C6D6: δ = 7.16). 13C chemical shifts are also expressed 
in ppm (δ scale) and are referenced to the carbon resonance of the NMR solvent 
(CDCl3: δ = 77.16, D6-DMSO: δ = 39.52, THF-d8: δ = 67.21, C6D6: δ = 128.06). NOTE: Due to 
the trans/cis isomerisation of some compounds containing an azobenzene functionality, more 
signals are observed in the 1H and 13C spectra than would be expected for the pure trans-
isomer. Only signals for the major trans-isomer are reported, however the identities of the 
remaining peaks were verified by 2D-COSY, HSQC and HMBC experiments. 
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 Infrared (IR) spectra were recorded as neat materials on a PERKIN ELMER Spectrum 
BX-59343 instrument. For detection, a SMITHS DETECTION DuraSam-plIR II Diamond ATR 
sensor was used. The measured wave numbers are reported in cm-1.  
 Low- and high-resolution electron ionization (EI) mass spectra were obtained on a 
MAT CH7A mass spectrometer. Low- and high-resolution electrospray ionization (ESI) mass 
spectra were obtained on a Varian MAT 711 MS instrument operating in either positive or 
negative ionization modes. 
 
Figure 9.1 | Wavelength vs. intensity screen of the Till Photonics Polychrome V. 
 
9.3 – Data reporting and error analysis 
For imaging experiments, “n” is the number of measurements made (individual cells). The 
number of independent experiments included in each panel is also described in the figure 
caption. For electrophysiological experiments, “n” represents the number of cells, each of 
which constitute an independent experiment. For insulin secretion experiments, “n” represents 
the number of independent experiments performed. For experiments in C. elegans, "n" 
represents the number of animals used, the number of independent experiments is also 
described in the figure caption. For all figure panels, results are plotted as mean ±s.e.m., using 
"n" as the number of samples. Where appropriate, the Mann-Whitney test was used to 
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